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Abstract 
Alterations in DNA methylation can have dramatic effects on gene transcription, 
and in particular, hypermethylation of promoter associated CpG islands is known to 
lead to gene inactivation. Altered patterns of DNA methylation play a key role in the 
development of cancer and may also play important roles in many other diseases. 
However, the mechanisms which lead to these changes in DNA methylation are 
unknown. DNA methylation patterns have also been found to change during normal 
ageing and these changes have similarities to those that occur during the development of 
cancer. This suggests that for some age-related diseases, most notably cancer, altered 
patterns of methylation may be an early initiating event and that disease may develop in 
cells which already possess changes in their DNA methylation landscape. Therefore, 
this study was designed to examine how methylation levels at a group of genes alters 
over the life-course and how these relate to methylation changes observed in major age-
related diseases (cancer, specifically acute lymphoblastic leukaemia (ALL) and 
Hereditary Nonpolyposis Colorectal Cancer (HNPCC) patients, and atherosclerosis). 
DNA was collected from healthy volunteers from different ages and from ALL, 
HNPCC and atherosclerosis patients. Methylation was quantified using pyrosequencing.  
The study produced a number of findings: 1) Genes exhibiting variable methylation in 
PBL samples from healthy volunteers are also highly methylated in leukaemia, 
suggesting a common underlying mechanism. 2) Increased methylation levels were 
observed in lymphoid compared to myeloid cells, in healthy individuals, mirroring the 
patterns seen in leukaemia. 3) A subset of genes exhibiting variable methylation in PBL 
samples from healthy volunteers and that are highly methylated in leukaemia are 
aberrantly methylated in HNPCC patients and atherosclerosis patients, suggesting 
shared risk factors. 4) While methylation levels increase during ageing, a substantial 
proportion of methylation is already present at birth and may thus alter disease 
susceptibility throughout life. 5) Blood samples from ALL patients in remission exhibit 
increased methylation levels (versus controls), not directly related to their leukaemic 
clone, and the extent of methylation correlates with overall survival.  
The studies to date are compatible with a hypothesis in which altered 
methylation of disease-related genes pre-exists in a subset of haematopoietic cells and 
that these cells may be at a significantly increased risk of progression to age-related 
diseases. Furthermore, monitoring DNA methylation may be a valuable tool for early 
diagnosis of these diseases, as well as for monitoring disease progression in patients. 
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Chapter 1. Background
 2 
 
1.1  Epigenetics 
Epigenetic changes are heritable changes in gene expression that do not involve 
changes in the deoxyribonucleic acid (DNA) sequence. Epigenetic mechanisms mediate 
diversified gene expression profiles, to allow the generation of the variety of cells and 
tissues required in multicellular organisms. All cells in an organism contain essentially 
the same genetic information, but not all genes are expressed simultaneously by all cell 
types (Moore, 2012). The primary mechanisms that are involved in epigenetic 
regulation of gene expression include; DNA methylation, which is a biological process 
by which a methyl group is added to a DNA nucleotide and which is a major epigenetic 
factor influencing gene activities (Moore, 2012); histone modification, which describes 
the post translation modification that histones undergo, such as methylation, acetylation, 
ubiquitylation and phosphorylation, which alters their interaction with DNA and nuclear 
proteins and affects chromatin structure, and which is involved in controlling 
transcription (Imhof, 2003); chromatin remodelling, which is the dynamic modification 
of chromatin architecture that enables access to nucleosomal DNA, and thereby controls 
gene expression (Saha, 2006); and Ribonucleic acid (RNA) associated gene silencing, 
where non coding microRNAs (miRNAs), single stranded, evolutionary conserved, 
small, noncoding RNA molecules, are negative regulators of gene expression that 
mediate post transcriptional gene repression (Avraham, 2012). 
Epigenetic events are necessary for the life of organisms and are important in 
orchestrating key biological processes, such as imprinting, which allows certain genes 
to be expressed in a parent-of-origin matter (Fedoriw, 2012); silencing of large 
chromosomal domains, such as inactivation of the X-chromosome in females (Li, 
2012);   and differentiation, which allows stem cells and multipotent progenitor cells to 
differentiate into multiple different cell lineages (Wu, 2006) (Figure 1.1). 
This project concentrated primarily on one epigenetic modification, DNA 
methylation, and therefore the rest of this section will primarily focus on DNA 
methylation. 
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Figure 1.1: The functional roles of epigenetics 
Epigenetic mechanisms play important roles in key biological processes, such as; 
differentiation, which allows stem cell and multipotent progenitor cells to differentiate into 
multiple different cell lineages; imprinting, which allows certain genes to be expressed in a 
parent-of-origin specific matter; and silencing of large chromosomal domains, such as 
inactivation of the X-chromosome in females. 
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1.1.1 DNA methylation 
DNA methylation is a biological process by which a methyl group is added to a DNA 
nucleotide. In humans, only cytosine bases are susceptible to normal biological 
methylation and this occurs almost exclusively at cytosine residues which are 
immediately followed by a guanine, forming the so-called CpG dinucleotide. A small 
percentage of methylation occurs in non-CG sites, however, this non-CG methylation 
has almost exclusively been observed in stem cells (Lister, 2009). The methyl group is 
added to the fifth carbon within the cytosine residue. This does not change the coding 
properties of the codon in which the base participates. 
CpG dinucleotides (CpGs) only comprise around 1% of the genome (Swartz, 1962). 
Around 85% of these CpGs are spread out in the genome and these sporadic CpG sites 
found throughout most of the genome are usually methylated, such that 70-80% of all 
CpGs in the genome are methylated. The remaining 15% of CpG sites are clustered in 
short regions of genomic DNA (Ehrlich, 1982), so called CpG islands (Cross, 1995). 
CpG islands comprise about 1-2% of the genome and they encompass the 
transcriptional start site (TSS) of approximately 60-70% of human protein encoding 
genes (Bird, 2002; Saxonov, 2006). CpG islands are generally defined as a region of 
DNA greater than 500 bp, with a GC content of over 55% and an observed CpG content 
to expected CpG content ratio of over 0.65, as described by Takai et all (Takai, 2002), 
although other slightly different criteria have also been suggested (Gardiner-Garden, 
1987). However, it must be noted that all the proposed definitions of CpG islands are 
based on sequence analysis and there is currently no functional definition of a CpG 
island. Jones et al showed that in the human genome, the frequency of CpGs is about 10 
times more frequent in CpG islands than in the surrounding DNA (Jones, 2012). These 
dense CpG clusters are usually devoid of CpG methylation. Clustering of unmethylated 
CpGs has allowed the CpG islands to be biochemically isolated as a relatively 
homogeneous fraction of DNA or chromatin (Jones, 2012). Outside the CpG islands, 
but within 2kb distance from the TSS is a stretch of CpG sites, named CpG shores 
(Irizarry, 2009). The region up to 4 kb distance from the TSS is described as CpG 
shelves (Sandoval, 2011).  
The CpG sites in the rest of the genome, outside the CpG islands, shores and shelves, 
are predominantly present in repetitive elements. These repetitive elements represent 
around 45% of the human genome and they contain much of the CpG methylation 
found in normal somatic tissues. The repetitive elements consist of interspersed repeats 
derived from non-autonomous or autonomous transposable elements and tandem repeats 
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of simple sequences or complex sequences; such as retroviruses, LINE1 elements, Alu 
elements and others (Jones, 2012; Weisenberger, 2005).  
 
1.1.2 DNA methyltransferase genes 
DNA methylation is carried out by the DNA methyltransferase genes (DNMTs) 
(Hermann, 2004a), with S-adenosylmethionine (SAM) as the methyl donor (Detich, 
2003) (Figure 1.2).  
 
 
 
 
 
 
 
Figure 1.2: The mechanisms of DNA methylation 
The mechanism of DNA methylation consists in the production of an altered 5-methylcytosine 
molecule by the action of the DNMTs. They catalyse the transfer of a methyl group from SAM 
to the carbon-5 position of a cytosine molecule. 
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The DNMT protein family in mammals has been shown to have five members, 
however only three have been shown to have catalytic DNA methyltransferase activity; 
DNMT1, DNMT3a and DNMT3b (Hermann, 2004a). 
DNMT1 had been shown to function primarily in the maintenance of methylation 
patterns. It was thought to be responsible for the propagation of the DNA methylation 
information by maintenance of DNA methylation patterns after DNA replication 
(Hermann, 2004a) and it is able to do this with high fidelity (Hermann, 2004b). DNMT1 
was shown to have a preference for hemimethylated sites (Arand, 2012) and whereas 
unmethylated DNA was a relatively poor substrate for DNMT1, hemi-methylated DNA 
was efficiently utilised to produce fully methylated sites. This is important to maintain 
the original methylation patterns of the DNA: during every S-phase, DNA replication 
converts ∼40 million methylated CG sequences into the hemimethylated state and as a 
result these hemimethylated CG sequences have to be efficiently methylated without 
methylation of unmethylated CG sites, thus maintaining the original methylation 
patterns (Hermann, 2004b).  
DNMT3a and DNMT3b have been shown to be essential for de novo methylation 
during early mammalian development. Inactivation of both DNMT3a and DNMT3b 
caused lethality in mice, where knockout of DNMT3b caused early embryonic lethality 
and inactivation of DNMT3a resulted in death shortly after birth (Okano, 1999) and 
DNMT3a and DNMT3b deficient induced pluripotent stem cells (iPSCs) were shown to 
be restricted in their developmental potential (Pawlak, 2011). DNMT3a is required for 
the establishment of both maternal and paternal imprints (Kaneda, 2004), and has been 
shown to be important in HSC differentiation (Challen, 2012). DNMT3a is thought to 
methylate a set of genes or repetitive sequences that are critical during later 
development or after birth, whereas DNMT3b may play more important roles during 
early development and is methylating a broader spectrum of target sequences (Okano, 
1999).  
Even though DNMT1s function is described as the maintenance of methylation 
patterns, and Dntm3a and Dntm3b being described as being important in the de novo 
methylation, in vivo, neither de novo methylation can be exclusively assigned to 
DNMT3a or DNMT3b nor maintenance methylation exclusively to DNMT1 (Arand, 
2012), suggesting a closer relationship between the different DNMTs. A different model 
has been suggested by Jones et al in 2009. They proposed that the bulk of DNA 
methylation in dividing cells is maintained by DNMT1, whereas DNMT3a and 
DNMT3b methylate sites that are missed by DNMT1. In this model, the main role of 
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DNMT1 is in reading the DNA sequence and applying methyl groups opposite to newly 
replicated hemimethylated CpG sites, without regard for the chromatin configuration in 
which the particular piece of DNA is located, while DNMT3a and DNMT3b are 
associated with specific regions of DNA that need to be maintained as highly 
methylated. If methylated regions remain associated with DNMT3a and DNMT3b, this 
would ensure that the methylation state of a region is maintained, rather than a specific 
methylation pattern (Jones, 2009). 
 
1.1.3 DNA de-methylation 
Even though DNA methylation is generally thought of as contributing to stable, 
long-term and heritable transcriptional repression, it is still possible to reverse DNA 
methylation. Demethylation can either be achieved passively, by the failure of the 
maintenance of DNA methylation after DNA replication, or actively, by replication-
independent processes (Chen, 2011). While until recently there were no known 
mechanisms for DNA demethylation the existence of such mechanisms had been 
inferred by observations that DNA methylation undergoes dramatic global changes at 
specific stages of mammalian development. Shortly after fertilization, the sperm-
derived pronucleus undergoes a rapid, global loss of DNA methylation that occurs 
independently of DNA replication, while the maternal pronucleus undergoes 
demethylation at a later stage, namely during the first few cell cycles of development 
and this demethylation is replication-dependent (Sanz, 2010; Wu, 2010).  
However, recently a family of proteins, known as the ten eleven translocation 
(TET) proteins, have been identified that appear to function as the primary DNA 
demethylases in mammalian cells. These TET proteins have shown to promote active 
DNA demethylation in mammalian cells in vitro and in the mouse brain in vivo (Guo, 
2011; Tahiliani, 2009). The suggested model of DNA demethylation by the TET 
proteins starts by the oxidation of 5-methylcytosines (5mCs) into 5-
hydroxymethylcytosines (5hmCs). 5hmCs are then deaminated into 5-hydroxyluracil 
(5hmU) by the deaminases activation-induced deaminase (AID) and apolipoprotein B 
mRNA-editing enzyme complex (APOBEC). Finally, 5hmU can be excised by 5hmU 
glycosylases and repaired by the base excision repair (BER) pathway with unmethylated 
cytosines (Guo, 2011; Cimmino).  
Another proposed mechanism of DNA de-methylation is the glycolase-dependent DNA 
demethylation model. In this model, 5mC is deamiated directly to thymine by AID and 
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APOBEC, which is then followed by excision of the T/G mismatch by MBD4 and the 
thymine-DNA glycosylase (TDG) (He, 2011). 
Other than these biological mechanisms of demethylation, methylation can be 
pharmacologically reversed by several drugs, such as the DNMT inhibitors 5-
azacytosine (azacytidine) and 5-Aza-2’-deoxycytidine (decitabine) (Yan, 2012; Mund, 
2005). These drugs cause an inhibition of the DNMTs, resulting in overall de-
methylation. Compounds from both drugs are imported by cells. In the cell it is 
converted to the activated triphosphate 5-Aza-dCTP and incorporated into the DNA. 
The presence of a nitrogen at the 5 position of the azacytidine nucleobase results in an 
irreversible covalent complex with DNMT1
 
and this triggers proteasome-mediated 
DNMT1 degradation. Azacytidine can also be converted to the ribonucleoside 
triphosphate, 5-Aza-CTP, into RNA.  
However, these DNMT inhibitors are not selective towards the different DNMTs, are 
chemically instable and have strong secondary effects, e.g. renal toxicity and 
myelotoxicity (Foulks, 2012; Gros, 2012). Nevertheless, these drugs are clinically used 
in myelodysplastic syndrome and acute myelogenous leukemia, where dose and 
exposure time are critical; in vitro experiments showed a significant effect on cell 
viability in higher doses or long exposure times (Kwon, 2012) and an in vivo study in 
mice has shown that high exposure of these drugs can have toxic side-effects and cause 
lethality’s (Chuang). 
 
 
1.1.4 The role of DNA methylation in cellular processes 
DNA methylation plays an important role in numerous cellular processes. It is 
classically assigned instructional modifications for germ line imprint control regions 
(ICRs), which are required to establish parental identity of imprinted loci and to 
maintain differential epigenetic pattern throughout development. Genomic regions of 
differential DNA methylation, called differentially methylated regions (DMRs), 
function as ICRs and they have been identified at almost all imprinted gene clusters 
(Fedoriw, 2012; Smith, 2013). 
Another role of DNA methylation is X-chromosome inactivation. Mammalian 
female cells contain two X chromosomes and as a result, a problem of X-linked gene 
dosage must be solved. As such, X-chromosome inactivation serves to balance sex-
chromosome-linked gene dosage in female somatic cells, by rendering one of the two X 
chromosomes largely transcriptionally silent by epigenetic mechanisms. DNA 
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methylation plays an important role in this X-chromosome silencing. This inactivation 
is mediated upstream of DNA methylation by the non-coding RNA X-inactivation-
specific transcript (Xist) and Polycomb-group-mediated H3K27 methylation (Fedoriw, 
2012; Smith, 2013). 
De novo methylation also plays a role in the transcriptional circuitry associated with 
pluripotency, which is rapidly silenced on differentiation as embryonic programmes are 
resolved towards specific lineages. In vivo experiments showed that differentiation of 
adult stem cells was associated with small but informative changes in the genomic 
distribution of DNA methylation (Bock, 2012; Smith, 2013), emphasizing the role of 
DNA methylation in cell differentiation processes. 
 
1.1.5 The role of DNA methylation in controlling gene expression 
Early experiments had provided evidence that DNA methylation was also likely to 
play a crucial role in repressing gene expression. The state of methylation of CpG 
islands near gene promoters was found to be associated with the transcriptional activity 
of a gene (Bird, 1986), and strong negative correlations have been observed between 
DNA methylation levels and the presence of histone marks that target active genes 
(Bell, 2011). CpG islands at promoters are hypomethylated corresponding to a 
permissive chromatin structure in order to poise genes for transcriptional activity 
(Antequera, 1993) and hypermethylation of gene promoter is related to an inactive state, 
preventing genes from being expressed. Besides CpG islands near gene promoters, CpG 
shores have been related to gene expression. In these CpG shores, tissue-specific 
differentially methylation region (T-DMR) methylation and cancer-specific 
differentially methylated region (C-MDR) methylation showed a strong inverse 
relationship with differential gene expression (Irizarry, 2009). 
These observations provide evidence that DNA methylation is associated with the 
transcriptional activity of genes and it can affect this transcription by two mechanisms. 
Firstly, methylation of cytosine bases can directly inhibit the binding of some 
transcription factors when present at their target site (Bird, 2002). Transcription factors 
that have CpGs in their recognition sequences and are thus methylation-sensitive 
include the Ah receptor, CREB/ATF, E2F, ETS factors, c-Myc, NF-κB and HiNF-P. 
Other transcription factors are not sensitive to methylation, for example Sp1, CTF and 
YY1 and, as a result methylation does not hinder binding of these gene-specific 
transcription factors, but rather prevents the binding of ubiquitous factors, and 
subsequently transcription (Baron, 2012). 
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In the second mechanism in which DNA methylation can affect transcriptional 
activity, both histone modification and DNA methylation act together to influence 
chromatin structure and as a result gene expression. To fully understand the interaction 
between DNA methylation and histone modifications, the next section will first go into 
more detail about the different histone modifications and then the next section will 
discuss the interplay between these two epigenetic modifications. 
 
1.1.6 Histone modifications 
DNA and histones are components of a chromosome, in which the DNA helix is 
wrapped around core histones to form the DNA structure. Histones are positively 
charged and can so from a tight interaction with the negative charged DNA phosphate 
groups, producing dense chromatin. The first step in the formation of this higher-order 
chromatin is the formation of the nucleosome core particle. This structure comprises an 
octamer of core histones; two copies of each histone; H2A, H2B, H3 and H4, around 
which are wrapped 146 base pairs of DNA in 1 ¾ superhelical turns (Luger, 1997). The 
N-terminal tails of these histone proteins are exposed in the area surrounding the 
nucleosomes and are subjected to a variety of post translational modifications, including 
phosphorylation, methylation, acetylation and ubiquitination (Molina-Serrano, 2013). 
These modifications may, singly or in combination, influence numerous biological 
processes. The possible complex interplay between the different modifications 
occurring on the histone tails is being described in the histone code hypothesis. This 
hypothesis predicts that a pre-existing modification affects subsequent modifications on 
histone tails and that these modifications serve as marks for the recruitment of different 
proteins or protein complexes to regulate diverse chromatin functions, such as 
transcription and gene expression, DNA replication and chromosome segregation 
(Strahl, 2000). 
Acetylation of Lys residues, predominantly in histones H3 and H4 is mediated 
by enzymes with histone acetyltransferase (HAT) activity, using acetyl-CoA as the 
acetyl donor. Acetylation removes the positive charge of lysine and alters interactions 
with DNA and other chromatin-associated proteins, resulting in decreased binding 
ability of the histones. In general, acetylation of core histone tails correlates with 
opening of chromatin structure to allow transcription. HATs can be categorized into 
three major families: the MYST family containing MOZ, Ybf2/Sas3, Sas2, Tip60, the 
Gcn5 related N-acetyltransferase or GNAT family, and the more recently characterized 
p300 family (Berndsen, 2008). 
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Conversely, acetyl groups are removed from the ε-N-acetyl-lysine by histone 
deacetylases (HDACs), allowing the histones to wrap the DNA more tightly to 
condense the DNA structure and this is preventing transcription. Mammalian HDACs 
can be divided into three subclasses. Class I enzymes are homologous to the yeast Rpd3 
protein and include the mammalian HDAC1, HDAC2, HDAC3 and HDAC8 enzymes. 
Class II HDACs (HDAC4, HDAC5, HDAC6 and HDAC7) are larger proteins that are 
related to the yeast Hda1 protein. Recently, a third class of HDACs, with homology to 
the yeast Sir2 protein and several putative mammalian members, has been identified. 
HDACs bind to many different proteins and usually exist in large complexes within the 
cell (Kramer, 2001).  
Both HAT and HDAC activities can be recruited to target genes in complexes with 
sequence-specific transcription factors and their cofactors. The dynamic interplay 
between HATs and HDACs dictates the ultimate state of acetylation. The fact that the 
amino-acid sequence of histones are some of the most highly conserved among 
eukaryotes and that there is high sequence conservation of HATs, underscores the 
critical nature of histone acetylation in genome regulation (Berndsen, 2008).  
Selected lysines and arginines can be methylated in the N-terminal tail domains 
of H3 and H4. The enzymes responsible, the histone methyl transferases (HMT), are 
either lysine or arginine specific and several have now been identified and 
characterized. Two families of HMTs have been described; protein arginine 
methyltransferases (PRMTs) catalyze the transfer of methyl groups from SAM to the 
guanidino nitrogens of arginine residues; and the SETdomain family is a second 
important signature motif for protein methyltransferases. The known functions of these 
two family of proteins predict that histone methylation is likely to play important roles 
in multiple biological processes including transcription, signal transduction, 
development, and cellular proliferation and differentiation (Zhang, 2001).   
 Many promoters in embryonic stem (ES) cells harbor a distinctive histone 
modification signature that combines the activating histone H3 Lys 4 trimethylation 
(H3K4me3) mark, imparted by the Set/MLL histone transferase and the repressive 
H3K27me3 mark, imposed by the polycomb group (PcG) proteins. These bivalent 
domains represent a preprogrammed epigenetic signature that is considered to poise 
expression of developmental genes, allowing timely activation while maintaining 
repression in the absence of differentiation signals (De Gobbi, 2011; Han, 2012). 
PcGs are histone modifiers that reside in two multi-protein complexes: Polycomb 
Repressive Complex 1 and 2 (PRC1 and PRC2). PRC2 catalyses the methylation of 
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H3K27, which is then accompanied by the recruitment of PRC1 members, leading to 
the formation of repressive chromatin (Radulovic, 2013).  
 
 
1.1.7 The interplay between DNA methylation and histone modifications 
Even though DNA methylation and histone modification are thought to be 
independent processes, they might influence each other in different ways. Firstly, DNA 
methylation might direct histone modifications. Methyl-CpG binding proteins (MBP), 
such as MBD1, MBD2, MBD3 and MeCP2, and HDAC complexes are recruited to the 
methylated region to induce histone deacetylation and silencing. The chromatin then 
HMTs which methylate the lysine 9 residues on histone H3 (H3K9) and this stabilises 
the inactive state of chromatin.  
Secondly, histone methylation might direct DNA methylation. Methyl H3-K9 acts as a 
signal for inactive chromatin by recruiting HP1 to methylated histones, which might in 
turn recruit DNA methyltransferases directly or indirectly to the silent chromatin to 
maintain DNA methylation and stabilize the inactive chromatin.  
The third way is a model of chromatin remodelling driving DNA methylation. The 
ATP-dependent chromatin remodelling and DNA helicase activities of proteins might 
facilitate DNA methylation and histone modification by unwinding nucleosomal DNA 
to increase its accessibility to DNMTs, HDACs and HMTs. The disruption of these 
proteins affects both DNA methylation and histone methylation (Li, 2002; Parry, 2011; 
Bronner, 2010).  
All these observations together suggest that DNA methylation does not necessarily 
play a general role as a transcriptional regulator (Antequera, 2003), but that it rather 
plays a role in maintaining the silenced state which has been induced by the associated 
epigenetic marks on histones and other epigenetic molecules (Feng, 2006). 
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1.2 Ageing and age-related diseases 
Important demographic changes occurring across most of the world are leading 
to an increasing elderly population (Christensen, 2009). Life expectancy has increased 
steadily over the past 2 centuries (Vaupel, 2010) and according to the World Health 
Organization (WHO), there will be 2 billion people aged 60 and older in 2050 (WHO, 
2013). However, a significant proportion of the extra life years are associated with 
morbidity, and as a result, aging and age-related diseases are becoming major health 
priorities.  
The fundamental defining manifestation of ageing is an overall decline in the functional 
capacity of various organs to maintain tissue homeostasis (Kirkwood, 2005) and to 
respond adequately to physiological needs under stress (Sahin, 2010). Ageing can result 
in both physical and psychological changes. During ageing, the capacity to adapt 
declines, which might affect personality, mood, attitude and self-concept of an 
individual. Changes may occur in perception and memory, leading to learning and 
problem solving difficulties. During ageing, degenerative changes can occur, such as the 
inability to see, hear, feel and react to stimulus. Spatial orientation, mobility and motor 
coordination decline and the work rate of body systems diminish (WHO, 2012).  
The stochastic theory of ageing suggest that organisms limit their investment in long-
term maintenance of somatic tissues and that, as a consequence, ageing develops 
through cumulative damage induced at various levels through a gradual accumulation of 
unrepair cellular defaults (Sozou, 2001). 
With the increasing number of aged individuals, age-related diseases are now the 
dominant health problems in most countries. The incidence of these diseases increases 
rapidly with age and examples of these age-related diseases include cardiovascular 
disease, cancer, arthritis, cataracts, osteoporosis, type 2 diabetes mellitus, hypertension, 
Alzheimer and dementia (WHO, 2012). Even though the incidence of all these diseases 
increases with age, the most common causes of death worldwide are cancer and cardio-
vascular disease (Figure 1.3) and the fraction of deaths attributable to these two disease 
is expected to increase in the next 10-20 years. Therefore, the main focus will be on 
these two diseases from here on. 
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Figure 1.3: Causes of death worldwide 
Nowadays, cancer and atherosclerosis are the most common cause of death in the world and this 
number is expected to increase in the next 10-20 years. This figure is adapted from Cannon et al  
(Cannon, 2013). 
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1.2.1 Cancer 
Cancer is a process in which cells divide and grow uncontrollably and so 
forming malignant tumours. Cancer arises from a stepwise accumulation of genetic  and 
epigenetic changes that allow neoplastic cells to escape from the homeostatic 
mechanisms that govern normal cell proliferation. In humans, it has been suggested that 
at least four to six mutations are required to reach this state (Hahn, 2002).  
Acquisition of several types of molecular alterations is necessary to drive a population 
of normal cells to become a cancer. These alterations include resisting cell death, 
sustaining proliferative signalling, evading growth suppressors, activating invasion and 
metastasis, enabling replicative immortality, inducing angiogenesis, obtaining the 
capability to reprogramming cellular metabolism and evading immunological 
destruction (Hanahan, 2011). When a single cell accumulates a number of these 
alterations, usually over a time span of several years, the cells can escape from most 
restraints on proliferation. The cell and its descendant can than develop additional 
alterations and accumulate in increasingly large numbers, forming a population that 
consists mostly of these abnormal cells, which are leading to a tumour formation, which 
consists of cells with diverse phenotypes.  
 
1.2.1.1 Haematopoietic malignancies 
Blood cancers can occur at all ages, but the majority of cases are observed in 
adults. In fact, 94% of cases diagnosed in the UK every year are adults (LLR, 2013).  
There are a number of different types of malignancy that occur in the 
haematopoietic system, although the majority can be defined as either types of 
leukaemia or lymphoma. Leukaemia, is a cancer of the tissue in the bone marrow and 
lymph nodes that manufacture blood cells. It is characterized by the excessive 
accumulation of leukocytes, or white blood cells. Leukaemias are mainly divided into 
four subgroups: acute lymphoblastic leukaemia (ALL), acute myeloid leukaemia 
(AML), chronic lymphoblastic leukaemia (CLL) and chronic myeloid leukaemia (CML) 
and these types differ substantially in their cellular origin and clinical behaviour. The 
acute leukaemias are characterized by a rapid increase in the numbers of immature cells 
(known as blasts), while the chronic leukaemias are characterized by the excessive 
build-up of relatively mature cells (Sawyers, 1999).  
The leukaemic transformation can occur at different points during 
haematopoietic differentiation. All the blood cells derive from the same pool of 
haematopoietic stem cells produced in the bone marrow and are then differentiated into 
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either the lymphoid stem cell pool or the myeloid stem cell pool. The lymphoid stem 
cells then give rise to the NK cells, T-lymphocytes and B-lymphocytes, while the 
myeloid stem cells give rise to the monocytes, erythrocytes, and granulocytes. The 
leukaemic transformation that leads to lymphoid leukaemias occur in the lymphoid 
precursors and as a result, can occur in both the B-lymphocyte and the T-lymphocyte 
lineages. Even though the lymphoid leukaemias have been related to age, CLL is largely 
found in adults over the age of 50 and the incidence of ALL rises after the age of 60 
(Frei, 1964), 60% of all ALL cases diagnosed are children under the age of 5, making it 
the most common form of cancer in children (LLR, 2013).  
AML is a disease that is caused by hyperproliferation of myeloid progenitor cells and 
the resulting leukaemia can have features of granulocytes, monocytes and/or the 
erythroid cells and megakaryocytes or more closely resemble immature progenitor cells.  
This disease can occur in children, although more rarely than ALL, and is much more 
common in adulthood, showing an exponential rise in incidence after the age of 40 
(Frei, 1964).  
The median age of CML onset is 45 to 55 years. CML is a clonal myeloproliferative 
disorder that is characterized by the presence of a BRC-ABL fusion, which causes a 
deregulated activity in the haematopoietic stem cell population, resulting in the over-
production of mature myeloid cells. In the blast crisis phase, CML is characterised by a 
major clonal expansion of immature progenitors, which have either myeloid or 
lymphoid features (Skorski, 2012; Sawyers, 1999).  
 
1.2.2 Cardiovascular diseases 
Cardiovascular diseases (CVDs) are pathologies of the heart, blood vessels and 
the vascular system of the brain. According to the WHO, CVDs are one of the leading 
causes of death and disability in the world population (WHO, 2011). Atherosclerosis is 
the progressive process underlying most cardiovascular diseases. Atherosclerosis 
involves the formation in the arteries of atherosclerotic plaques, which are characterized 
by inflammation, lipid accumulation, cell death and fibrosis. These lesions are a 
heterogeneous mixture of cells, predominantly vascular smooth muscle cells, 
lymphocytes, macrophages and extracellular lipids, collagen and matrix. The release of 
growth factors and inflammatory cytokines from these various cell types promotes 
further accumulation of inflammatory cells and deposition of extracellular matrix 
components causing the lesion to develop into an advanced plaque and causing the inner 
layer of the artery wall to thicken (Ross, 1993). This results in a reduction of the artery's 
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diameter and a decrease in blood flow and oxygen delivery. When this plaque raptures 
or cracks open, the sudden formation of a blood clot can cause thrombosis. 
Atherosclerosis can lead to myocardial infarction and heart failure if the blood flow to 
the heart is blocked and in the arteries that perfuse the brain it can cause ischaemic 
stroke and transient ischaemic attacks. In other arterial branches, atherosclerosis can 
results in renal impairment, hypertension, abdominal aortic aneurysms and critical limb 
ischaemia (Oxford University Press., 2010). Results from Olivetti et al suggested that 
ageing of the human heart is characterized by myocyte loss, reactive myocyte cellular 
hypertrophy and reduced ventricular mass and that these processes that may underlie the 
cause of myocardial dysfunction with age (Olivetti, 1991). Several other studies have 
observed that with age, left ventricular stiffness and vascular and ventricle wall 
thickness increases. At the same time arterial compliance, endothelial function and 
ventricular contractility decline with age (Arbab-Zadeh, 2004; Lakatta, 2003). These 
observations indicate that cardiac functions decrease with age, leading to an increased 
risk of cardiac dysfunction with age. 
 
1.2.3 Molecular pathways involved in ageing and age-related diseases 
Identifying the underlying molecular changes that contribute to ageing and to the 
development of these diseases related to age will be critical for improving health 
outcome for elderly patients and also in under-pinning potential preventative strategies. 
Different molecular pathways of haematopoietic cell ageing have been linked to age-
associated changes on the molecular level and these same pathways have been shown to 
play a role in the development of the age-related diseases cancer and cardiovascular 
disease.  
 
1.2.3.1 Cell signalling pathways associated with ageing 
In most cases, the longevity response is under active control by specific 
regulatory proteins and with age this protein homeostasis declines and damage 
accumulates (Kenyon, 2010). These changes lead to a functional decline of the 
haematopoietic stem cells (HSCs) with an increasing age. Several molecular pathways 
have been linked to these age-related changes in the haematopoietic system.  
The first molecular pathway is the phosphoinositide 3-kinase (PI3K) pathway, 
which is one of the major pathways modulating cell survival, cell growth, proliferation, 
metabolism and angiogenesis (Figure 1.4). One of the components of this pathway is the 
mammalian target of rapamycin (mTOR). Recently, it has been shown that differential 
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expression of in vivo mTOR signalling is associated with human ageing (Harries, 2012). 
The expression patterns as observed in human studies are similar to the expression 
patterns as observed in mice studies, where was shown that an increase in mTOR 
signalling is sufficient to cause premature ageing of HSCs in young mice (Chen, 2009). 
Age-associated changes have been observed in other components of the PI3K pathway 
in rat studies; the Forkhead box protein O (FoxO) showed age-induced decreases in the 
nuclear binding activity and also sirtuin 1 deacetylase decreased with age (Kim, 2012).  
The second molecular pathway of age-related changes on the molecular levels is 
the cellular mortality pathway. Several studies have shown a link between senescence 
and accelerated ageing (Figure 1.5). For example, a study in mice showed that the 
induction of senescence, triggered by p53 deficiency, leads to an accelerated aging 
phenotype (Keyes, 2005). Expression of p16
INK4a
 and Ink4a/Arf were shown to correlate 
in vivo with impaired proliferation and failure of HSCs (Krishnamurthy, 2004). Both 
p16
Ink4a
 and p19
Arf
 (one of the parts of Ink4a/Arf) have been implicated as downstream 
effectors of BMI-1 expression, which was shown to be involved in the control of 
proliferation and efficient self-renewing cell divisions of adult HSCs (Park, 2003). 
Indeed, BMI-1 was found to be much more expressed in young individuals compared to 
older subjects in keratinocytes and the age-related increase of p16
INK4a
 expression in 
primary human keratinocytes could be principally attributed to the modulation of BMI-1 
levels (Cordisco, 2010).  
The third molecular pathway that is linked to age-associated changes is the DNA 
repair pathway (Figure 1.6). Rossi et al showed that genetic deficiencies in telomere 
maintenance, nucleotide excision repair (NER) and non-homologous end-joining 
(NHEJ) intrinsically diminish long-term reconstituting-HSC function in an age-
dependent manner under conditions of stress. Rudolph et al showed a diminished 
capacity of the aged telomerase-deficient mice to respond to a stress. These results 
indicate that DNA damage may underlie the reduced capacity of stem cells to mediate a 
return to homeostasis after exposure to injury or stress (Rossi, 2007; Rudolph, 1999). 
 
 
 19 
 
 
 
Figure 1.4: The PI3K pathway 
A simplified version of the PI3K pathway shows the of this pathway in  protein synthesis, cell 
survival, cell proliferation, glucose metabolism, etcetera (Cellsignal, 2011). 
 
 
 
 
 
Figure 1.5: The cellular mortality pathway 
Several proteins are involved in the cellular mortality pathway, including p19, p16, p53, p21 
and Rb. 
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Figure 1.6: The DNA repair pathway 
Several DNA repair mechanisms are known. These include base excision repair (BER), 
Nucleotide excision repair (NER), recombinational repair, which includes both homologous 
recombination (HR) and non-homologous end-joining (NHEJ) and mismatch repair (MMR) 
(Jeppesen, 2011). 
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1.2.3.2 Cell signalling pathways associated with age-related diseases 
The pathways that are involved in ageing have also been implicated in the 
development of both cancer and cardiovascular diseases. With an increasing age, DNA 
damage accumulates and therefore a properly established DNA damage response 
network is necessary. If the damage is too extensive to be repaired, the network can 
trigger the onset of senescence or cell death to eliminate cells. When the DNA remains 
unrepaired this can lead to the development of cancer (Signer, 2013). Unsuccessful 
DNA repair can also result in an accumulation of both nuclear and mitochondrial DNA 
damage. These affected cells undergo senescence or apoptosis and secrete 
proinflammatory cytokines, causing a build-up of atherosclerotic plaque, leading to 
cardiovascular diseases (Wang, 2012).  
Aging-associated telomere shortening can contribute to the evolution of genome 
instability and cancer formation by inducing chromosome end resection, fusions, and 
breakage. Transient telomere dysfunction has been shown to increase cancer initiation 
and to promote the development of malignant tumours (Begus-Nahrmann, 2012) and 
deregulation of downstream transcription factors in the PI3K/Akt signalling pathway, 
such as RUNX2, mTORC1 and mTORC2, have also been indicated to contribute to 
tumorigenesis (Pande, 2013; Gulhati, 2011). This telomere shortening is also associated 
with increased levels of cellular senescence, which can facilitate heart failure. However, 
it is not clear whether short telomere length directly contributes to the development and 
progression of heart failure, or if the underlying cause of heart failure lead to 
accelerated telomere shortening (Wong, 2010). And finally, proteins involved in the 
cellular mortality pathway of ageing, such as p53 and p16
Ink4a
,
 
are known to function as 
tumour suppressor genes (Nobori, 1994). 
 
1.2.4 Epigenetics changes associated with ageing and age-related diseases 
Epigenetic changes have been observed during normal ageing and during the 
development of several age-related diseases. It may therefore be one of the key players 
in contributing to the development of these diseases related to ageing. 
 
1.2.4.1 Epigenetic changes associated with ageing 
Alterations in the patterns of DNA methylation are one of the hallmarks of ageing 
(Mathers, 2006). These changes include reduced levels of global DNA methylation 
across the genome, in conjunction with local areas of hypermethylation, often centring 
on promoter associated CpG islands. Furthermore, DNA methylation levels have been 
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observed to change with age in multiple tissue types in both mice and human studies 
(Wilson, 1983; Maegawa; Teschendorff; Bell, 2012; Issa, 1994), implying that altered 
patterns of methylation are an inevitable consequence of ageing in mammalian cells. 
The exact timing of these changes in methylation, and the biological driving forces 
behind them, remains unclear, but several human and animal studies have suggested 
that it is not a process solely associated with old age, but that it is an on-going process 
across the life-course (Bell, 2012; Takasugi). A recent study by  Teschendorff et al 
indicated that increased levels of DNA methylation in promoter regions are steadily 
acquired during the life-course (Teschendorff) and it has been observed by Talens et al 
that epigenetic variation in the population also increases gradually with age. The rate at 
which these changes occurred differed between different loci and these changes can be 
substantial at loci regulating transcription of nearby genes (Talens, 2012). While several 
studies reported that regions near gene promoters become hypermethylated with age, 
several repetitive sequences lose methylation with increasing age, such as the Alu 
elements (Bollati, 2009), Line-1 (Zhu, 2012) and HERV-K (Jintaridth). Even though 
age-related methylation changes are observed in many tissues, patterns of DNA 
methylation are tissue specific (Davies, 2012), and during ageing, individual genes 
acquire differential methylation patterns in different tissue-types (Maegawa; Thompson, 
2010). Inter-individual changes in DNA methylation was shown to have some degree in 
familial clustering, indicative of a genetic component (Bjornsson, 2008), while another 
study in monozygotic twins, genetically identical individuals, showed that an increase in 
epigenetic differences was observed between twin pairs with age in different tissues 
(Fraga, 2005). Talens et al showed that an increasing discordance in epigenetic 
differences of monozygotic twins occurred during ageing (Talens, 2012) and in the 
study of Gordon et al, monozygotic twins were shown to exhibit a range of within-pair 
methylation differences at birth, although they showed discordance levels that were 
generally lower than those seen in dizygotic twins (Gordon, 2012). These observations 
suggest that external and/or internal factors can have an impact by altering the 
epigenetic modifications, and that this is not solely relying on genetic information (this 
section was written as part of a review (van Otterdijk, 2013)). The increased global 
epigenetic differences with age that was observed in the study of Fraga et al was not 
observed in another monozygotic twin study. In this study, a general change with age in 
genome-wide methylation was not observed. However, they did identify a subset of loci 
to be highly correlated with age, which was enriched for genes known to influence age-
related diseases, mainly cardiovascular and neurological diseases (Bocklandt).   
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Besides epigenetic changes, age-related changes in histone modifications have 
also been observed. In mammals, H3K27me3 regulators play important roles in stem 
cell aging. BMI1, a member of the mammalian H3K27me3 PRC1, is necessary for the 
self-renewal of adult stem cells, in large part through repression of the 
p16INK4a/p19ARF locus (Figure 1.5). Perturbations in H3K27me3 and H3K4me3 
regulators both result in defects in stem cell proliferation, suggesting that a delicate 
balance between activation and repression of distinct sets of target genes is required 
during the stem cell ageing process (Han, 2012). Genes that harbor both the H3Kme3 
and H3K27me3 histone marks, the so called bivalent chromatin domains, were shown 
to be highly enriched targets for preferential methylation in both ageing and cancer 
(Rakyan). 
 
1.2.4.2 Epigenetic changes associated with cancer 
During cancer development, reduced levels of global DNA methylation is 
observed, together with hypermethylation of some CpG islands in gene promoters 
(Gama-Sosa, 1983). These changes in methylation of promoters may mimic the effect 
of mutations of various tumour suppressor genes or proto-oncogenes and promoter 
hypermethylation leads to the transcriptional gene silencing. Hypomethylation of 
regulatory DNA sequences in the genome can activate the transcription of proto-
oncogenes, retrotransposons and genes encoding proteins involved in genomic 
instability and malignant cell metastasis. In this way, both hypermethylation and 
hypomethylation can play an instrumental role in cancer development (Luczak, 2006). 
Hypermethylation is frequently observed in the same genes that are often 
mutated in familial cancers, emphasising their causal importance in tumorigenesis. For 
example, loss of function of DNA MMRs, including MLH1, are causal for hereditary 
nonpolyposis colorectal cancer (HNPCC) (Crepin, 2012), while in sporadic colorectal 
cancer, loss of microsatellite instability (MSI)(an effect of MMR) is due to 
hypermethylation of MLH1 (Wheeler, 2000). Another example is the congenital BRCA1 
mutation, which is a cause of breast and ovarian cancer. It is the same gene however, 
that becomes frequently hypermethylated in sporadic breast and ovarian cancers (Bal, 
2012; Press, 2008). In some cases, frequent hypermethylation of genes can be used to 
identify novel tumour suppressor genes, as was the case for RASSF1 (Dammann, 2001), 
HACE1 (Kucuk, 2012), and TWIST2 (Thathia, 2012). Hypermethylation of tumour 
suppressor genes is a feature of several cancers, including the p15 gene in leukaemia 
(Wong, 2000), the Rb gene in retinoblastoma (Sakai, 1991), and the VHL gene in renal 
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tumours (Prowse, 1997). On the other hand, hypomethylation was oberved in several 
cancers in tumour promoting or metastasis promoting genes, such as the uPA gene in 
breast cancer (Pakneshan, 2004) and the MAGEB2 gene in head and neck squamous cell 
carcinomas (Pattani, 2012) (this section was written as part of a review (van Otterdijk, 
2013)).   
 
1.2.4.3 Epigenetic changes associated with cardiovascular disease  
Changes in methylation patterns have also been observed during cardiovascular 
diseases and the genes affected by changes in their methylation patterns are thought to 
be involved in lipid oxidation, inhibition of endothelial cell migration and formation, 
the control of cell proliferation and angiogenesis (Friso, 2012; Hiltunen, 2002; 
Movassagh; Post, 1999). Gene expression is dysregulated in heart failure, and it is 
hypothesized that a subset of this connecting end-stage disease with different etiologies 
may be explained by differential DNA methylation, together with other epigenetic 
mechanisms. The interaction between histone deacetylation and DNA methylation in 
myocardial disease will be particularly important to understand, since the role of HDAC 
in cardiac hypertrophy and heart failure has already been established (Gallo, 2008). A 
global DNA hypo- and hypermethylation has been observed in atherosclerotic lesions 
and lesion development (Hiltunen, 2003). Hypomethylation of satellite repetitive 
sequences was observed in diseased hearts compared to healthy hearts  (Haider, 2012) 
and genomic hypomethylation was observed in human atherosclerotic lesions compared 
to healthy arteries and in proliferating smooth muscle cells in vitro and in rabbits in vivo 
(Hiltunen, 2002). Several genes were reported to become hypomethylated in 
cardiovascular diseases. For example, hypomethylation of  ALOX15 and F7, genes that 
are involved in lipid oxidation, were observed in atherosclerotic plaques and in the 
venous blood of patients suffering from a coronary atherosclerotic disease (CAD), in the 
absence of a -323del/ins polymorphism (Hiltunen, 2002; Friso, 2012). Hypomethylation 
of AMOTL2, a gene involved in the inhibition of endothelial cell migration and 
formation, was observed in the left ventricular of end-stage heart failure patients 
compared to healthy controls (Movassagh). Besides hypomethylation, several genes 
were described to become hypermethylated in cardiovascular diseases. For example, as 
ERα, a gene involved in the control of cell proliferation, was observed to become 
hypermethylated in coronary atheroma’s (Post, 1999). In the left ventricular of end-
stage heart failure patients, hypermethylation of PECAM1 and ARHGAP24 was 
observed, genes involved in angiogenesis and tube formation (Movassagh).  
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The research of Chang et al showed that homocysteine might promote the methylation 
of the FGF2 promoter and in this way, repress the FGF2 transcriptional activity in 
arterial endothelial cell proliferation, migration and tube formation (Chang, 2008). 
Elevated plasma homocysteine levels are a known potential risk factor for vascular 
diseases. Homocysteine might also change DNA methylation levels in other functional 
relevant genes, such as iNOS, repressing its regulation of blood vessel function (Yideng, 
2008) and APOE, a gene that is crucial for the hepatic clearance of remnant lipoprotein 
(Yi-Deng, 2007).  
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2.1 Project hypothesis 
In healthy individuals, CpG islands remain mostly methylation free, whereas 
most of the non-island associated CpG sites in the bulk of the genome are methylated 
(Cooper, 1989). Even though patterns of methylation are inherited through cell 
divisions, the copying of methylation patterns from parental to daughter strand is not 
100% efficient and methylation errors accumulate (Ushijima, 2003). The rate at which 
these errors are accumulated increases with age and during disease development. The 
changes in DNA methylation patterns observed during ageing are reminiscent of the 
methylation alterations seen during the development of cancer and potentially other age-
related diseases. This includes loss of DNA methylation at the genome wide level in 
combination with gains in methylation levels in CpG islands in or near gene promoters. 
This raises the possibility that the acquisition of methylation changes during healthy 
ageing and during the development of age related diseases might be linked to each 
other. The methylation patterns of functionally important promoter regions are reported 
to be more stable as opposed to non-promoter regions and the corresponding genes 
might be involved in longevity (Bell, 2012; Kaminsky, 2009). Global DNA methylation 
levels were reported to correlate negatively with frailty measurements in individuals 
over 65 years of age (Bellizzi). Indeed, there is some evidence that genes that are 
differentially methylated during normal ageing and those abnormally methylated in 
diseased tissue show a degree of overlap, suggesting that age related changes in DNA 
methylation may underlie the methylation defects reported in some age-related diseases. 
Teschendorff et al showed that there was an overlap between the genes that showed 
age-related methylation changes and genes that were reported previously to be 
methylated in cancers, such as the genes TP73 and SFRP1, two genes that were shown 
to become methylated in different types of cancers  (Teschendorff). Rakyan et al 
showed a significant correlation specifically between bivalent chromatin domain DMRs 
that showed age-related hypermethylation and aberrantly methylated promoters in 
primary AML (Rakyan).  
Several hypothesis can be put forward to explain the high frequency with which 
methylation abnormalities are seen during cancer development. The first hypothesis 
describes the changes in methylation levels as events that occur during the process of 
clonal expansion, perhaps because the diseased cells have a reduced capacity for stably 
maintaining their epigenome. This suggests that methylation changes are not the driving 
force behind the development of the disease, but rather a side effect of disease 
development. Many of these methylation changes would likely represent “passengers”, 
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with no direct role in the pathology of the disease, although some would likely provide 
a growth or survival advantage and thus be selected for during disease progression. A 
second hypothesis states that diseases develop in cells that are pre-primed by aberrant 
patterns of DNA methylation, similar to the epigenetic progenitor origin of human 
cancer, proposed by Feinberg et al (Feinberg, 2006). Thus altered patterns of 
methylation may pre-exist in a subset of apparently normal cells. If cancer driving 
mutations occur in a cell with a pre-existing methylation pattern, this cell can rapidly 
proliferate and produce diseases (Figure 2.1). This hypothesis is supported by the 
observation that methylation patterns are already present in apparently normal tissues 
from those at higher cancer risk (Belshaw, 2008) and in pre-cancerous tissues (Sproul, 
2012) and by the relatively ubiquitous nature of methylation changes in tumours, 
suggesting that alterations in DNA methylation must occur early in disease 
development.  
These two hypotheses are not mutually exclusive and both may have a role in cancer 
development.  
Furthermore, as discussed above, the altered methylation found in cancer shows 
clear similarities to the ageing related methylation that is seen in apparently healthy 
cells. One potential explanation for this would be that both age-related and cancer-
related DNA methylation changes might be driven by similar mechanisms, which is 
causing the similar patterns of altered methylation during cancer and ageing. If true, this 
hypothesis would suggest that the altered methylation identified in healthy individuals 
as they age would potentially have little or no role in the tumourigenic process. For 
example, the same lifestyle factors which influence the ageing process influence the risk 
of cancer and of other age-related diseases and modulate patterns of DNA methylation 
(Tapp, 2012; Mathers, 2010), but this does not have to happen in a causative manner. 
Alternatively, a second hypothesis would be that age-related DNA methylation may 
underlie the development of cancers, and possibly other age-related diseases. In this 
second hypothesis methylation is already present in apparently healthy individuals 
before the development of the disease and the disease then develops specifically or 
preferentially in cells with altered methylation patterns (Figure 2.1). Thus increasing 
accumulation of age related methylation changes would lead to increased risk of 
development of age related diseases. This hypothesis is supported by the observation 
that in CLL, global DNA methylation was shown to be relatively stable over time and 
similar within different CLL compartments (Cahill, 2012), suggesting that cancer cells 
are not necessarily highly methylation unstable and that continued methylation 
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instability is not necessary an intrinsic feature of cancer cells. Other evidence to support 
this hypothesis is that alterations in the DNA methylation levels are already observed in 
early stages of the disease (van Hoesel, 2013; Heuck, 2013). These observations suggest 
that methylation patterns must occur very early in cancer development and that cancer 
cells can stably maintain their methylation patterns (this section was written as part of a 
review (van Otterdijk, 2013)). 
Therefore this project was designed to study the potential for age-related 
changes in DNA methylation as a causative agent in the development of age-related 
diseases.  
 
 
 
 
 
 
 
 
 
Figure 2.1: The possible role of DNA methylation during disease development  
Three possible hypotheses can explain the role of DNA methylation in disease development; 
1A) Methylation changes are an effect of the clonal expansion of cells prior to the disease 
development, but it does not play a role in the development of the disease.  
1B) Methylation changes occur during the clonally expansion of cells that occur prior to 
disease development. The methylation events will then produce further growth 
advantages, promoting disease development. 
2) Methylation levels are already present in a subset of normal cells. Disease develops 
when these ‘methylation-primed’ cells clonally expand. 
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2.2 Project aims 
This project was designed to examine the link between methylation changes during 
normal ageing and during the development of age-related diseases. The primary focus 
of this study was to understand how abnormal methylation develops in and contributes 
to age-related diseases and to investigate the potential of altered DNA methylation in 
apparently normal cells as a significant factor in the development of the two most 
important age-related diseases, cancer (especially haematological malignancies) and 
heart disease. Specifically:  
 To investigate whether variations in DNA methylation levels at susceptible loci 
are age related both in terms of overall methylation levels and in terms of 
variability across the population and if genes exhibiting age related methylation 
changes are related to genes that exhibit aberrant methylation levels in acute 
lymphoblastic leukaemia. 
 To profile how methylation patterns are distributed among the different alleles in 
healthy individuals and how these patterns relate to methylation patterns 
observed in leukaemia patients. 
 To investigate whether genes which display cell type specific patterns of 
leukaemia methylation exhibit similar cell type specific methylation in normal 
cells and when during the differentiation process altered DNA methylation 
occurs. 
 To investigate whether methylation patterns in non-diseased cells from 
leukaemia patients exhibit aberrant patterns of DNA methylation.  
 To profile DNA methylation from atherosclerosis and HNPCC patients to 
determine if altered DNA methylation is a common feature of the disease, and to 
determine whether these genes are related to those targeted by methylation in 
ageing or in leukaemia. 
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3.1 Samples 
 
3.1.1 Sample collection 
 DNA was extracted from peripheral blood leukocytes (PBL) samples of 197 
healthy volunteers in 4 different age groups. The samples from the neonates (n=49) and 
young adults (17-42 years of age, with an average of 27.7 years, n=48) were collected 
as part of the North Cumbria Community Genetics Project (NCCGP) (Chase, 1998). 
The samples from the adults (50 years of age, n=50) were collected as part of the 
Newcastle Thousand families study (Pearce, 2009) and the samples from the older 
adults (85 years of age, n=50) were collected as part of the Newcastle 85
+
 study 
(Collerton, 2007). The DNA samples from the neonates and the young adults were 
child-mother pairs, and selected in such a way that all the samples included in this study 
were paired samples (Table 3.1). 
Peripheral blood samples were taken from healthy young adults (24-31 years of 
age, with an average of 27.6, n=10) and adults (43-60 years of age, with an average of 
51.6, n=8) to isolate out specific cell types. Cell types were isolated straight after the 
blood samples were taken. To isolate out stem cells and early progenitor cells, 
granulocyte-colony stimulating factor (G-CSF) mobilized CD34 peripheral blood cells 
were obtained from healthy young adults, via the Newcastle Haematology Biobank. 
These cells were stored in liquid nitrogen until further implication in medium 
containing 10% DMSO to prevent cell lysis and to allow cells to remain intact (Table 
3.2).  
PBL DNA was extracted from patients with ALL, in the age-range of 1-65 
years. The samples were taken at diagnosis and, where available, remission samples 
(between 1 and 4 per patient taken between 4 weeks and 2 years post diagnosis) and 
relapse samples were also obtained. The leukaemia samples were obtained via the 
Newcastle Haematology Biobank. From the patients with childhood ALL (1-17 years of 
age, with an average age of 3.14 years, n=24), 3 subsequently relapsed but they 
survived the disease. In the adult ALL patients group (21-65 years of age, with an 
average age of 45.46 years, n=30), 14 subsequently relapsed. Six patients were long 
time survivors (>5 years). Two of these long term survivors first went into relapse 
(Table 3.3). 
  PBL DNA was extracted from patients with HNPCC, also known as Lynch 
syndrome (age 28-65 years, with an average of 49 years, n=50). They were collected as 
part of the Concerted Action Polyp Prevention (CAPP) study (Table 3.3). 
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DNA was extracted from mononuclear cells (MNC), which were obtained from 
patients who suffered from a heart attack and who participated in the ‘Role of T-cells in 
Coronary Artery Disease’ study (age 42-74 years, with an average age of 58.26 years, 
n=55) (Table 3.3). 
All samples were selected at random and further patient details were not 
provided until after the analyses were performed 
 
 
 
 Neonates Young adults Adults Older adults 
Age (years) 
 
0 
 17 – 42 
(average 27.7) 
50 85 
Gestational 
age (weeks) 
35-42 
(average 39.6) 
Number of 
participants 
49 48 50 50 
Extra 
information 
Related to 
young adults 
(child). 
Related to the 
neonates 
(mother). 
Pregnant at 
time of blood 
collection 
  
Cohort NCCG Project NCCG Project 
Newcastle 
Thousand 
Families Study 
Newcastle 85+ 
Study 
Table 3.1: An overview of the age-related DNA methylation study population 
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 Young adults Adults G-CSF samples 
Age (years) 
24-31 
(average 27.6) 
43-60 
(51.6 average) 
24-33 
(average 26.2) 
DNA samples 
PBL 
MNC 
Lymphocytes 
B-lymphocytes 
 
Monocytes 
PBL 
MNC 
Lymphocytes 
B-lymphocytes 
T-lymphocytes 
Monocytes 
Granulocytes 
Stem- and early progenitor 
cells 
Early B-cell progenitors 
Stem- and early progenitor 
cells minus B-cell progenitors 
B-lymphocytes 
T-lymphocytes 
Monocytes 
Number of 
participants 
10 8 6 
Table 3.2: An overview of the cell type specific DNA methylation study population 
 
 
 
 
 
 
Childhood 
ALL patients 
Adult ALL 
patients 
HNPCC 
patients 
Heart disease 
patients 
Age (years) 
1-17 
(average 3.14) 
21-65 
(average 45.46) 
28-65 
(average 49) 
42-74 
(average 58.26) 
Number of 
patients 
24 30 50 55 
Source of DNA PBL PBL PBL MNC 
Cohort 
Newcastle 
Haematology 
Biobank 
Newcastle 
Haematology 
Biobank 
CAPP study 
Role of T-cells 
in Coronary 
Artery Disease 
Table 3.3: An overview of the age-related diseases study population 
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3.1.2 DNA extraction 
DNA was either extracted using a phenol/chloroform protocol, or using the 
Purelink
tm
 genomic DNA mini kit (Invitrogen). 
DNA was extracted from the healthy individuals and the different patient groups 
using the phenol/chloroform protocol.  340µl of Reagent B (Appendix A, Table A.1) 
was added to the cell pellet and resuspended. 100µl of 5M sodium perchlorate 
(Appendix A, Table A.1) was added and the sample was incubated at 37 ºC for 20 
minutes, followed by 65 ºC for 20 minutes. 440µl of phenol/440µl of chloroform was 
added to the tube. The tube was centrifuged for 10 minutes at full speed. Afterwards, the 
supernatant was transferred to a new tube, 880µl of chloroform was added to this tube 
and the tube was centrifuged for 10 minutes at full speed. Again, the supernatant was 
transferred to a new tube and the sample was precipitated by adding 2 volumes of cold 
100% ethanol. The tube was centrifuged for 10 minutes at full speed. After washing 
with 70% ethanol and a 5 minute spin in the centrifuge at full speed, the pellet was dried 
and resuspended in the appropriate volume of dH2O. All samples were stored at 4 ºC 
until further implication.  
  DNA was extracted from the sorted Lymphocytes, B-lymphocytes, T-
lymphocytes, Monocytes,  stem and progenitor cells, B-lymphocyte progenitors, and 
stem and progenitor cells – B-lymphocyte progenitors and the collected PBL and MNC 
cells from the same individuals, using the Purelink
tm
 genomic DNA mini kit 
(Invitrogen), according to manufactures protocol. The samples were stored at 4 ºC until 
further implication.  
Quantitation of DNA was performed using a NanoDrop® ND-1000 spectrophotometer 
which measures the absorbance of UV light at 260 nm passed through a 1μl aliquot of 
extracted DNA, and performs the necessary calculations according to the Beer Lambert 
Law to provide DNA concentration (in ng/μl). 
 
3.1.3 Cell type specific cell sorting 
B-lymphocytes, T-lymphocytes, monocytes and the stem and early progenitor 
cells were sorted using the dynabeads method. The cells were sorted from either MNCs, 
which were obtained after density gradient centrifugation using Ficoll-Hypaque 
(Biochrom
AG
); or from G-CSF mobilized CD34 peripheral blood cells. Neutrophils and 
granulocytes were isolated using density gradient centrifugation from PBL. 
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3.1.3.1 Isolation of mononuclear cells by gradient centrifugation 
A PBL sample was taken and collected in a tube treated with 
ethylenediaminetetraacetic acid (EDTA tube) (Invitrogen). The blood was diluted in 
phosphate-buffered saline (PBS) in a 1:1 ratio. Half the amount of the PBL-PBS 
solution of Bicoll separating solution (Biochrom
AG
) was added to a 50 ml tube and the 
PBL-PBS solution was carefully layered on top of the Bicoll. The tube was centrifuged 
at 700xG for 30 minutes at 4 ºC, after which five layers occurred in the falcon tube 
(Figure 3.1), including a layer of MNCs. The MNC interphase was carefully aspirated 
and transferred to a new tube. 1 ml of MNC was pelleted down and this pellet was 
stored at -80 ºC, to allow DNA isolation from MNCs. The rest of the MNCs were used 
for further sorting of specific cell types. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1: MNC cell isolation with density gradient centrifugation using Bicoll separating 
solution  
Treating peripheral blood with a density gradient centrifugation using Bicoll separating solution 
resulted in different layers of cell types; plasma with thrombocytes and PBS, a layer of MNC, a 
layer of Bicoll, a layer of granulocytes and cell-debris and a pellet of erythrocytes. 
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3.1.3.2 Cell-type specific cell isolation 
 Different cell types were sorted from MNCs or G-CSF mobilized cells, using the 
Invitrogen dynabeads methods. B-lymphocytes (CD19
+
 cells), T-lymphocytes (CD3
+
 
cells), Monocytes (CD14
+
 cells) and stem- and progenitor cells (CD34
+ 
cells) were 
isolated with this magnetic bead separation methods, which depends largely on the use 
of antibodies directed against cell surface ligands found specifically on the cell types of 
interest. This procedure  works in 3 steps; first, the beads will bind to the desired target 
cell, relying on the specific affinity of the ligand on the surface of the beads; secondly, 
the bead-cell complex will respond to a magnetic field, efficiently separating the bead-
cell complex from the rest of the sample and lastly; the bead-cell complex is released in 
a suitable volume for use in downstream applications (Invitrogen, 2010) (Figure 3.2:).  
 
 
 
 
 
 
 
 
 
   
 
Figure 3.2: Cell sorting using the dynabeads method 
The magnetic bead cell separation contains of 3 steps; the beads will bind to the desired target 
cells; the bead cell complex will respond to a magnetic field to separate the bead-cell complex 
from the rest of the cells; and afterwards, the cells can be released and used for downstream 
applications. 
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3.1.3.2.1 CD19, CD3 and CD14 isolation 
  The desired volume of CD19, CD14 and CD3 beads (Dynabeads CD19 pan B, 
Dynabeads CD14 or Dynabeads CD3, Invitrogen) was transferred into a tube (in our 
study 50µl of beads were used per sample). The beads were pre-washed by adding 1 ml 
of the cell type specific separation buffer (Appendix A, Table A.1) to the beads. The 
CD3 and CD14 beads required separation buffer 2, while for the CD19 isolation, 
separation buffer 1 was required. The tube was placed in a magnetic rack to pellet the 
beads, the supernatant was discarded and the washed beads were resuspended in the 
same volume of buffer as the initial volume of the beads.  
50µl of beads were added to the MNC sample and incubated for 20 min at 4 ºC 
on a rotator, rotating 20 rounds per minute (rpm). Afterwards the tube was placed in a 
magnetic rack. The supernatant was either transferred to another tube (the supernatant 
from the CD14 isolation contained mainly lymphocytes and was stored) or discarded. 
The beads-bound cells were washed 4 times by adding 1 ml of the cell type specific 
separation buffer. After each wash step, the tube was placed in a magnetic rack to pellet 
the beads and the supernatant was discarded.  
The supernatant from the CD14 isolation was pelleted down by centrifuging the sample 
at 500 x g for 8 minutes. All samples were stored, with the beads attached to the isolated 
cells, at -80 ºC until further implication. 
 
3.1.3.2.2 CD34 isolation 
 The ste m- and early progenitor cell were isolated during the CD34 dynabeads 
(Dynal CD34 progenitor cell selection system, Invitrogen). These beads could be 
detached after cell isolation, to allow the samples for further isolation into lineage 
specific progenitor cells. 
The desired amount of CD34 dynabeads was transferred to a tube (in this study 200µl of 
beads were used per sample).  The beads were pre-washed by adding 1 ml of separation 
buffer 1 (Appendix A, Table A.1) to the beads. The tube was placed in a magnetic rack 
to pellet the beads, the supernatant was discarded and the washed beads were 
resuspended in the same volume of separation buffer 1 as the initial volume of the 
beads.   
The G-CSF mobilized peripheral blood cells sample was defrosted, pelleted down to 
discard the freezing down media and resuspended carefully in the cell type specific 
separation buffer to prevent cell clumps. 200µl of beads were added to the sample and 
vortexed for 2-3 seconds. The sample was incubated for 30 minutes at 4 ºC on a rotator, 
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rotating 20 rpm. Afterwards, the tube was filled with 1 ml of cold separation buffer 1 
and mixed well by pipetting. The tube was placed in a magnetic rack and the 
supernatant discarded. The bead-bound cells were washed 3 times by adding 1.5 ml of 
separation buffer 1. After the last wash step, the bead-bound cells were resuspended in 
150µl of separation buffer 1. 50µl of this sample was collected and stored at -80 ºC until 
further implication, with the beads still attached to the cells. The other 100µl was used 
to detach the beads from the cells, allowing further isolations into lineage specific 
progenitor cells. To detach the beads, the bead-bound cells were resuspended in 100µl 
of DETACHaBEAD (Dynal CD34 progenitor cell selection system, Invitrogen) and 
incubated at room temperature for 45 minutes on a rotator, rotating 20 rpm. 1.5 ml of 
separation buffer 1 was added to the tube and the tube was vortexed for 2 seconds to 
enhance detachment of the beads from the cells. The tube was placed in a magnetic rack 
and the supernatant, containing the detached cells, was transferred into a fresh tube. To 
obtain the residual cells, the beads were washed 3 times by resuspending them in 500µl 
of separation buffer 1. All the collected supernatants were pooled together and washed 
with 10 ml of separation buffer 1 and the cells were centrifuged for 10 minutes at 4 ºC 
at 400xG to remove excess DETACHaBEAD.  
The cell pellet was resuspended in 1ml of separation buffer 1. To isolate out early B-cell 
progenitors, 50µl of CD19 beads (Dynabeads CD19 pan B) were added to the CD34+ 
cells  and the sample was treated  in the same fashion as described earlier in ‘3.1.3.2.1 
CD19, CD3 and CD14 isolation’. After this CD19 isolation, the supernatant was 
collected and stored, as this sample contains the stem-and early progenitor cells minus 
the early B-cell progenitors (CD34+CD19-). All the samples were stored at -80 ºC until 
further implication 
 
3.1.3.3 Isolation of granulocytes 
A PBL sample was taken from a healthy individual and collected in an EDTA 
tube (Invitrogen). Straight after the blood samples were taken, a gradient centrifugation 
was performed to isolate out the granulocytes. 
A red blood cell lysis was performed prior to the gradient centrifugation. The PBL 
sample was diluted 2:1 with a 6% Dextran solution (Dextran solution, Sigma) and 
mixed by inverting the tube 15 times. The PBL-Dextran mix was incubated at room 
temperature for 45 minutes, to allow the red blood cells to sediment. The supernatant 
with the leukocyte and platelet cell suspension was collected and transferred into a new 
falcon tube. This tube was centrifuged for 10 minutes at 300xG at 4 ºC to pellet the 
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leukocytes, but leaving the platelets in suspension. The leukocyte pellet was collected 
and resuspended in 1 ml of 1x PBS and 9 ml of dH2O. This mixture was incubated for 
15 seconds and then 1 ml of 10x PBS was added. The tube was centrifuged at 300xG 
for 10 minutes at 4 ºC, which resulted in a milky pellet formation at the bottom of the 
tube containing the leukocytes. This pellet was resuspended in 3 ml of 1x PBS. 
3 ml of Bicoll separating solution (Biochrom
AG
) was added to a new tube, and the PBS-
cell mixture was carefully layered on top of the Bicoll. The tube was centrifuged at 
700xG for 30 minutes at 4 ºC. The centrifugation step resulted in the formation of a 
pellet containing the granulocytes. This pellet was washed and stored at -80 ºC until 
further implication. 
 
3.1.3.4 Validation of cell isolations 
 The cell isolations were validated by assessing the expression of cell surface 
markers specific for the individual cell types in the various isolated cell populations, 
using either a quantitative Polymerase Chain Reaction (qPCR) to assess messenger 
RNA (mRNA) expression levels or by flow cytometry using antibodies directed against 
the cell surface markers. 
 
3.1.3.4.1 Validation of cell isolations by qPCR 
To validate the cell isolation for the T-lymphocytes, B-lymphocytes and 
monocytes, RNA was extracted, from the different cell types. Complementary DNA 
(cDNA) was synthesised and expression of cell surface markers was measured using a 
qPCR.  This method was used to validate the cell isolations, because the CD19, CD3 
and CD14 beads used in this study could not be detached from the cells after isolation. 
These beads are able to respond to the different antibodies used for flow cytometry, 
which are supposed to be directed against specific cell surface makers. This makes it not 
possible to perform the validation of the isolation of these specific cell types by flow 
cytometry and as a result, the validations of these cell isolations were performed using 
the qPCR technique. 
 
3.1.3.4.1.1 RNA isolation 
The beads-bound cell pellet was resuspended in 1 ml of Trizol (Invitrogen) and 
incubated for 5 minutes at 30 ºC. 0.2 ml of chloroform was added to the sample, shaken 
by inverting the tube by hand for 15 seconds and incubated for 3 minutes at 30 ºC. After 
incubation, the tube centrifuged at 12,000xG for 15 minutes at 4 ºC. The aqueous phase 
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was transferred to a fresh tube and 0.5 ml of isopropanol was added to the sample. The 
sample was incubated for 10 minutes at 30 ºC and centrifuged at 4 ºC, at 12,000xG for 
20 minutes. The isopropanol was removed and the pellet was washed by adding 1 ml of 
75% ethanol to the cell pellet. The sample was vortexed and centrifuged at 7,500xG for 
5 minutes at 4 ºC. The ethanol was removed and the pellet air dried for 10 minutes. 20µl 
of dH2O, free of desoxyribonuclease (DNAse) and ribonuclease (RNAse), was added to 
the pellet followed by 10 minutes incubation at 57 ºC. After this incubation, the RNA 
sample was put on ice directly and stored at -80 ºC. 
  
3.1.3.4.1.2 cDNA extraction 
cDNA extraction was performed using the Superscript
®
 III Cells Direct cDNA 
Synthesis System kit (Invitrogen), following the manufacturing protocol: between 0.62 
and 2.33µg of total RNA, 1µl OLIGODT (500 µg/µl) and 1µl dNTP (10 mM) were 
mixed in a PCR tube, and filled up to a total of 12µl with dH2O. This mixture was 
incubated for 5 minutes at 65 ºC. 4µl 5x first strand buffer (5xRT), 2µl DTT (0.1M) and 
1µl of RNAse out (40 units/µl) was added to the tube and mixed well by pipetting. This 
mixture was incubated for 2 minutes at 42 ºC and 1µl of superscript III RT (200 
units/µl) was added to mixture and again incubated for 50 minutes at 42 ºC. The 
reaction was inactivated by incubating the sample for 15 minutes at 70 ºC. 1µl of RNAh 
(40 units/µl) was added and again incubated for 20 minutes at 37 ºC. After this 
incubation step, the cDNA sample was stored at -20 ºC until further implication. 
 
3.1.3.4.1.3 qPCR  
During a qPCR, the progress of the Polymerase Chain Reaction (PCR) can be 
monitored as it occurs and data is collected throughout the PCR process. The qPCR 
technique is similar to traditional PCR, with the major difference being that with qPCR 
the amount of PCR product is measured after each round of amplification while with 
traditional PCR, the amount of PCR product is only measured at the end point of 
amplification. The concept of the qPCR is that amplification products are measured as 
they are produced using a fluorescent label. The fluorescence signal is directly 
proportional to DNA concentration over a broad range and the linear correlations 
between PCR product and fluorescence intensity is used to calculate the amount of 
template present at the beginning of the reaction (Sigma-Aldrich, 2008). 
This technique allowed us to test the expression of the different cell surface 
markers in our sorted cell types. To validate the cell sort, the isolated cell types were 
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tested for expression of the cell-surface markers; CD19 (B lymphocytes); CD3 (T 
lymphocytes); CD14 (Monocytes); and GAPDH (control) (Table 3.4).  
All qPCR amplifications were carried out in a volume of 10µl, using 0.5µl of 
cDNA, 150 ng of both the forward and the reverse primer (|Eurofins MWG 
Operon)(Table 3.4), 5µl SYBRgreen (Sigma-Aldrich) and 4.25µl dH2O. All samples 
were done in triplicates.  
PCR was performed with thermocycling conditions of 15 min on 95 ºC, followed by 40 
cycles of 30 sec on 95 ºC, 30 seconds on the gene specific annealing temperature (Table 
3.4), 30 seconds on 72 ºC and 30 seconds on the gene specific reading temperature 
(Table 3.4), followed by 30 seconds on 95 ºC, 15 seconds on 76 ºC and 15 seconds on 
95 ºC (Taqman 7900, Applied Biosystems). Specific cell lines, each known to express 
one of the individual cell surface markers, were used as controls and one of the positive 
cell lines was used to produce a standard curve. These cell lines were; HL60 (a 
promyelocytic cell line), Molt4 (a T lymphoblastic cell line), Lama84 (a chronic 
myelocytic cell line), Ky01 (a chronic myelocytic cell line) and Nalm6 (a pre B 
lymphocyte cell line).  
 
 
 
 
 
 
 Forward primer Reverse primer 
Annealing 
temperature 
(◦C) 
Reading 
temperature 
(◦C) 
CD3 
5’-CTTCTCTCGCAAG 
TGAGC-3’ 
5’-CAGACATTACAAG 
ACTGGACC-3’ 
61 78 
CD14 
5’-GAAGACTTATCG 
ACCATGGAG-3’ 
5’-GCAACTTCTCCGA 
ACCTCA-3’ 
55 82 
CD19 
5’-ACTGCTCGGCCAG 
TACTATG-3’ 
5-‘GAAAGCGAATGA 
CTGACCCC-3’ 
63 80 
GAPDH 
5′-GTCAAGCTCATT 
TCCTGGTATG-3′ 
5′-GTCTACATGGCAA 
CTGTGAG-3′ 
57 80 
Table 3.4: Primers used for qPCR 
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3.1.3.4.2 Validation of cell isolation by flow cytometry 
The stem and progenitor cell isolation was validated by flow cytometry 
(FACSCanto, BD Bioscience). Flow cytometry allows us to simultaneously measure 
and analyse multiple physical characteristics of single cells, as they flow through a 
beam of light. An antibody, specific for the specific cell type and with a known 
fluorescence marker, is added to the cells before the cells run through the flow 
cytometer. This will distinguish the cell surface marker positive cells, from the negative 
cells.  
To validate our cell sort for CD34+ cells, a CD34 antibody with the PE 
fluorescence marker (BD Biosciences) was used. 10,000 events of live cells were 
analysed for the marker specificity. When the sorted samples consisted of a minimum of 
90 % positive cells, the sort was marked as successful and DNA was isolated from the 
samples in that specific sort. 
  
3.2 Methylation analysis 
Several methods were used to analyse the methylation levels in our sample set; 
pyosequencing, a method to accurately measure methylation levels in a small number of 
CpG sites per individual; and bisulphite sequencing, to investigate the distribution of 
methylation within an individual. 
 
3.2.1 Preparing for methylation analysis 
Prior to the methylation analyses, bisulphite modification had to be performed to 
distinguish between the methylated and unmethylated cytosines, gene specific primers 
had to be designed and PCRs had to be performed.  
 
3.2.1.1 Sodium bisulphite modification 
The bisulphite-based DNA modification is used to discriminate between 
cytosine and methylated cytosine. DNA is treated with bisulphite salt to convert 
cytosine residues to uracil, while methylated cytosines are protected from modification 
and thus remain as cytosine (Figure 3.3). This converts the methylation difference into a 
sequence difference, which can then be assessed by various PCR based methods or 
directly assessed by sequencing. 
200ng of DNA was modified using the Methylation
TM
 One-Step DNA 
Modification Kit (Epigentek), following the manufacturing protocol; 200ng of DNA 
was added to a PCR tube and mixed with 110µl DNA modification solution. The tubes 
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were placed in a PCR machine with thermocycling conditions of 99°C for 6 minutes, 
followed by 65°C for 90 minutes. 300µl of modified DNA capture solution was added 
to a spin column together with the sample from the previous step. The column was 
centrifuged for 20 seconds at 12,000 rpm and the flowthrough was discarded. The 
columns were washed 3 times; the first washing step was conducted by adding 200µl of 
modified cleaning solution to the column, followed by two washing round with 200µl 
of 90% ethanol. After each round, the tube was centrifuged for 20 seconds at 12,000 
rpm and the flow through was discarded. After these wash steps, all samples were 
eluted in 15µl of elution buffer and centrifuged for 20 seconds at 12,000 rpm. After the 
modification, the samples were stored at -20 ºC. 
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Figure 3.3: Bisulphite modification of DNA 
DNA was treated with bisulphite salt. The methylated cytosines remain cytosines, while the 
unmethylated cytosine residues are converted to uracil in a single-stranded DNA. After PCR 
amplification, uracil is converted in tymine. 
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3.2.1.2 Primer design 
Gene sequences were obtained from GenBank entry on NCBI and the region 
surrounding the TSS was examined for the presence of CpG islands, by searching the 
sequence for high numbers of CpG sites. Primers, specific for sodium bisulphite 
modified DNA were designed, using the primer designing programme ‘PSQ assay’ 
(Biotage). This designed forward and reverse primers for initial amplification and a 
sequencing primer for use in the final pyrosequencing reaction (Table 3.5). The 
sequencing primer was designed to be placed between the forward and the reverse 
primers. One of these primers was designed with a biotin label to allow strand 
separation during pyrosequencing. All primers were designed as such that all primers 
had penalty levels lower than 50, indicated by the PSQ assay software, for potential 
mispriming sites for all the different primers, potential homopolymer sequences 
adjacent to the target sites, the presence of possible template loops at the amplicon, etc. 
(for a full list of genes examined in this study, see Appendix A, Table A.2). 
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Table 3.5: The primers used for the pyrosequencing assays 
All primers were designed around the TSS of the gene. The primers for IGF2 were designed for the DMR0, upstream of exon 2.
 Forward primer Reverse primer Sequencing primer CpG sites 
Distance from 
TSS (bp) 
TWIST2 5‘-AACAACTATTTAACAACCCAA 
CCCAAC-3’ 
5’-GGGYGAGTTGGAGTTTTTTTT 
TATGG-3’ 
5’-CAAAACCTTTCCAACAAC-3’ 4 -26 → +208 
TUSC3 5’-GAATAGGATGTTTTGTTAGTT-3’ 5’-TAACTAAACCCTCCCAAATA-3’ 5’-CCAAATAACAACCACTTTAC-3’ 6 +25 → +116 
HOXD4 5’-GAAATTAATGGTTATGAGT-3’ 5’-CCCRAAACTAAAAATCTA-3’ 5-‘ATTTGTAGGGYGGTTATTTAGG 
YGAG-3’ 
5 +242 → +398 
EphA10 5’-ATTATTTATGGGAATTAATTAT 
TAG-3’ 
5’-CCCACCAATTAAATATTC-3’ 5’-TATTTATGGGAATTAATTATTAG 
GTA-3’ 
3 +28 → +143 
HAND2 5’-CCAAATTTTAATTATCTTATA-3’ 5’-GGATTTTTTAGTAAGATTT-3’ 5’-ATTTTATTACCCAAAACTC-3’ 4 -29 → +185 
HOXA5 5’-CCACAAATCAAACACACATATC-3’ 5’-GGTTGGTTGTATTTGGGT-3’ 5’-CTACRACTACAATAACATAAATCT-3’ 5 +30 → +327 
HOXA4 5’-TACACTTCACAAATTAATAACCAT 
AAACTC-3’ 
5’-GTTGTTGTAGYGGTAGGTGTTG-3’ 5’-AACCCAAATTCCCTCCCTT-3’ 4 +31 → +219 
IGF2 5’-GGGTTAAGGTAGTTTTTTTGGGA 
ATG-3’ 
5’-AAATATAAAAACCTCCTCCACC 
TCC-3’ 
5’-AGGGGGTTTATTTTTTTAGGAA-3’ 3 DMR0 
MLH1 5’-AGTTTTTTTTTTAGGAGTGAAGG-3’ 5’-ATAAAACCCTATACCTAATCT 
ATC-3’ 
5’-GTAGTATTYGTGTTTAGTTT-3’ 6 -569 → -375 
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3.2.1.3 PCR 
All PCR amplifications were carried out in a volume of 25μl, using 1μl of 
modified DNA (~13.3µg), 2.5μl of manufacturers’ 10x buffer (Roche), 0.5μl of dNTPs 
(20 mM, Roche), 0.2μl of FastStart taq DNA polymerase (5 U/μl, Roche), 1-4mM of 
MgCl2  Roche) and 150ng of both the forward and the reverse primer (Eurofins MWG 
Operon) (Table 3.5 and Table 3.6). PCR was performed with thermocycling conditions 
of one cycle at 95°C for 5 minutes, followed by 40-50 cycles of 95°C for 30 seconds, 
primer set specific annealing temperature for 30 seconds and 72°C for 30 seconds, 
followed by a single cycle of 72°C for 5 minutes.  
 
 
 
 
 
 
 
 
 
 
 
MgCl2 concentration 
(mM) 
Annealing temperature 
(°C) 
Cycle numbers 
TWIST2 2 63 40 
TUSC3 4 55 40 
HOXD4 3.5 51 40 
EphA10 4 53 45 
HAND2 3.5 51 45 
HOXA5 2.5 58 50 
HOXA4 3 63 40 
IGF2 3 63 50 
MLH1 4 58 40 
Table 3.6: PCR conditions for the pyrosequencing assays 
  
 49 
 
3.2.1.4 Agarose gel electophoresis 
PCR amplification was checked prior to pyrosequencing analysis by agarose 
electrophoresis. An agarose gel was prepared, containing 1.5 mg of agarose (Alpha 
laboratories) in 150 ml of 1x TAE buffer (Appendix A, Table A.1). 5μl of GelRed™ 
(Biotium) staining was added for visualisation. 4μl of PCR product was added to each 
of the slots in the gel, and ran on the gel using electrophoresis on 150 volt for 45 
minutes. Gels were analysed using an the G:box imager (Syngene). 
 
3.2.2 Pyrosequencing  
The sodium bisulphite modification converted the methylation difference in a 
sequencing difference. The amount of methylation can now be detected by DNA 
sequencing. 
Pyrosequencing is a DNA sequencing technique that is based on the sequencing 
by synthesis approach. Quantification of the amount of a specific base can by achieved 
by an enzymic cascade to measure the release of pyrophosphate (PPi) during DNA 
synthesis. As a result this system can accurately quantify the amount of specific bases 
added at a polymorphic site, such as that produced at a CpG site following bisulfite 
modification. 
4 enzymes are included in the pyrosequencing system to allow quantification of the 
released pyrophosphate; DNA polymerase 1, Adenosine triphosphate (ATP) 
sulfurylase, luciferase and apyrase (illustrated in Figure 3.4A). The reaction mixture 
also contains the enzyme substrates adenosine phosphosulfate (APS), d-luciferin and 
the sequencing template with an annealed sequencing primer to be used as a starting 
material for the DNA polymerase. During the cascade of enzymatic reactions, visible 
light is generated that is proportional to the number of incorporated nucleotides. The 
cascade starts with a nucleic acid polymerisation reaction in which PPi is released from 
a nucleotide triphosphate, following incorporation into the DNA strand by polymerase. 
The released PPi is converted to ATP by ATP sulfurylase, which provides the energy to 
luciferase to oxidise luciferin and generate light. The four different nucleotides are 
added stepwise, in a cyclic manner, and incorporation is followed using the enzyme 
ATP sulfurylase and luciferase. The light that is produced will be detected by a charge 
coupled device (CCD) camera. Apyrase removes unincorporated nucleotides and ATP 
between the additions of different bases. 
This degradation between base additions is crucial for synchronized DNA synthesis 
asserting that the light signal detected when adding a certain nucleotide only arises from 
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incorporation of that specific nucleotide (Figure 3.4A). The results are displayed as a 
pyrogram (Figure 3.4B). The height of the curve is determined by the signal, caused by 
the activity of luciferase (Ahmadian, 2006; Ronaghi, 2001). 
 
 
 
 
 
 
 
 
 
 
Figure 3.4: Pyrosequencing 
A) The nucleotide composition of a DNA-strand is determined by an enzyme cascade system.  
The single stranded DNA template is first hybridised with the sequencing primer and mixed 
with the enzymes along with the two substrates APS and luciferin. One of the four nucleotides 
is then added to the reaction. If the nucleotide is complementary to the base in the template 
strand, DNA polymerase incorporates it into the growing strand. PPi is released and converted 
to ATP by sulfurylase in the presence of APS.  
Detection is based on the amount of visible light produced during the following ATP-mediated 
conversion of luciferin to oxyluciferin by the luciferase. Any unincorporated nucleotides are 
degraded by apyrase, before the next nucleotide is added to the tube and the cascade of reactions 
repeated (Invitrogen). 
B) The light signals are detected and converted into a pyrogram, where the height of the peak is 
related to one of more identical bases.  
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Each individual pyrosequencing primer set was validated, by testing 
CpGenome™ Universal Methylated Control DNA (Millipore) (100% methylated) 
diluted to different levels of DNA methylation to produce a range of approximately 0-
100% methylated DNA. A peripheral blood sample from a young volunteer was used as 
a negative control of around 2-5 % methylated DNA. This was done to ensure that the 
level that the pyrosequencer (Pyromark Q96 MD pyrosequencer) is measuring reflects 
the amount of methylated DNA in the sample (5).  
For assessing methylation levels in individual samples, 10µl of PCR product 
was used for each pyrosequencing reaction and 5pmol of sequencing annealing primer 
(Table 3.5). The pyrosequencer has an internal quality control (QC) and identifies the 
samples for which the methylation levels were unreliable. All the samples with 
warnings, or the samples that passed the internal QC but showed low pyrosequencing 
peak heights, were repeated. All PCRs were performed in duplicate, in such a way that 
each sample had repeats that both passed the internal QC. If the difference in 
methylation levels in a sample between the 2 different runs was less than 2%, the 
average was calculated and used for further analysis. If the difference in methylation 
levels was greater than 2%, the sample was tested another time. For samples and genes 
with high levels of methylation (above 40%), a cut off of 5% difference in methylation 
levels was used. 
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Figure 3.5: Validation of the pyrosequencing primers 
To validate the pyrosequencing assay, samples with known levels of methylation (~0-100%) 
were measured. The average of the CpG sites measured during pyrosequencing was calculated 
and plotted against the expected methylation values. For the unmethylated control (~0%), a PBL 
samples was used with methylation levels around 2.7%. The test was performed in duplicates 
and resulted in a line with an R
2
 value, indicating the degree of overlap between the measured 
and expected methylation levels.  
In this graph, MDR1 is shown as example of one of the genes for which the pyrosequencing 
assay is validated.  
Validation of all the different genes under study was done in collaboration with Hannah Gautrey 
(Gautrey, 2012). 
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3.2.3 Bisulphite sequencing 
To examine the allelic distribution of identified DNA methylation in greater 
detail, bisulphite sequencing was performed for the TUSC3 gene on two ALL remission 
samples. The sequencing allowed us to measure the methylation levels of 7 CpG sites 
per allele. 11 alleles were sequenced for both samples.  
 
3.2.3.1 Preparing clones for bisuphite sequencing 
To prepare the clones for bisulphite sequencing, the TUSC3 PCR was performed 
(as described in 3.2.1.3). This PCR product was cloned into a pCR2.1 vector by mixing 
1µl of the PCR product with 1μl  of 10x ligation buffer, 2µl of the pCR 2.1 vector 
(25ng/μl), 1µl T4 DNA ligase (5.0 Weiss units/μl) and 5.5µl of dH2O (TA Cloning Kit, 
Invitrogen). This ligation mixture was incubated overnight at 14 °C.  
One vial of 50μl frozen One Shot competent cells (Invitrogen) per transformation were 
thawed on ice. 2μl of ligation product was added into the vial of competent cells and 
mixed by gently stirring with a pipette tip. The vial was incubated on ice for 30 minutes 
and afterwards the cells were put in a 42 °C water bath to perform a heat shock. 
Immediately after the heat shock, the vial was put back on ice. 250μl of S.O.C medium 
(Invitrogen) was added to the vial of cells. The vials were shaken at 225 rpm in a 
shaking incubator at 37 °C for 1 hour. Afterwards, the cells were spreaded over an Agar 
plate (Appendix A, Table A.1) and incubated overnight at 37 °C.  
 
3.2.3.2 Performing minipreps 
15 individual colonies were picked for analyses per plate. These colonies were 
added to a tube containing 5 ml of LB media, containing 50µg/ml kanamycin 
(Appendix A, Table A.1) and incubated overnight at 37 °C. 
The tube was removed from the incubator and centrifuged at 5000 rpm for 10 minutes at 
4 °C. A miniprep was performed using the Qiaprep Spin Miniprep kit (Qiagen), 
according to manufactures protocol; the media was removed and the pelleted cells were 
resuspended in 250μl of buffer P1 and transferred into an eppendorf tube. 250μl of 
buffer P2 was added and mixed thoroughly by inverting the tube 4-6 times. 350μl buffer 
N3 was added and mixed immediately by inverting the tube. The tube was centrifuged 
for 10 minutes at 13,0000 rpm. The supernatant was transferred into the QIAprep spin 
column and centrifuged for 1 minute at 13,000 rpm. The spin column was washed by 
adding 500μl  of buffer PB and centrifuged for 1 minute at 13,000 rpm. Afterwards, the 
column was washed another time by adding 750μl of buffer PE and centrifuged for 1 
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minute at 13,000 rpm. The flow trough was discarded and the column was centrifuged 
another time for 1 minute at 13,000 rpm to remove any residual wash buffer. 
Afterwards, the column was placed in a eppendorf tube, 50μl of elution buffer ED was 
added and the tube was centrifuged for 1 minute at 13,000 rpm.  
 
3.2.3.3 Analysing the transformants 
The product was checked for the insertion by performing an EcoR1 restriction 
digest. 2μl of Buffer H, 2μl  of 10x BSA, 0.5μl of EcoR1 enzyme, 5.5μl  of dH2O and 
10μl  of the Miniprep DNA was mixed and incubated at 37 °C for 2 hours. The 
digestion product was ran on a 2% agarose gel (as described in 3.2.1.4). The sample was 
quantified using the NanoDrop® ND-1000 spectrophotometer (in ng/μl). For the 
samples that had the PCR product inserted, 100μl  per sample was send away for 
sequencing. 
 
 
3.3 Statistical analysis 
Methylation levels were measured for a set of genes by pyrosequencing. For 
each of these genes, between 3 and 6 CpG sites in or near the TSS were examined. The 
statistical analyses were performed on the average levels of methylation of these CpG 
sites per gene. The methylation levels varied between the different CpG sites, but this 
variation was relatively consistent between individuals (Figure 3.6). 
Our data set consisted of different cohorts of patients and controls. Each cohort 
was examined individually for normal distribution using the Robvar regression, as well 
as the equality in variance using the Levene’s test for equal variances (STATA). 
Depending on those results, either parametric- or non-parametric statistical tests (SPSS) 
were performed. For the unrelated samples, the parametric tests performed were the one 
way repeated ANOVA, to examine overall methylation differences, and the 
Independent samples T-test, to examine differences between groups. The non-
parametric equivalents for these tests for the unrelated samples were the Kruskal-Wallis 
test, to examine overall methylation differences, and the Wilcoxon rank sum tests, to 
examine differences between groups. For the related samples, the parametric tests 
performed were the one-way repeated ANOVA, to examine overall methylation 
differences, and a Paired samples T-test, to examine differences between groups. The 
non-parametric equivalent for these related samples were the Friedman test, to examine 
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for overall methylation differences, and a Wilcoxon signed rank test, to examine 
differences between groups. 
Correlations between genes were investigated using the Pearson’s correlation (SPSS).  
Differences were called significant when a p value smaller than 0.05 was measured. 
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Figure 3.6: Methylation levels across the different CpG sites 
Methylation levels per CpG site are shown for four neonate samples, to show overall 
methylation patterns across the different CpG sites around the TSS from each individual gene. 
Variation existed across the different CpG sites, however the methylation patterns were very 
similar within individuals. 
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Chapter 4. Alterations of DNA methylation patterns with age 
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4.1 Introduction 
Alterations in the patterns of DNA methylation are one of the hallmarks of ageing 
(Mathers, 2006; Lopez-Otin, 2013). These changes include reduced levels of global 
DNA methylation across the genome (Bollati, 2009), in conjunction with local areas of 
hypermethylation, often centring on promoter associated CpG islands (Fraga, 2007). 
The acquisition of aberrant patterns of methylation with increasing age could play a role 
in differential susceptibility to develop several age-related diseases. However, the extent 
and the variance in CpG island methylation across the population is not yet well 
understood.  
Therefore, this study was designed to examine the patterns of DNA methylation 
in peripheral blood during ageing. Both the change in extent of methylation and the 
variance in methylation were examined. The genes of interest included seven genes 
previously described to become methylated during leukaemia development; TUSC3, 
TWIST2, HOXD4, EphA10, HAND2, HOXA5 and HOXA4 from which the last two 
genes showed age-related methylation changes in other tissues than blood, and two 
genes that were not reported to be involved in either leukaemia development or to be 
methylated during ageing in other tissue types, namely the imprinted gene IGF2 and 
MLH1, a gene involved in the DNA mismatch repair pathway (for more information 
about the genes under study, see Appendix A, Table A.2). 
 
4.2 Samples 
Peripheral blood leukocyte, or cord blood, DNA was collected from healthy 
volunteers in different age-groups; neonates (n=49), young adults (n=48), adults (n=50) 
and older adults (n=50) (Table 4.1). All the samples were collected as part of the 
NCCGP, The Newcastle Thousand Families Study and the Newcastle 85
+
 study. The 
analysis of the methylation levels in the Newcastle 85+ population was performed by 
Hannah Gautrey (Gautrey, 2012). 
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 Neonates Young adults Adults Older adults 
Age (years) 
 
0 
 17 – 42 
(average 27.7) 
50 85 
Gestational 
age (weeks) 
35-42 
(average 39.6) 
Number of 
participants 
49 48 50 50 
Gender 
33 male 
15 female 
1 unknown 
 
48 female 
18 male 
32 female 
23 male 
27 female 
Smoking 
habits 
 19 never 
smoked 
2 ex-smokers 
4 smokers 
23 unknown 
19 never 
smoked 
14 ex-smokers 
16 smokers 
1 unknown 
16 never 
smoked 
31 ex-smokers 
3 smokers 
Extra 
information 
Related to 
young adults 
(child) 
Related to the 
neonates 
(mother) 
Pregnant at 
time of blood 
collection 
  
Cohort 
North Cumbria 
Community 
Genetics 
Project 
North Cumbria 
Community 
Genetics 
Project 
Newcastle 
Thousand 
Families Study 
Newcastle 85+ 
Study 
Table 4.1: The age-related methylation study population 
The study population consisted of 197 participants in 4 different age groups; neonates, young 
adults, adults and the older adults. 
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4.3 Results 
 
4.3.1 Inter-individual differences in methylation levels within age groups and 
differences in methylation between age groups 
To examine changes in methylation patterns during normal ageing, methylation 
levels were analysed from 197 individuals in four age groups, between 0 and 85 years 
of age. Methylation levels for seven of the genes under study increased significantly 
with an increasing age; TUSC3, TWIST2, HOXD4, EphA10, HAND2, HOXA4 and 
HOXA5. For five of the genes under study; TUSC3, TWIST2, HOXD4, EphA10 and 
HAND2 the extent of methylation increased steadily with increasing age. However, 
although the age-related changes in methylation levels for these five genes were 
relatively similar, not all between age group differences were statistically significant. 
TUSC3, HOXD4 and EphA10 showed significant increases in methylation levels 
between all 4 age groups (p<0.05 for TUSC3, p≤0.006 for HOXD4 and p≤0.004 for 
EphA10). For TWIST2 no significant difference was observed between the neonates and 
the young adults, but methylation levels were significantly increasing between the three 
older age groups (p<0.001). HAND2 showed a significant increase in methylation 
between the 3 youngest age groups (p<0.001), but there were no significant differences 
observed in methylation levels between the adults and the older adults (Figure 4.1A-E). 
The age-related methylation differences were observed in the individual CpG sites from 
the genes analysed, showing that these patterns of age-related methylation are not 
relying on a subset of CpG sites per gene, but that is was a more gene-specific 
phenomenon (Figure 4.2 and Appendix B, Table B.1). 
In contrast, HOXA4, HOXA5 and IGF2 do not show a steady increase in 
methylation levels across the different age groups and the methylation levels for these 
three genes were generally more stable than for the other five genes. Compared to these 
other five genes, HOXA4, HOXA5 and IGF2 had much higher levels of methylation at 
all ages. Methylation of HOXA5 and IGF2 were significantly higher for the neonates 
than for the young adults (p=0.026 for HOXA5 and p=0.003 for IGF2), while 
methylation levels did not change significantly at older ages. Methylation levels for 
HOXA4 were significantly lower in the neonates compared to the young adults 
(p<0.001), while methylation levels were stable among the other age groups (Figure 
4.1F-H). 
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MLH1 was the only gene under study that did not show any significant 
differences in methylation levels between the different age groups (Figure 4.1I)
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Figure 4.1A-C: Patterns of DNA methylation in different age groups 
A) For TUSC3, the extent of methylation was increasing significantly with an increasing age (p<0.001, 
Kruskal Wallis, SPSS) and within the different age groups (p<0.001 between the younger three age groups, 
p=0.046 between the adults and the older adults, Wilcoxon signed rank test  and Wilcoxon rank sum test 
(SPSS)). The variance of methylation was increasing significantly with an increasing age (p<0.001) and between 
the different age groups (p=0.008, p=0.027 and p<0.001, respectively between the four different age groups, 
Levene’s test for equal variances (STATA)). 
 
B) For TWIST2, both the extent of methylation and the variance of methylation were increasing 
significantly with an increasing age (p<0.001, Kruskal Wallis (SPSS) and Levene’s test for equal variances 
(STATA)) and between the three older age groups (p<0.001 for the extent of methylation between the three 
older age groups, Wilcoxon rank sum test (SPSS) and p=0.015 and p<0.001 between the young adults and the 
adults and the adult and the elderly respectively, for the variance of methylation, Levene’s test for equal 
variances (STATA)). 
 
C) For HOXD4, both the extent of methylation and the variance of methylation were increasing 
significantly with an increasing age (p<0.001, Kruskal Wallis (SPSS) and Levene’s test for equal variances 
(STATA)). The extent of methylation was increasing significantly between the four different age groups 
(p<0.001 between the three youngest age groups, p=0.006 between the adults and the older adults, Wilcoxon 
signed rank test and Wilcoxon rank sum test (SPSS)). The variance of methylation increased significantly 
between the neonates and the young adults and between the adults and the older adults (p<0.001, Levene’s test 
for equal variances (STATA)). 
The analysis of the methylation levels in the Newcastle 85+ population was performed by Hannah Gautrey 
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Figure 4.1D-F: Patterns of DNA methylation in different age groups 
D) For Epha10, both the extent of methylation and the variance of methylation were increasing 
significantly with an increasing age (p<0.001, Kruskal Wallis (SPSS) and Levene’s test for equal variances 
(STATA)). The extent of methylation was increasing significantly between the four age groups for EphA10 
(p=0.004 between the neonates and the young adults, p<0.001 between the older three age groups, Wilcoxon 
signed rank test and Wilcoxon rank sum test (SPSS)), while the variance of methylation only increased 
significantly between the adults and the older adults (p<0.001, Levene’s test for equal variances (STATA)). 
 
E) For HAND2, both the extent of methylation and the variance of methylation were increasing 
significantly with an increasing age (p<0.001, Kruskal Wallis (SPSS) and Levene’s test for equal variances 
(STATA)). The extent of methylation increased significantly between the three younger age groups (p<0.001, 
Wilcoxon signed rank test and Wilcoxon rank sum test (SPSS)) and the variance of methylation increased 
significantly between the adults and the older adults (p=0.003, Levene’s test for equal variances (STATA)). 
 
 
F) For HOXA4, both the extent and the variance of methylation were increasing significantly with an 
increasing age (p<0.001, Kruskal Wallis (SPSS and Levene’s test for equal variances (STATA)). A significant 
increase in methylation levels was observed between the neonates and the young adults (p<0.001, Wilcoxon 
signed rank test (SPSS)), but no significant differences in methylation levels were observed between the other 
age groups. The variance of methylation was increasing significantly with an increasing age and between the 
neonates and the young adults and the adult s and the older adults (p=0.015 and p=0.011 respectively, Levene’s 
test for equal variances (STATA).  
The analysis of the methylation levels in the Newcastle 85+ population was performed by Hannah Gautrey 
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Figure 4.1G-I: Patterns of DNA methylation in different age groups 
G) For HOXA5, the variance of methylation was increasing significantly with an increasing age (p<0.001, 
Levene’s test for equal variance (SPSS)), but no differences were observed in the extent of methylation levels 
with age. A significantly decrease in methylation levels was observed between the neonates and the young 
adults (p=0.026, Wilcoxon signed rank test (SPSS)). Variance of methylation was increased significantly 
between the adults and the older adults (p=0.002, Levene’s test for equal variances (STATA)). 
 
 
H) For IGF2, both the extent of methylation and the variance of methylation were increasing significantly 
with an increasing age (p<0.001 for the extent of methylation, Kruskal Wallis (SPSS), p=0.05 for the variance 
of methylation, Levene’s test for equal variance (SPSS)). A significant decrease in the extent of methylation 
was observed between the neonates and the young adults (p=0.003, Wilcoxon signed rank test (SPSS)). 
Significant differences in variance of methylation were observed between the three younger age groups 
(p=0.030 and p=0.018 respectively, Levene’s test for equal variances (STATA)). 
 
 
I) For MLH1, no significant difference in both the extent and the variance of methylation was observed 
with an increasing age, or between individual age groups. 
The analysis of the methylation levels in the Newcastle 85+ population was performed by Hannah Gautrey 
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Figure 4.2: Patterns of methylation within age-groups in each individual CpG site for the 
TUSC3 gene 
The patterns of methylation were relatively similar between the different CpG sites for the 
TUSC3 gene, showing that the age-related methylation levels for this gene was not relying on 
one specific CpG site. 
An overview of the CpG site specific methylation changes within age groups for the other genes 
under study can be found in Appendix B, Table B.1. 
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4.3.2 Difference in variance of methylation within age groups 
To examine differences in the variance of methylation with an increasing age, 
the differences in methylation patterns in the different age groups were examined for 
these differences. Seven of the nine genes under study showed an overall significant 
increase in variance of methylation between the four age groups.  
The five genes that showed clear increases in the extent of age-related 
methylation levels; TUSC3, TWIST2, HOXD4, EphA10 and HAND2, also showed 
significantly increased levels of variance of methylation between the different age 
groups. Only for TUSC3 this significant increase in variance of methylation existed 
between all four age groups (p=0.008, p=0.027 and p<0.001 respectively). 
 HOXD4 showed an increase in variance of methylation between the neonates and the 
young adults and between the adults and the older adults (p<0.001), but not between the 
young adults and the adults. For TWIST2 an increase in variance of methylation 
between the young adults and the adults and between the adults and the older adults was 
observed (p=0.015 and p<0.001 respectively), but not between the neonates and the 
young adults and for EphA10 and HAND2 a significant increase in variance of 
methylation was observed between the adults and the older adults (p<0.001 for EphA10 
and p=0.003 for HAND2), but not between the other age groups (Figure 4.1A-E).  
The three genes that were relatively stable in the extent of methylation between 
the different age groups; HOXA4, HOXA5 and IGF2 did show a significant increase in 
variance of methylation between the different age-groups. For IGF2 a significant 
difference in variance of methylation between the neonates and the young adults and 
between the young adults and the adults was observed (p=0.030 and p=0.018 
respectively), but not between the adults and the older adults. HOXA5 showed a 
significant increase in variance of methylation between the adults and the older adults 
(p=0.002), but not between the other age groups. HOXA4 showed an increase in 
variance of methylation between the neonates and the young adults and between the 
adults and the older adults (p=0.015 and p=0.011 respectively), but not between the 
young adults and the adults (Figure 4.1F-H). 
MLH1 was the only gene under study that did not show any difference in 
variance of methylation between the different age groups (Figure 4.1I).  
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4.3.3 Correlations between genes in the different age groups 
For five of the genes under study, TWIST2, TUSC3, EphA10, HOXD4 and 
HAND2, there was a very clear similarity in the age related changes in the patterns of 
DNA methylation seen in the four age groups, implying that the factors controlling age 
related changes at these five loci may be the same or at least very similar. To examine 
these similarities in greater detail, the methylation patterns were examined for 
correlations. 
 In the older adult population, there was a correlation observed between the 
levels of methylation of all five of these genes (p<0.05) (Table 4.2A), such that an 
individual with high levels of methylation at one of the five loci tends to have high 
methylation at the other four loci as well. HOXA5, HOXA4, IGF2 and MLH1 did not 
show a correlation with these genes, except between HOXA5 and EphA10 and EphA10 
and IGF2 (p<0.05). However, despite the strong similarity in their average methylation 
patterns, the correlation within individuals was not as evident in the adults. 
Comparisons between the different genes showed similarities in this age group, from 
which some, but not all, reached statistically significant levels (Table 4.2B). In the 
young adult age group, fewer correlations were observed between the different genes 
(Table 4.2C). In the neonates these correlations were even less visible, the only 
observed correlations were between HOXD4 and HOXA5 (p<0.05) (Table 4.2D). It 
should be noted however, that due to the low levels of methylation generally observed 
in this population, and the lower levels of variation (and to some extent also in the 
young adult and adult populations), the sensitivity of the pyrosequencing method used 
might not be sufficient to identify any co-methylation of the genes that may exist in our 
sample set. It might be that our sample set was too small to detect significant 
correlations; therefore increased numbers of samples is required to draw more definite 
conclusions.  
These results do suggest that co-methylation occurs in healthy individuals in a 
pattern that is similar to the CpG island methylator phenotype (CIMP) described in 
cancer. 
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A. 
 TWIST2 TUSC3 HOXD4 EphA10 HAND2 HOXA5 HOXA4 IGF2 
TWIST2 
 R=0.471 
P=0.001
*** 
R=0.494 
P<0.001
*** 
R=0.531 
P=0.006
** 
R=0.371 
P=0.008
** 
R=0.195 
P=0.175 
R=0.115 
P=0.426 
R=-0.149 
P=0.302 
TUSC3 
 
 
R=0.612 
P<0.001
*** 
R=0.306 
P=0.03
* 
R=0.614 
P<0.001
*** 
R=0.124 
P=0.392 
R=0.059 
P=0.683 
R=-0.242 
P=0.090 
HOXD4 
 
  
R=0.312 
P=0.027
* 
R=0.527 
P<0.001
*** 
R=0.112 
P=0.437 
R=0.090 
P=0.532 
R=-0.183 
P=0.203 
EphA10 
 
   
R=0.383 
P=0.006
** 
R=0.398 
P=0.004
** 
R=0.094 
P=0.517 
R=-0.297 
P=0.036
* 
HAND2 
 
    
R=0.270 
P=0.058 
R=0.077 
P=0.594 
R=-0.270 
P=0.058 
HOXA5 
 
     
R=-0.029 
P=0.839 
R=-0.020 
P=0.890 
HOXA4 
 
      
R=0.024 
P=0.867 
Table 4.2A: Correlations between the examined genes in the older adult age-group 
In the older adult samples (n=50) there were correlations observed between the genes TWIST2, TUSC3, HOXD4, EphA10 and HAND2 and between EphA10 with 
HOXA5 and IGF2. The R is indicating the correlation coefficient and the P the observed p-values (Pearson correlation (SPSS)). 
The analysis on the Newcastle 85+ population was performed by Hannah Gautrey. 
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B. 
 TWIST2 TUSC3 HOXD4 EphA10 HAND2 HOXA5 HOXA4 IGF2 
TWIST2  
R=0.424 
P=0.002
** 
R=0.170 
P=0.244 
R=0.432 
P=0.002
** 
R=0.293 
P=0.041
* 
R=0.056 
P=0.701 
R=0.020 
P=0.893 
R=-0.419 
P=0.007
** 
TUSC3   
R=0.270 
P=0.061 
R=0.291 
P=0.041
* 
R=0.444 
P=0.001
*** 
R=0.097 
P=0.501 
R=-0.009 
P=0.948 
R=-0.241 
P=0.133 
HOXD4    
R=0.157 
P=0.282 
R=0.116 
P=0.431 
R=0.251 
P=0.082 
R=-0.017 
P=0.908 
R=-0.159 
P=0.327 
EphA10     
R=0.130 
P=0.373 
R=-0.080 
P=0.579 
R=0.265 
P=0.063 
R=-0.179 
P=0.270 
HAND2      
R=0.047 
P=0.751 
R=0.193 
P=0.183 
R=-0.100 
P=0.540 
HOXA5       
R=-0.419 
P=0.002
** 
R=-0.058 
P=0.724 
HOXA4        
R=0.020 
P=0.904 
Table 4.2B: Correlations between the examined genes in the adult age-group 
In the adult age group (n=50), there were correlations observed between TWIST2 with TUSC3, EphA10, HAND2 and IGF2, between TUSC3 with EphA10 and 
HAND2, between HAND2 and MLH1 and between HOXA5 and HOXA4. 
The R is indicating the correlation coefficient and the P the observed p-values (Pearson correlation (SPSS)).   
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C. 
 TWIST2 TUSC3 HOXD4 EphA10 HAND2 HOXA5 HOXA4 IGF2 
TWIST2  
R= 0.317 
P=0.028
* 
R= 0.212 
P=0.148 
R= 0.138 
P=0.349 
R= 0.318 
P=0.028
* 
R= 0.338 
P=0.019
* 
R= 0.008 
P=0.959 
R= -0.250 
P=0.090 
TUSC3   
R= 0.118 
P=0.424 
R= 0.528 
P<0.001
*** 
R= 0.029 
P=0.845 
R= 0.205 
P=0.163 
R= 0.041 
P=0.783 
R= 0.007 
P=0.963 
HOXD4    
R= -0.016 
P=0.912 
R= 0.203 
P=0.166 
R= -0.032 
P=0.827 
R= 0.136 
P=0.357 
R= -0.011 
P=0.939 
EphA10     
R= 0.076 
P=0.608 
R= 0.235 
P=0.108 
R= -0.201 
P=0.170 
R= -0.073 
P=0.627 
HAND2      
R= 0.192 
P=0.191 
R= 0.025 
P=0.864 
R= -0.055 
P=0.715 
HOXA5       
R= -0.271 
P=0.063 
R= -0.122 
P=0.415 
HOXA4        
R= 0.173 
P=0.245 
Table 4.2C: Correlations between the examined genes in the young adult age-group 
In the young adult samples (n=48) there were correlations observed between TWIST2 with TUSC3, HAND2 and HOXA5 and between TUSC3 and EphA10. 
The R is indicating the correlation coefficient and the P the observed p-values (Pearson correlation (SPSS)). 
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D. 
 TWIST2 TUSC3 HOXD4 EphA10 HAND2 HOXA5 HOXA4 IGF2 
TWIST2  
R= 0.194 
P=0.182 
R= 0.133 
P=0.363 
R= 0.197 
P=0.175 
R= -0.012 
P=0.937 
R= 0.016 
P=0.915 
R= -0.087 
P=0.553 
R= -0.154 
P=0.317 
TUSC3   
R= -0.039 
P=0.788 
R= 0.172 
P=0.238 
R= 0.068 
P=0.642 
R= 0.065 
P=0.658 
R= -0.102 
P=0.488 
R= 0.068 
P=0.661 
HOXD4    
R= 0.010 
P=0.947 
R= -0.025 
P=0.866 
R= -0.306 
P=0.033
* 
R= -0.012 
P=0.936 
R= 0.026 
P=0.865 
EphA10     
R= -0.095 
P=0.514 
R= 0.075 
P=0.609 
R= 0.271 
P=0.059 
R= 0.219 
P=0.152 
HAND2      
R= -0.063 
P=0.670 
R= -0.066 
P=0.651 
R= 0.008 
P=0.957 
HOXA5       
R= -0.028 
P=0.848 
R= -0.052 
P=0.735 
HOXA4        
R= -0.062 
P=0.688 
Table 4.2D: Correlations between the examined genes in the neonate age-group 
In the neonate samples (n=49), the only observed correlation was between the genes HOXD4 and HOXA5. 
The R is indicating the correlation coefficient and the P the observed p-values (Pearson correlation (SPSS)). 
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4.3.4 Methylation levels of correlated genes combined 
Patterns of five genes under study; TWIST2, TUSC3, HOXD4, EphA10 and 
HAND2, showed strong similarities in their patterns of methylation changes with an 
increasing age and strong correlations were observed between these five genes in the 
older adults, which suggests that these genes may be influenced by similar mechanisms. 
Combining the methylation levels at all five genes might give a more accurate 
measurement of the impact of age on DNA methylation at these (and other similar) 
genes. To do this, the average methylation levels of these five genes were calculated per 
individual. Using this combined methylation measure, a significant increase in the 
extent of methylation with an increasing age is observed, as well as a significant 
increase between the four individual age groups (p<0.001) and a significant increase in 
the variability of methylation with age was observed and within three of the four age 
groups (p≤0.009) (Figure 4.3). Interestingly the figure showing these five genes 
combined produces an almost perfect straight line for the increase in methylation with 
age, suggesting that methylation is steadily acquired throughout the ageing process and 
is not specifically a feature of old age. 
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Figure 4.3: The overall levels of methylation increase steadily across the life course 
Methylation levels of five genes combined, for which all individual genes showed similar 
patterns of DNA methylation changes between the different age-groups; TWIST2, TUSC3, 
HOXD4, EpHA10 and HAND2, showed a significant increase in both the variance and the 
extent of methylation with an increasing age. The extent of methylation increased significantly 
between all four age groups (p<0.001 between all the age groups, Wilcoxon signed rank test  
and Wilcoxon rank sum test (SPSS)), while the variance of methylation increased significantly 
between the neonates and the young adults and between the adults and the older adults (p=0.009 
and p<0.001 respectively, Levene’s test for equal variances (STATA). These results suggest that 
methylation is steadily acquired throughout the ageing process. 
The analysis of the methylation levels in the Newcastle 85+ population was performed by Hannah 
Gautrey. 
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4.3.5 Methylation levels of the neonates and their mothers 
The neonates and the young adults were related, as they were child-mother pairs. 
To examine the possible effect on methylation of these related groups in greater detail, 
Pearson’s correlations were performed to examine for a potential correlation between 
methylation levels of the mothers and their new-borns, to examine an effect of the 
mother’s age on methylation levels in the neonates and to examine the effect of the 
neonates gestational age on their levels of methylation at birth. No correlation was 
observed between the methylation levels measured in the neonates and the methylation 
levels of their mothers (the young adults). The mother’s age had no significant influence 
on the methylation levels in the neonates and no correlation was observed between the 
methylation levels measured in the neonates and their gestational age (Table 4.3). 
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 TWIST2 TUSC3 HOXD4 EphA10 HAND2 HOXA5 HOXA4 IGF2 
Methylation mothers- 
Methylation neonates 
R= 0.220 
P= 0.137 
R= -0.046 
P= 0.759 
R= -0.101 
P= 0.501 
R= 0.050 
P= 0.724 
R= 0.097 
P= 0.517 
R= -0.006 
P= 0.970 
R= 0.075 
P= 0.616 
R= 0.047 
P= 0.793 
         
Mothers age– 
Methylation neonates 
R= 0.052 
P= 0.731 
R= 0.202 
P= 0.173 
R= 0.001 
P= 0.994 
R= -0.048 
P= 0.749 
R= 0.212 
P= 0.152 
R= -0.094 
P= 0.531 
R= 0.029 
P= 0.846 
R= -0.127 
P= 0.394 
         
Gestational age- 
Methylation neonates 
R= -0.267 
P= 0.063 
R= -0.264 
P= 0.067 
R= -0.101 
P= 0.501 
R= 0.087 
P= 0.552 
R= -0.153 
P= 0.293 
R= 0.042 
P= 0.775 
R= -0.020 
P= 0.893 
R= 0.116 
P= 0.426 
Table 4.3: Correlations between the methylation levels of the neonates and the methylation levels of their mothers, their gestational age and their mother’s 
age 
No correlations were observed between the methylation levels of the neonates and the methylation levels of their mothers, no correlations were observed between the 
methylation levels of the neonates and their gestational age and no correlations were observed between the methylation levels of the neonates and their mother’s age 
for any of the genes under study (n=47).  
The R is indicating the correlation coefficient and the P the observed p-values (Pearson correlation (SPSS)). 
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4.3.6 Analyses stratification 
To ensure that the age-related methylation changes that we observed between 
the different age groups were not significantly influenced by the different male-female 
ratios in the different age groups, stratification analyses were performed. First, the 
differences between the methylation levels of the males and females were examined in 
the individual age groups that consisted of both male and female participants. A 
difference in methylation levels was observed in the adult age group for the TUSC3 
gene, where the male participants showed higher average levels of methylation than the 
female participants, but this difference was not observed for the TUSC3 gene in the 
neonate or older adult age groups (Table 4.4). None of the other genes showed 
significant differences in methylation levels between the male and the female 
participants (Table 4.4).  
The young adult age group consisted of only females, so to perform further stratification 
analyses on the potential influence of the participant’s genders on the overall patterns of 
methylation changes with age, the male participants in this study were excluded from 
the analyses. After the exclusion of the male population, the same statistical analyses 
were performed as before, namely the Kruskal-Willis test and the Wilcoxon signed rank 
test (SPSS). The general pattern of age-related methylation did not differ between the 
analyses performed on the whole population or on the female participants only (Table 
4.5). No significant differences in the results were observed between the female 
population alone and the whole study population in the three older age groups. The 
significant differences between the neonates and the young adults that were observed 
for EphA10, HOXA5 and IGF2 when the whole population was included were not 
observed when only the female participants were included (Table 4.5).  However, there 
were significantly less participants included in the analysis, namely 15 participants per 
age group, so it is possible that the number of samples was too small to detect 
significant differences for these genes in the small number of patients. 
The smoking habits of the participants differed between the different age groups. 
To ensure that the methylation differences we observed in the different age groups were 
not influenced by the number of participant that smoked, stratification analyses were 
performed. First, the potential differences in methylation levels between the participants 
that had never smoked and the participants that were current- or previous smokers were 
examined. In these analyses, the young adult, adult and older adult age groups were 
included. A difference in methylation levels was observed in the older adult age group, 
between the participants that had never smoked and the current- and previous smokers 
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for the IGF2 gene, but none of the other genes showed a significant difference in 
methylation levels between the participants that had never smoked and the current- and 
previous smokers in any of the age groups (Table 4.6).  
To perform further stratification analyses on the potential influence of the participants 
smoking habits on the overall methylation patterns as observed with age, all the current 
smokers and previous smokers were excluded from these analyses and only the 
participants that had never smoked were included. After the exclusion of the previous- 
and current smokers, the same statistical analyses were performed as before, namely the 
Kruskal-Willis test and the Wilcoxon signed rank test (SPSS). The general pattern of 
age-related methylation did not differ between the analyses performed on the whole 
population or on the population only including the participants that had never smoked 
(Table 4.7). No significant differences were observed in the age-related methylation 
changes between the analyses performed on the whole study population and on the 
analyses performed on only the participants that had never smoked for any of the genes 
under study in the older three age groups. However, the significant differences between 
the neonates and the young adults that were observed for EphA10, HOXA5 and IGF2 
when the whole population was included, were not observed anymore when only the 
participants that never smoked were included (Table 4.7). However, there were 
significantly less participants included in this analysis (namely 19 participants per age 
group). Therefore, it is possible that the number of samples was too small to detect 
significant differences for these genes in these small numbers of patients. 
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A. 
 TWIST2 TUSC3 HOXD4 EphA10 HAND2 HOXA5 HOXA4 IGF2 
Methylation levels whole 
population (%) 
4.17 3.88 4.98 6.53 3.28 60.52 26.69 46.64 
Methylation levels males (%) 4.22 4.00 5.16 4.48 3.39 61.33 26.63 46.20 
Methylation levels females (%) 4.08 3.67 4.58 6.68 3.01 58.89 27.01 47.62 
Difference between  
males and females 
P=0.885 P=0.155 P=0.225 P=0.824 P=0.417 P=0.081 P=0.747 P=0.973 
Table 4.4A: Differences in methylation levels between the male and the female participants in the neonate age-group 
In the neonate age group, no significant differences were observed between the methylation levels of the male (n=33) and female (n=15) participants for any of 
the genes under study (Independent samples T-test for HAND2, Wilcoxon rank sum tests for the other genes under study (SPSS)). 
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B. 
 TWIST2 TUSC3 HOXD4 EphA10 HAND2 HOXA5 HOXA4 IGF2 
Methylation levels whole 
population (%) 
5.54 7.51 11.17 8.59 7.14 56.69 39.58 42.34 
Methylation levels males (%) 5.89 8.27 11.69 8.65 7.43 59.46 40.62 40.68 
Methylation levels females (%) 5.41 7.11 10.96 8.59 7.00 55.59 39.17 43.25 
Difference between males and 
females 
P=0.443 P=0.004
** P=0.258 P=0.686 P=0.195 P=0.110 P=0.534 P=0.144 
Table 4.4B: Differences in methylation levels between the male and the female participants in the adult age group 
In the adult age group, a significant difference was observed between the methylation levels of the male (n=18) and the female (n=32) participants for the 
TUSC3 gene (p=0.004), but not for any of the other genes under study (Independent samples T-test for TUSC3 and HOXD4, Wilcoxon rank sum test for the 
other genes under study (SPSS)). 
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C. 
 TWIST2 TUSC3 HOXD4 EphA10 HAND2 HOXA5 HOXA4 IGF2 
Methylation levels whole 
population (%) 
8.41 8.92 14.81 11.98 7.34 61.49 41.51 40.16 
Methylation levels males (%) 7.96 8.20 14.06 12.14 7.43 64.76 42.29 39.68 
Methylation levels females (%) 8.79 9.26 15.43 11.85 7.27 58.59 40.86 40.57 
Difference between males and 
females 
P=0.345 P=0.992 P=0.477 P=0.953 P=0.938 P=0.089 P=0.674 P=0.540 
Table 4.4C: Differences in methylation levels between the male and the female participants in the older adult age-group 
In the older adult age group, no significant differences were observed between the methylation levels of the male (n=23) and the female (n=27) participants for 
any of the genes under study (Independent samples T-test for HOXA4 and HOXA5, Wilcoxon rank sum test for the other genes under study (SPSS)). 
 
  
 81 
 
 TWIST2 TUSC3 HOXD4 EphA10 HAND2 HOXA5 HOXA4 IGF2 
Whole population 
(Neonates-Young adults) 
Z=-0.215 
P= 0.829 
Z=-5.298 
P<0.001
*** 
Z=-5.857 
P<0.001
*** 
Z=-2.841 
P=0.004
** 
Z=-5.898 
P<0.001
*** 
Z=-2.231 
P=0.026
* 
Z=-4.359 
P<0.001
*** 
Z=-3.003 
P=0.003
** 
Females only 
(Neonates-Young adults) 
Z=-0.454 
P= 0.650 
Z=-3.096 
P=0.002
** 
Z=-3.351 
P=0.001
*** 
Z=-1.477 
P= 0.140 
Z=-3.408 
P=0.001
*** 
Z= 0.000 
P=1.000 
Z=-2.727 
P=0.023
* 
Z=-1.591 
P= 0.209 
         
Whole population  
(Young adults-Older adults) 
C=72.831 
P<0.001
*** 
C=62.707 
P<0.001
*** 
C=44.253 
P<0.001
*** 
C=77.293 
P<0.001
*** 
C=36.144 
P<0.001
*** 
C= 3.791 
P=0.150 
C =3.680 
P=0.159 
C=3.428 
P=0.180 
Females only 
(Young adults-Older 
adults) 
C=52.596 
P<0.001
*** 
C=48.548 
P<0.001
*** 
C=34.826 
P<0.001
*** 
C=50.710 
P<0.001
*** 
C=28.073 
P<0.001
*** 
C= 1.195 
P=0.550 
C= 2.057 
P=0.358 
C= 4.636 
P=0.098 
Table 4.5: Gender stratification analyses 
When only the female population was included, there were significant differences observed between the analyses done on the whole population and the analyses 
done on only the female population when comparing the methylation levels of the neonates and the young adults (n=15) for EphA10, HOXA5 and IGF2. For the 
older three age groups, no significant differences were observed between the analyses performed on the whole study population and the female population alone. 
The Z is indicating the Z value, the C is indicating the Chi-square value and the P the observed P values (Wilcoxon signed rank test for the analyses performed on 
the Neonates and Young adults, Kruskal-Willis test for the analyses performed on the other age groups (SPSS)). 
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A. 
 TWIST2 TUSC3 HOXD4 EphA10 HAND2 HOXA5 HOXA4 IGF2 
Methylation levels whole population (%) 4.14 5.20 8.65 7.32 5.54 56.36 37.32 42.05 
Methylation levels never smoked (%) 4.21 4.28 8.43 7.30 5.51 55.53 40.29 41.23 
Methylation previous smokers (%) 3.80 5.05 8.26 8.07 5.94 52.64 28.11 42.30 
Methylation levels smokers (%) 3.99 4.93 7.46 6.70 5.96 52.24 36.05 42.60 
Difference between never smoked and 
previous- and current smokers 
P=0.783 P=0.860 P=0.597 P=0.916 P=0.317 P=0.549 P=0.113 P=0.930 
Table 4.6A: Differences in methylation levels between smokers and non-smokers in the young adult age-group 
In the young adult age group, no significant differences were observed between the participants that had never smoked (n=19) and the current- and previous 
smokers (n=6) for any of the genes under study (Independent samples T-test for HAND2, HOXA5, HOXA4 and IGF2, Wilcoxon rank sum test for the other 
genes under study (SPSS)). 
 
  
 83 
 
B. 
 TWIST2 TUSC3 HOXD4 EphA10 HAND2 HOXA5 HOXA4 IGF2 
Methylation levels whole population (%) 5.54 7.51 11.17 8.59 7.14 56.69 39.58 42.34 
Methylation levels never smoked (%) 5.31 7.56 10.73 8.58 7.23 58.93 38.02 42.85 
Methylation previous smokers (%) 5.84 7.85 11.24 8.75 7.15 55.97 40.39 40.37 
Methylation levels smokers (%) 5.70 7.22 11.81 8.54 7.06 55.65 41.11 43.35 
Difference between never smoked and 
previous- and current smokers 
P=0.068 P=0.894 P=0.234 P=0.894 P=0.697 P=0.182 P=0.251 P=0.335 
Table 4.6B: Differences in methylation levels between smokers and non-smokers in the adult age-group 
In the adult age group, no significant differences were observed between the participants that had never smoked (n=19) and the current- and previous smokers 
(n=30) for any of the genes under study (Independent samples T-test for TUSC3 and HOXD4, Wilcoxon rank sum test for the other genes under study (SPSS)).  
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C. 
 TWIST2 TUSC3 HOXD4 EphA10 HAND2 HOXA5 HOXA4 IGF2 
Methylation levels whole population (%) 8.41 8.92 14.81 11.98 7.34 61.49 41.51 40.16 
Methylation levels never smoked (%) 8.87 8.85 16.06 11.50 7.64 64.43 41.71 43.06 
Methylation previous smokers (%) 7.59 8.49 13.51 11.91 6.82 58.78 41.41 39.34 
Methylation levels smokers (%) 14.41 13.66 22.13 15.31 11.15 72.92 41.55 33.20 
Difference between never smoked and 
previous- and current smokers 
P=0.448 P=0.803 P=0.405 P=0.795 P=0.236 P=0.261 P=1.000 P=0.003
** 
Table 4.6C: Differences in methylation levels between smokers and non-smokers in the older adult age-group 
In the older adult age group, a significant difference was observed between the methylation levels of the participants that had never smoked (n=16) and the 
current- and previous smokers (n=34) for the IGF2 gene, but not for any of the other genes under study (Independent samples T-test for HOXA4 and HOXA5, 
Wilcoxon rank sum test for the other genes under study (SPSS)). 
The analysis of the methylation levels in the Newcastle 85+ population was performed by Hannah Gautrey. 
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 TWIST2 TUSC3 HOXD4 EphA10 HAND2 HOXA5 HOXA4 IGF2 
Whole population 
(Neonates-Young adults) 
Z= -0.215 
P= 0.829 
Z= -5.298 
P< 0.001
*** 
Z= -5.857 
P< 0.001
*** 
Z= -2.841 
P= 0.004
** 
Z= -5.898 
P< 0.001
*** 
Z= -2.231 
P= 0.026
* 
Z= -4.359 
P< 0.001
*** 
Z= -3.003 
P= 0.003
** 
Participants that never smoked only 
(Neonates-Young adults) 
Z= -0.540 
P= 0.598 
Z= -2.897 
P= 0.004
** 
Z= -3.124 
P= 0.002
* 
Z= -1.533 
P= 0.125 
Z= -3.408 
P= 0.001
*** 
Z= -1.420 
P= 0.156 
Z= -2.953 
P= 0.003
** 
Z= -1.682 
P= 0.093 
         
Whole population 
(Young adults-Older adults) 
C=72.831 
P< 0.001
*** 
C=62.707 
P< 0.001
*** 
C=44.253 
P< 0.001
*** 
C=77.293 
P< 0.001
*** 
C=36.144 
P< 0.001
*** 
C= 3.791 
P= 0.150 
C = 3.680 
P= 0.159 
C=3.428 
P= 0.180 
Participants that never smoked only 
(Young adults-Older adults) 
C=22.110 
P< 0.001
*** 
C=20.217 
P< 0.001
*** 
C=17.253 
P< 0.001
*** 
C=26.750 
P< 0.001
*** 
C=17.664 
P< 0.001
*** 
C= 5.612 
P= 0.060 
C= 1.120 
P= 0.571 
C= 2.208 
P= 0.332 
Table 4.7: Smoking stratification analyses 
When only the participants that had never smoked were included, there were significant differences observed between the analyses done on the whole population and 
the analyses done on only the participants that have never smoked when comparing the methylation levels of the neonates and the young adults (n=19) for EphA10, 
HOXA5 and IGF2. For the older age groups, no significant differences were observed between the analyses performed on the whole study population and the 
participants that had never smoked. 
The Z is indicating the Z value, the C is indicating the Chi-square value and the P the observed P values (Wilcoxon signed rank test for the analyses performed on 
the Neonates and Young adults, Kruskal-Willis test for the analyses performed on the other age groups (SPSS)). 
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4.4 Discussion 
The results of our study indicate that, for at least five of the genes, clear age-
related methylation changes were observed, where both the extent of methylation as 
well as the variance of methylation increases significantly with age. Our results also 
suggest that these age-related methylation changes were steadily acquired during the 
ageing process and that they were not just a feature of an old age. What is causing these 
methylation changes during aging is currently unclear, but it might be caused by an 
unstable maintenance of the replication of DNA methylation patterns during cell 
divisions during aging. In addition to an intrinsic biological effect of aging on DNA 
methylation levels, the methylation levels might be influenced by several environmental 
factors. Altered intake of several nutrients can affect DNA methylation. These nutrients 
include folate, selenium, phytochemicals and polyphenolics and food contaminants, 
such as arsenic (Mathers, 2006). Air pollution, such as diesel exhaust and PM10 
exposure, were shown to alter both global and promoter specific DNA methylation 
levels (Christensen, 2011) and smoking was shown to alter levels of promoter 
methylation in a dose-dependent matter, where the degree of methylation increases with 
the intensity of smoking (Talikka, 2012). Older individuals might have been more 
exposed to all of these environmental modulators of methylation, and the levels of 
which they are exposed might vary more than in the younger age groups, which might 
explain the increase in variance of methylation in the older age groups. A study carried 
out by Fraga et al in monozygotic twins showed that an increase in epigenetic 
differences was observed between twin pairs with an increasing age (Fraga, 2005). 
These are genetically identical individuals, and the observed increase in the differences 
in epigenetic patterns in these individuals with an increasing age can possibly be 
explained by both external and internal factors. 
Five of the genes in our study seem to follow similar patterns of age related 
changes in DNA methylation. Strong correlations between the methylation levels of 
these five genes were observed in the older age groups, suggesting that changes in the 
DNA methylation of these genes are closely related to each other in healthy individuals 
and that there might be similar mechanisms underlying methylation of these genes, and 
potentially other genes in the genome. The genes under study were identified from the 
literature and selected due to their role in leukaemia development. It is highly unlikely 
that these five genes are the only genes in the genome showing such age-related 
methylation patterns, suggesting that many other genes might undergo similar patterns 
of methylation. Interestingly, these methylation patterns were observed in leukaemia-
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related genes, whereas the genes that were unrelated to leukaemia development, such as 
MLH1 and IGF2, did not show the same extent of age related methylation changes. This 
suggests that the genes that become methylation in peripheral blood during normal 
ageing may be closely related to the genes that become methylated in the cancer type 
developed from this tissue type. The observation that methylation changes during 
normal ageing are following similar patterns to the methylation changes during 
leukaemia development, leads to the hypothesis that increased levels of methylation, 
acquired during the ageing process, might be a precursor for the development of 
leukaemia, and potentially other disease related to age. This hypothesis is strengthened 
by the observations that co-methylation of several genes were also already present in 
healthy individuals, similar to the CIMP described in cancer, describing the presence of 
widespread CpG island methylation in tumours. 
Three of the other genes under study: HOXA4, HOXA5 and the imprinted gene 
IGF2 showed different patterns in methylation levels during aging compared to the 
earlier discussed five genes. The methylation levels for these genes are relatively stable 
during aging, although the methylation levels for these genes are changing significantly 
between the two youngest age groups. Both HOXA5 and IGF2 showed significantly 
higher levels of methylation in the neonates compared to the young adults, while 
HOXA4 showed significantly lower levels of methylation in the neonates compared to 
the other, older, age groups. As there were no samples taken between 0 and 17 years of 
age it is not clear if the difference in methylation for these genes after birth occurs 
rapidly or if it is more gradual over the first two decades of life.  
DNA methylation levels of all of these three genes have been associated with early 
development. Both HOXA4 and HOXA5 play a role in development and differentiation, 
while placental DNA methylation changes at the IGF2/H19 imprinted locus are 
associated with fetal development and birth weight in a normal pediatric population (St-
Pierre, 2012). Due to the importance of these genes in early development, it is well 
possible that the methylation levels of these genes change rapidly during the first years 
of life. 
Our results for IGF2 also suggests that methylation patterns for imprinted genes are 
better preserved than for other genes, indicating the importance of the imprinted genes.  
In this study, there was no correlation observed between the methylation levels 
of the neonates and their mother’s age. This is contrary to the observations made in the 
study of Adkins et al, where they found a correlation with maternal age and methylation 
levels in the neonates for 144 CpG sites belonging to 142 genes. The genes that were 
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associated with oncogenesis and cancer progression were significant over-represented 
among the genes that correlated with maternal age (Adkins). Unfortunately, our sample 
set did not allow us to examine the possible link between parental age and the fathers’ 
methylation levels and the methylation levels in the neonates, since in the study of 
Adkins et al a trend was observed between the paternal age and methylation levels in 
the neonates. The only overlapping gene between our study and the study of Adkins et 
al was the imprinted gene IGF2, a gene that showed a correlation between the 
methylation levels in the neonates and maternal age in their study. In our study, no 
evidence of a possible correlation between IGF2 methylation levels in the neonates and 
the mother’s age was observed. However, it is possible that a correlation between the 
maternal age and methylation levels in the neonates in our study was not detected due to 
the low number of samples in our study; we examined 49 samples, compared to 96 
samples in the study of Adkins et al. It is also possible that the different techniques used 
in these studies can explain the differences in correlations observed. In our study, 
methylation levels were assessed using pyrosequencing, which is a highly accurate 
measurement of CpG methylation. In the study of Adkins et al they performed a 
Humanmethylation27 BeadChip method. After the Humanmethylation27 BeadChip, 
they confirmed some genes on the pyrosequencer. Unfortunately, IGF2 was not among 
those genes. However, the methylation results gathered by both methods in their study 
indicated that the correlation between maternal age and newborn DNA methylation 
levels is replicable, but that the absolute methylation values derived from the 
Humanmethylation27 array for some sites may be biased indicators of the true values 
and may overestimate the true level of inter-individual variation in methylation levels 
(Adkins). As a result, it is possible that the correlation observed between maternal age 
and the neonates methylation levels as observed in their study is an overestimation due 
to the technique used in their study. 
The results of our study might suffer from confounding factors related to the 
study set-up. First of all, the DNA samples of the 4 different age groups were collected 
as part of different study cohorts. Although the method of DNA isolation is unlikely to 
influence the methylation results, especially since all DNA samples were stored in a 
similar fashion after blood collection, it is still a possibility. Our different study 
populations were not matched for several other factors, such as racial background and 
socio-economic status (SES), factors that might have influenced the results. Differences 
in CpG site methylation were reported between neonates with an African-American and 
Caucasian racial background (Adkins, 2011) and in adults from Caucasian and non-
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Caucasian racial backgrounds (Lam, 2012). Correlations were observed between early 
life SES and methylation levels in adults, where differences in methylation levels were 
observed in adults with low early-life SES and high early-life SES (Lam, 2012; 
Borghol, 2012). However, it should be noted that the cohorts used in this study all 
collected their samples in similar regions and as a result it is likely that most of these 
factors are relatively similar between the study populations. 
 The DNA from the neonate samples were isolated from cord blood, 
while all the other DNA samples in this study were isolated from PBL. The different 
source of DNA might have influenced methylation levels. The young adults 
participating in our study were pregnant at time of blood collection. What a pregnancy 
does to individuals methylation levels is, by our knowledge, not examined into detail, 
but it might be possible that the methylation levels have been changed due to the 
pregnancy. Although our results suggest that it is unlikely that these methylation 
patterns are changed significantly, since the overall methylation levels produced an 
almost perfect straight line with an increasing age.Overall, our results showed clear age-
related methylation changes in several genes under study. Five genes under study 
showed clear similarities in the change in methylation patterns within different age 
groups. Three of the other genes under study showed more stable levels of methylation 
during ageing although increases in variance of methylation were observed in the older 
age group and one of the genes under study did not show any changes in both the extent 
and variance of methylation with an increasing age. The genes showing these variable 
methylation levels during ageing were closely related to genes that were known to be 
altered in leukaemia, suggesting a potential link between increased levels of methylation 
and the susceptibility of leukaemia development. 
 90 
 
 
 
 
 
Chapter 5. Cell type specific DNA methylation
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5.1 Introduction 
Tissues are made up of a number of different cell types. For example, a blood 
sample contains of plasma and formed elements, such as erythrocytes (red blood cells), 
thrombocytes (platelets) and leukocytes (white blood cells). The leukocytes are again a 
mixture of different cell types, including neutrophils, eosinophils, basophils, 
lymphocytes (T- and B-lymphocytes), monocytes, macrophages and dendritic cells. 
Unlike the genetic make-up, where generally all the cells are virtually identical, 
different cell types have different epigenetic make-ups and express genes differentially 
(Ehrlich, 1982; Byun, 2009). These tissue and cell type specific differences in DNA 
methylation patterns can cause a number of difficulties in clearly understanding age-
related alterations in DNA methylation. Almost all studies are carried out using tissue 
samples, which are a mixture of different cell types. This means interpretation of the 
results obtained for methylation patterns in the tissues may be confounded by age-
related changes in the cellular make-up of tissues. In addition, the extent of age-related 
changes may be underestimated if the changes occur only in one specific cell type in the 
tissue being assessed. The cellular composition of blood changes with age, with a 
decrease in lymphocyte counts observed at older ages (Huenecke, 2008), possibly as a 
result of a reduced efficiency of bone marrow or HSCs to generate lymphoid progeny, 
as was described in several studies using mouse models (Linton, 2004). A study by 
Teschendorff et al showed that these changes in cell composition during ageing could 
potentially explain hypomethylation that was observed with an increasing age, but this 
was not the case for age-related hypermethylation, since they were able to correlate the 
age-associated hypomethylation signature in blood with changes in blood cell-type 
composition in a set of cancer-related genes, but not so for the age-hypermethylated 
signature (Teschendorff).  
It has been suggested that DNA methylation plays a role in lineage restriction in 
blood cells and in regulating commitment to lymphoid versus myeloid cell fates (Cedar, 
2011). Many genes that are initially methylated in stem cells were found to undergo 
selective demethylation in a tissue- or lineage-specific manner, which was shown not to 
be necessarily linked to gene expression. Besides alterations in methylation levels 
between cell lineages, alterations were also observed during haematopoietic 
differentiation of specific cell types (Calvanese). Genomic DNA methylation profiles 
were found to define distinct cell types and profiles  of haematopoietic cells of the same 
type are more closely related to each other than to other cell types (Bocker). It has been 
proposed that these lineage-specific DNA methylation patterns are established prior to 
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terminal differentiation of adult progenitor cells (Hupkes). The study of Lee et al 
showed that in progenitor cells before complete B-cell lineage commitment, the 
promoters of the majority of the CpG islands in gene promoters are hypomethylated. 
During progression through B-cell stages, these promoter regions maintained their 
hypomethylation status, whereas alterations in methylation occurred specifically to the 
gene body regions of genes (Lee, 2012).  
This study was designed to examine methylation patterns in different cell types 
in the promoters of nine genes and to examine how these methylation patterns are 
maintained during ageing, to assess if the age-related DNA methylation changes 
measured in PBL could be related to altered cellular make-up of the blood with an 
increasing age or if these changes in methylation are genuine increased levels of 
methylation in the different cell types. Another aim of this study was to understand the 
impact of differences in cellular make up between individuals to assess the potential 
links between methylation levels and disease development at an individual level.  
Methylation differences between cell types and within different age groups were 
assessed on specific isolated cell types from PBL samples from a group of young adults 
and a group of older adults. Isolating stem-and early progenitor cells, as well as cells 
later during differentiation, from a set of G-CSF mobilized samples, allowed us to 
examine methylation patterns of this same set of genes during cell differentiation. Seven 
of the genes under study had been previously identified to show age-related methylation 
changes (as described in Chapter 4), one gene is a known imprinted gene and one was a 
control gene not affected by age related DNA methylation in PBL.  
 
5.2 Samples 
Blood samples were collected from 10 young adults, between 24 and 31 years of 
age, with an average age of 27.6, and from 8 adults, between 43 and 60 years of age, 
with an average age of 51.6 (Table 5.1). MNCs were isolated using Biocoll gradient 
centrifugation. B-lymphocytes, T-lymphocytes and monocytes were isolated from the 
MNCs using the dynabead separation protocol for these specific cell types, as described 
in Chapter 3. The monocyte depleted MNC samples were also stored as this sample 
represents a total lymphocyte population. The granulocytes were isolated by gradient 
centrifugation. DNA was extracted from the different cell types and from both the PBL 
and MNC samples. 
G-CSF mobilized CD34 peripheral blood cells were collected from six young 
adults, between 24 and 33 years of age, with an average age of 26.2 and stored in liquid 
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nitrogen in medium containing DMSO to prevent cell lysis. The cells were defrosted 
and CD34
+
 cells were isolated from these samples using the dynabead separation 
protocol, as described in Chapter 3. Further isolation into early B-cell progenitors led to 
a collection of CD34
+
CD19
+
 and CD34
+
CD19
- 
cells. B-lymphocytes, T-lymphocytes 
and monocyte were also isolated from these samples (Table 5.1). 
 
 
 
 
 
 
 
 
 
 Young adults Adults G-CSF samples 
Age (years) 24-31 
(average 27.6) 
43-60 
(51.6 average) 
24-33 
(average 26.2) 
Gender 4 female 
6 male 
5 female 
3 male 
Unknown 
DNA samples PBL 
MNC 
Lymphocytes 
B-lymphocytes 
 
Monocytes 
PBL 
MNC 
Lymphocytes 
B-lymphocytes 
T-lymphocytes 
Monocytes 
Granulocytes 
Stem- and early progenitor 
cells 
Early B-cell progenitors 
Progenitor cells- B-cell 
progenitors 
B-lymphocytes 
T-lymphocytes 
Monocytes 
Number of 
participants 
10 8 6 
Table 5.1: The cell type specific methylation study population 
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5.2.1 Validation of cell isolation 
The cell isolation was validated using two different methods. After the CD34 
isolation by the use of dynabeads, these beads could be detached, which allowed 
validation by flow cytometry. After isolation of the CD34
+
 cells, the cells were stained 
with a fluorescence antibody specific for CD34 to distinguish the CD34 positive cells, 
from the negative cells. The beads for the CD19, CD14 and CD3 isolations could not be 
detached after isolation. These beads were also able to respond to the different 
antibodies used for flow cytometry, which are supposed to be directed against specific 
cell surface makers. This made it impossible to perform the validation of the isolation of 
these specific cell types by flow cytometry and as a result, the validations of these cell 
isolations were performed using the qPCR technique (as described in Chapter 3). 
 
5.3 Results 
 
5.3.1 Validation of cell isolation 
CD34 cells were isolated from G-CSF mobilized CD34 peripheral blood 
samples that were stored in liquid nitrogen in medium containing 10% DMSO, by the 
dynabead isolation method, as described in Chapter 3. 
After isolation of the CD34
+
 cells, the cells were stained with a fluorescence antibody 
specific for CD34. This showed that after isolation, 88% of the stained isolated cells 
were positive for the CD34 antibody, compared to 4.4% in for the unstained sample, 
indicative of the positive isolation (Figure 5.1).  
To validate the other cell isolations, CD19, CD14 and CD3 cells were isolated 
using the dynabead isolation method, as described in Chapter 3, from PBL samples. 
Expression of cell type specific markers CD19 (a B-lymphocyte marker), CD14 (a 
monocyte marker), CD3 (a T-lymphocyte marker) and GAPDH (control) was quantified 
in extracted RNA using qPCR. Cell lines, known to be expressing each marker, were 
used as positive controls. All of the cell lines expressed the markers they were supposed 
to be positive for, ensuring us that the qPCR worked properly. As expected, the PBL 
and MNC samples expressed all the cell type specific markers. The sorted B-
lymphocytes expressed CD19, but were negative for CD14 and CD3. The sorted T-
lymphocytes expressed CD3, but were negative for CD19 and CD14 expression. The 
sorted monocytes expressed CD14, but were negative for CD19 and CD3 and the 
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expression for the MNC sample minus the B-lymphocytes was negative for CD14 and 
positive for CD19 and CD3 (Table 5.2).  
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1: Validation of the CD34 isolation by flow cytometry 
In the unsorted cells, 93.8% of the cells were placed in the Q3 quarter, indicative of a CD34 
negative population, while only low numbers of cells were placed in the upper half of the Q1 
quarter. 
After sorting CD34 cells, a large number of cells were placed in the upper half of the Q1 
quarter, indicative of a CD34 positive population.  
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Sample 
CD14 expression 
(fold enrichment 
compared to PBL) 
CD19 expression 
(fold enrichment 
compared to PBL) 
CD3 expression 
(fold enrichment 
compared to PBL) 
MNC 0.60 0.47 0.45 
T-lymphocytes 0.08 0 3.98 
B-lymphocytes 0.02 3.55 0 
Monocytes 0.20 0.07 0.01 
MNC- monocytes 0.02 0.21 1.04 
Table 5.2: Validation of the cell isolation using qPCR 
Isolation of the T-lymphocytes, B-lymphocytes and the monocytes were validated using qPCR. 
This table shows the fold enrichment of the individual markers in the different cell types relative 
to the PBL sample. All the cell types were positively expressing their cell type specific cell 
surface markers and negative (or close to negative) for the cell surface markers specific for the 
other cell types.  
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5.3.2 Cell type specific DNA methylation patterns were observed in the young adult 
population 
Methylation levels were assessed by pyrosequencing in the isolated cell types 
from the young adults in a set of nine genes, the examine cell type specific methylation 
patterns. 
The five genes under study that were previously described to show similar 
patterns of age-related methylation changes (as described in Chapter 4); TUSC3, 
TWIST2, HOXD4, EphA10 and HAND2, exhibited similar patterns of cell type specific 
methylation differences in the young adults. The lymphoid cells showed significantly 
higher levels of methylation compared to the myeloid cell type (the monocytes) (Table 
5.2). However, it were the B-lymphocytes that showed the highest levels of methylation 
for all these cell types analysed and the methylation levels in these B-lymphocytes were 
even significantly increased compared to the total amount of lymphocytes (Table 5.3).  
For example for the TUSC3 gene, methylation levels of 6.62% were observed in the 
PBL sample. The lymphoid cells showed higher levels of methylation, namely 8.11%. 
However, TUSC3 methylation levels in the B-lymphocytes were 16.50%, which was 
significantly higher than any of the other cell types assessed. This was significantly 
higher than in any of the other cell types (Table 5.3 and Figure 5.2A-E). 
HOXA4 and HOXA5 were previously described to show changes in the variance 
of methylation with an increasing age, while the extent of methylation was relatively 
stable with an increasing age. These genes exhibited significantly higher levels of 
methylation in the normal PBL samples compared to the earlier described five genes in 
these young adults (38.50% for HOXA4 and 53.57% for HOXA5). Cell type specific 
methylation changes were observed even in these genes. The methylation levels of the 
lymphoid cells were significantly higher than the methylation levels in the myeloid cell 
type (the monocytes) (Table 5.3 and Figure 5.2A F-G).  
Even though the imprinted gene IGF2 was previously described to show similar 
patterns of age-related methylation as the HOXA4 and HOXA5 genes, it did not show 
any differences in methylation levels within the different cell types in the young adults 
(Table 5.3 and Figure 5.2AH), nor did the MLH1 gene. However, methylation levels at 
this MLH1 locus were found to be very low in all cell types assessed (Table 5.3 and 
Figure 5.2AI). 
 These results show that cell-type specific methylation patterns are present in 
peripheral blood. The existence of both this cell type specific methylation, which is 
primarily present in the B-lymphocytes, and age-related DNA methylation, as described 
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in Chapter 4, in this same set of genes, suggests that the observed methylation changes 
during ageing are not accumulated in the stem cells (all these cell types derive from the 
same pool of stem cells), but that they rather occur during the process of differentiation.  
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 TWIST2 TUSC3 HOXD4 EphA10 HAND2 HOXA5 HOXA4 IGF2 MLH1 
Methylation levels PBL (%) 4.86 6.62 10.07 8.27 8.80 53.57 38.50 43.93 1.97 
Methylation levels MNC (%) 5.61 8.48 12.50 9.80 8.45 52.62 39.62 43.98 1.54 
Methylation levels total 
lymphocytes (%) 
6.51 8.48 13.48 10.73 8.26 54.41 41.23 45.19 1.69 
Methylation levels  
B-lymphocytes (%) 
13.74 16.50 22.02 15.80 10.87 56.31 44.58 47.43 2.03 
Methylation levels monocytes 
(%) 
3.14 5.07 6.79 6.89 6.34 51.29 36.82 43.41 1.54 
          
PBL – MNC P=0.169 P=0.005** P=0.028* P=0.013* P=0.878 P=0.199 P=0.169 P=0.575 P=0.056 
Lymphocytes- monocytes P=0.003
** 
P=0.005
**
 P=0.005
**
 P=0.005
**
 P=0.022
* 
P=0.032
* 
P=0.013
* P=0.214 P=0.382 
B-lymphocytes- Lymphocytes P=0.006
** 
P=0.005
**
 P=0.005
**
 P=0.005
**
 P=0.005
**
 P=0.241 P=0.037
* P=0.374 P=0.183 
B-lymphocytes- monocytes P=0.003
** 
P=0.005
**
 P=0.005
**
 P=0.005
**
 P=0.005
**
 P=0.005
**
 P=0.005
**
 P=0.086 P=0.066 
Table 5.3: Methylation levels differ between cell types in the young adult population 
Significant differences in methylation levels were observed between the different cell types in the young adults (n=10) for seven of the genes under study (Paired 
samples T-test for the genes HOXA5 and MLH1, Wilcoxon signed rank test for all the other genes under study (SPSS)). 
A complete overview of the statistical analyses performed on the methylation levels between all cell types can be found in Appendix C, Table C.1. 
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Figure 5.2A-D: Cell type specific methylation patterns in the young adult population for the TUSC3, TWIST2, HOXD4 and EphA10 
A-D) Clear cell type specific methylation differences are observed in the young adults for TUSC3, TWIST2, HOXD4 and EphA10. Significantly higher levels of 
methylation were observed in the lymphoid cells compared to the monocytes (Table 5.3). The B-lymphocytes exhibited highest levels of compared to the other 
cell types analysed, namely the monocytes and the total lymphocytes. 
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Figure 5.2E-G: Cell type specific methylation patterns in the young adult population for the HAND2, HOXA5 and HOXA4 
E-G) Cell type specific methylation differences are observed in the young adults for HAND2, HOXA5 and HOXA4. Significantly higher levels of methylation 
were observed in the lymphoid cells compared to the monocytes (Table 5.3). The B-lymphocytes exhibited highest levels of DNA methylation compared to the 
methylation levels of the other cell types, namely the monocytes and the total lymphocytes. 
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Figure 5.2H and I: Cell type specific methylation patterns in the young adult population for the IGF2 and MLH1 
H and I) No significant difference in methylation levels were observed between the different cell types for IGF2 and MLH1. 
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5.3.3 Cell type specific DNA methylation patterns were observed in the adult 
population 
Cell type specific methylation patterns were observed in the cell types isolated 
from the young adults. The observations that methylation differences were present 
between cell-lineages in peripheral blood, suggests that alterations in these cells have to 
occur during haematopoietic differentiation, since all the cell types in blood are derived 
from the same pool of stem cells in the bone marrow. An alternative hypothesis for 
altered epigenetic states to develop in different cell types is that different epigenetic 
states in stem cells could bias differentiation down one lineage or another, such that 
highly-methylated stem cells differentiate in one lineage, while the stem cells with low 
levels of methylation differentiate into the other lineage. It is possible that ageing may 
result in further differences in methylation levels between cell types, either just by 
random drift or because different cell types may be differentially sensitive to age-related 
influences on the epigenome.  
To examine cell-type specific methylation patterns with an increasing age, cell 
types were isolated from a group of adults. In these adults, T-lymphocytes and 
granulocytes were isolated at the same time as the B-lymphocytes and the monocytes to 
get a more complete set of cell types in blood.  
The five genes that showed both age-related methylation patterns and differential 
methylation in the specific cell types isolated from the young adults; TUSC3, TWIST2, 
HOXD4, EphA10 and HAND2, exhibited similar patterns of cell type specific 
methylation in this group of adults. For these five genes, the lymphoid cells (T-
lymphocytes and B-lymphocytes) exhibited more methylation than the myeloid cells 
(monocytes and granulocytes). Differences in methylation levels were also observed 
between cell types from the same lineage; the B-lymphocytes exhibited higher levels of 
methylation than the T-lymphocytes and the granulocytes exhibited higher levels of 
methylation than the monocytes.  
Even though all the genes followed similar patterns of methylation changes in the 
different cell types, some of the methylation differences between the cell types were 
smaller for some of the genes, such that some of the differences in those genes fell short 
of statistical significance (Table 5.4 and Figure 5.3A-E).  
 As observed in the young adult population, both HOXA5 and HOXA4 also 
showed cell type specific methylation patterns. No significant differences were 
observed between all the cells from the lymphoid and the myeloid lineage, however 
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differences in methylation levels were observed between some cell types; for HOXA5 
significant differences were observed between the T-lymphocytes and the myeloid cells 
and HOXA4 exhibited differences in methylation levels between the B-lymphocytes and 
the myeloid cells. Differences in methylation levels were observed between cell types 
from the lymphoid lineage for HOXA5, but neither of these genes showed differences in 
methylation levels between the cell from the myeloid lineage (Table 5.4 and 
Figure5.3F-G). 
IGF2 did not show any significant differences in methylation levels in the cell 
types isolated from the young adults. However, in the adults, differences were observed 
between the B-lymphocytes and the myeloid cells and between the lymphoid cell types 
(Table 5.4 and Figure5.3H). 
 These results show that different cell types in peripheral blood still exhibit cell 
type specific methylation patterns in adults. Differences were even observed in different 
cell types from the same lineage, showing that these methylation patterns are not just 
lineage-specific.
 105 
 
 TWIST2 TUSC3 HOXD4 EphA10 HAND2 HOXA5 HOXA4 IGF2 
Methylation levels PBL (%) 5.00 6.39 11.32 10.78 9.58 61.22 46.09 42.97 
Methylation levels MNC (%) 6.61 8.29 13.88 12.49 10.07 62.03 48.33 44.97 
Methylation levels lymphocytes (%) 7.09 8.79 16.27 13.34 10.67 62.60 48.60 41.60 
Methylation levels T-lymphocytes (%) 8.28 9.29 16.55 14.67 10.41 64.77 48.24 43.18 
Methylation levels B- lymphocytes (%) 12.31 13.28 19.79 16.08 14.13 58.54 53.44 48.03 
Methylation levels monocytes (%) 2.75 3.42 6.69 8.07 7.60 56.98 44.08 43.49 
Methylation levels granulocytes (%) 4.58 5.71 9.89 9.37 9.18 59.51 44.92 44.33 
         
PBL- MNC P=0.036
* 
P=0.012
*
 P=0.012
*
 P=0.036
* P=0.262 P=0.398 P=0.149 P=0.225 
Lymphocytes- monocytes P=0.012
* 
P=0.012
* 
P=0.012
*
 P=0.012
*
 P=0.012
*
 P=0.237 P=0.185 P=0.090 
Lymphocytes- granulocytes P=0.012
* 
P=0.017
*
 P=0.012
*
 P=0.012
*
 P=0.093 P=0.398 P=0.194 P=0.064 
T-lymphocytes- B-lymphocytes P=0.012
*
 P=0.012
*
 P=0.036
* 
P=0.327 P=0.012
**
 P=0.043* P=0.243 P=0.017
* 
Monocytes- granulocytes P=0.017
*
 P=0.017
*
 P=0.012
*
 P=0.05
*
 P=0.208 P=1.000 P=0.541 P=0.445 
Table 5.4: Methylation levels differ between cell types in the adult population 
Significant differences in methylation levels were observed between the different cell types in the adult population (n=8) for seven of the genes under study (Paired 
samples T-test for the genes HOXA4 and IGF2, Wilcoxon signed rank test for all the other genes under study (SPSS)). 
A complete overview of the statistical analyses performed on the methylation levels between all cell types can be found in Appendix C, Table C.2. 
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Figure 5.3A-D: Cell type specific methylation patterns in adult population for TUSC3, TWIST2 and HOXD4 
A-C) For TUSC3, TWIST2 and HOXD4, the cells from the lymphoid lineage showed significantly higher levels of methylation than the cells from the myeloid lineage. 
Significant differences were observed between the isolated cell types per lineage; the B-lymphocytes showed significantly higher levels of methylation than the T-
lymphocytes; and the granulocytes showed significantly higher levels of methylation than the monocytes (Table 5.4). 
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Figure 5.3D and E: Cell type specific methylation patterns in adults for EpHA10 and HAND2  
D) For the EphA10 gene, the cells from the lymphoid lineage showed significantly higher levels of methylation than the cell from the myeloid lineage. No significant 
differences were observed between the cell types from the lymphoid lineage, whereas significant differences were observed between the isolated cell types from the 
myeloid lineage; the granulocytes showed significantly higher levels of methylation than the monocytes (Table 5.4). 
E) For the HAND2 gene, significantly higher levels were observed in the isolated B-lymphocytes compared to the isolated cell types from the myeloid lineage and the T-
lymphocytes showed significantly higher levels of methylation than the monocytes (Table 5.4). 
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Figure 5.3F-H: Cell type specific methylation patterns in adults for HOXA4, HOXA5 and IGF2  
F) For the HOXA5 gene, significantly higher levels of methylation were observed in the T-lymphocytes compared to the other isolated cell types: the B-lymphocytes, 
monocytes and granulocytes (Table 5.4). 
G) For the HOXA4 gene, there were only significant differences observed between the B-lymphocytes with the lymphocytes, T-lymphocytes and the monocytes (Table 
5.4). 
H) For the IGF2 gene, significantly higher levels of methylation were observed in the isolated B-lymphocytes compared to the other isolated cell types: T-lymphocytes, 
monocytes and granulocytes (Table 5.4). 
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5.3.4 Age-related methylation changes in the different cell types  
To examine the age-related differences in methylation levels in individual cell 
types, the methylation levels for each individual cell type was compared between the 
young adults and the adults. The main aim of this comparison was to examine whether 
the changes that we observed in PBL during ageing occurred in all the different cell 
types, or in just a subset of the cell types and as a result, whether age-related 
methylation must occur in the stem cells or if age-related methylation mainly occurs 
during the process of differentiation. 
Five of the genes under study; TUSC3, TWIST2, HOXD4, EphA10 and HAND2, 
showed similar patterns of both age-related and cell types specific methylation 
differences, and similar patterns of methylation in the specific cell types was observed 
in both the young adults and the adults. A general increase in methylation levels were 
observed for these genes during ageing in PBL and in the lymphocytes. In contrast, the 
isolated B-lymphocytes did not show consistent increases in methylation at the five loci. 
In fact, for three of the five loci, TWIST2, TUSC3 and HOXD4, methylation levels were 
reduced in the older age group for this cell type (Table 5.5 and Figure 5.4A-E). The 
apparent drop in methylation of the B-lymphocytes may be a little misleading as the 
young adult group contained a single outlier sample with an especially high level of B-
lymphocyte methylation. If the comparison is done using the median average (as 
opposed to the mean) then the apparent reduction in B-lymphocyte methylation is 
largely lost (Appendix C, Table C.3). However there is still a lack of a clear increase in 
the levels of methylation in the B-lymphocytes across the 5 genes. 
In the monocytes, no differences in methylation levels between the two age groups were 
observed for TWIST2 and HOXD4, a slight increase was observed for EphA10 and 
HAND2, while significantly lower levels of methylation was observed in the monocytes 
for the TUSC3 gene (Table 5.5 and Figure 5.4A-E).  
The HOXA4 and HOXA5 genes both showed increased levels of methylation in 
the adults compared to the young adults in most of the different cell types analysed, 
with the exception of methylation levels of the B-lymphocytes for HOXA5. For this 
gene, the methylation levels for the B-lymphocytes did not change between the two age 
groups (Table 5.5 and Figure 5.4F-G).  
The IGF2 gene did not show any sign of differences in methylation levels of the 
specific cell types between the two age groups (Table 5.5 Figure 5.4H) 
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In this study, we examined patterns of DNA methylation in different cell types 
during ageing to examine whether the age-related methylation patterns are restricted to a 
specific cell type or if there is a more general increase in methylation in all the different 
cell types. All the blood cells develop from the same pool of stem cells, so to explain 
the differences in methylation levels between the cell types, the alterations in 
methylation levels have to occur during haematopoietic differentiation. Ageing may 
result in further differences in methylation levels between cell types by loss of fidelity 
of replication of methylation patterns during the differentiation process. However, in 
our study, there was no evidence to support the hypothesis that an increase in 
methylation occurred mainly in a specific cell type, arguing against this potential 
explanation. Instead, our results are more compatible with the hypothesis that altered 
methylation during ageing accumulates in the stem cells, although our sample numbers 
were limited, and a greater number of samples have to be examined to draw more 
definite conclusions.  
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  TWIST2 TUSC3 HOXD4 EphA10 HAND2 
1st 5 genes 
combined 
HOXA5 HOXA4 IGF2 
P
B
L
 
Methylation levels young adults (%) 4.86 6.62 10.07 8.27 8.80 7.72 53.57 38.50 43.93 
Methylation levels adults (%) 5.00 6.39 11.32 10.78 9.58 8.61 61.22 46.09 42.97 
          
Young adults- Adults P=0.929 P=0.594 P=0.328 P=0.004** P=0.424 P=0.328 P=0.172 P=0.076 1.00 
M
N
C
 
Methylation levels young adults (%) 5.61 8.48 12.50 9.80 8.45 8.97 52.62 39.62 43.98 
Methylation levels adults (%) 6.61 8.29 13.88 12.49 10.07 10.27 62.03 48.33 44.97 
          
Young adults- Adults P=0.310 P=0.790 P=0.248 P=0.010** P=0.026* P=0.131 P=0.051 P=0.033* P=0.534 
L
y
m
p
h
o
cy
te
s Methylation levels young adults (%) 6.51 8.48 13.48 10.73 8.26 9.49 54.41 41.23 45.19 
Methylation levels adults (%) 7.09 8.79 16.27 13.34 10.67 11.23 62.60 48.60 41.60 
          
Young adults- Adults P=0.790 p=0.424 P=0.026* P=0.006** P=0.010** P=0.041
* P=0.430 P=0.155 P=0.083 
B
-l
y
m
p
h
o
cy
te
s Methylation levels young adults (%) 13.74 16.50 22.02 15.80 10.87 15.79 56.31 44.58 47.43 
Methylation levels adults (%) 12.31 13.28 19.79 16.08 14.13 15.12 58.54 53.44 48.03 
          
Young adults- Adults P=0.722 P=0.286 P=0.594 P=0.929 P=0.026* P=0.534 P=0.845 P=0.091 P=0.773 
M
o
n
o
cy
te
s 
Methylation levels young adults (%) 3.14 5.07 6.79 6.89 6.34 5.65 51.29 36.82 43.41 
Methylation levels adults (%) 2.75 3.42 6.69 8.07 7.60 5.70 56.98 44.08 43.49 
          
Young adults- Adults P=0.182 P=0.001*** P=1.000 P=0.091 P=0.131 P=0.897 P=0.064 P=0.183 P=0.929 
Table 5.5: Methylation levels of the specific cell types in the young adult population compared to the adult population 
Statistical differences were observed between the young adults (n=10) and the adults (n=8) in a small number of genes (Wilcoxon rank sum tests (SPSS)). 
 112 
 
  
Figure 5.4A-C: Cell type specific methylation patterns with an increasing age for TWIST2, TUSC3 and HOXD4  
A) No differences in methylation levels were observed between the two age groups for the TUSC3 gene for the PBL, MNC and lymphocyte samples. The B-
lymphocytes and the monocytes showed lower levels of methylation in the older age group, although this difference was only significantly lower in the monocytes 
(Table 5.5). 
B) No significant differences were observed in the methylation of the isolated cell types within the different age-groups for TWIST2. 
C) An increase in methylation levels with an increasing age were observed in PBL, MNC and the lymphocytes for the HOXD4 gene, although this difference was only 
statistically significant in the lymphocytes (Table 5.5).  
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Figure 5.4D-F: Cell type specific methylation patterns with an increasing age for EphA10, HAND2 and HOXA5 
D) For the EphA10 gene, significant increased levels of methylation were observed in PBL, MNC and the lymphocytes in the adults compared to the young adults 
(Table 5.5). 
E) Increases in methylation levels were observed in all the different cell types under study with an increasing age for the HAND2 gene, although this increase was only 
statistically significant for the MNC, Lymphocytes and the B-lymphocytes samples (Table 5.5).  
F) No significant differences in methylation levels in the different cell types were observed within the different age groups for HOXA5. 
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Figure 5.4G and H: Cell type specific methylation patterns with an increasing age for HOXA4 and IGF2 
G) HOXA4 showed higher levels of methylation in all the different cell types under study with an increasing age, although this difference was only statistically 
significant for the MNCs (Table 5.5). 
H) No significant differences in methylation levels in the different cell types were observed within the different age groups for HOXA5 and IGF2 (Table 5.5). 
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5.3.5 Methylation levels in stem- and early progenitor cells 
Methylation levels were assessed in isolated stem/progenitor cells (CD34
+
), 
early B-cell progenitors (CD34
+
/CD19
+
) and in differentiated cells from a number of  
G-CSF mobilized samples (isolation as described in section 5.2). This was done to 
examine whether the differences in methylation patterns in the specific cell types, as 
observed in the cells isolated from peripheral blood, arise during the process of 
differentiation, or if these cell type specific methylation patterns are already present in 
the CD34
+
 cells. If the differences observed between the different isolated differentiated 
cells were due to increased lymphoid differentiation of stem cells with increased levels 
of CpG island methylation, then such differences would be present at all stages of 
lymphoid differentiation. 
Analyses of methylation levels of the isolated CD34
+
 cells of the five genes that 
showed clearest differences in methylation patterns within different cell types; TUSC3, 
TWIST2, HOXD4, EphA10 and HAND2, revealed that CD34
+
 cells exhibited 
methylation levels comparable to the methylation levels as observed in the monocytes. 
No significant differences were observed between the methylation levels of the CD34
+
 
population as a whole and the isolated CD34
+
/CD19
+ 
B-cell progenitors for any of the 
genes under study. 
Unexpectedly though, the cell-type specific methylation patterns of the differentiated 
cells in the G-CSF mobilized samples was clearly different from that seen in isolated 
cells from peripheral blood samples, most obviously for the differentiated B-
lymphocytes. For example, the average methylation across the five age-related genes in 
the B-lymphocytes from the sorted PBL samples was 15.8% and 15.12% for the 
younger adults and adults respectively. However, for the sorted G-CSF mobilised 
samples the average B-cell methylation was much lower (8.0%). The overall pattern of 
methylation was somewhat conserved, as lymphoid cells in general and B-lymphocytes 
in particular retained methylation levels higher than in myeloid (monocyte) cells, 
however the differences were greatly reduced. 
No differences in methylation levels were observed between the B-lymphocytes and the 
T-lymphocytes in the G-CSF mobilized samples. However, both the B-lymphocytes and 
the T-lymphocytes showed higher levels of methylation than the monocytes for four of 
these genes (Table 5.6 and Figure 5.5A-E). 
For the other two genes under study: HOXA4 and HOXA5, there were no 
significant differences in methylation levels between all the different cell types isolated 
from these G-CSF mobilized samples. However, for these two genes, increased levels of 
 116 
 
methylation were observed in the CD34
+
CD19
+
 B-cell progenitor cells, compared to 
any of the other cell types, including the CD34
+
 cells and the B-lymphocytes. For 
example for HOXA5, average methylation for the CD34
+
CD19
+
 B-cell progenitor cells 
were 86.14%, compared to 63.19% and 67.66% for the CD34
+
 cells and the B-
lymphocytes respectively (Table 5.6 and Figure 5.5A-E). 
These results show that methylation levels do not differ between the stem-and 
early progenitors as a whole, and the early B-cell progenitors, suggesting that the high 
levels of methylation observed in the B-lymphocytes are not already present at the first 
stage of lineage-commitment. However, these results are a bit preliminary due to the 
low number of samples and due to the unexpected low methylation of the differentiated 
lymphocytes.  
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 TWIST2 TUSC3 HOXD4 EphA10 HAND2 HOXA5 HOXA4 
Methylation levels stem-and early 
progenitor cells (CD34
+
) (%) 
4.04 3.83 8.93 7.06 7.32 63.19 35.00 
Methylation levels early B-cell 
progenitors (CD34
+
CD19
+
) 
6.71 2.68 8.44 7.26 7.14 86.14 44.47 
Methylation levels Stem- and early 
progenitor cells minus B-cell progenitors 
(CD34
+
CD19
-
) (%) 
4.59 3.00 8.67 6.32 7.82 77.47 32.11 
Methylation levels B-lymphocytes (%) 6.70 5.59 10.80 9.13 7.88 67.66 37.03 
Methylation levels T-lymphocytes(%) 5.87 5.28 10.26 8.95 7.75 65.04 38.33 
Methylation levels monocytes (%) 4.04 3.83 12.4 7.06 7.32 63.19 35.00 
        
Stem-and early progenitor cells-  
B-cell progenitors 
P=0.600 P=0.232 P=0.893 P=0.204 P=0.893 P=0.109 P=0.651 
B-cell progenitors- B-lymphocytes P=0.752 P=0.038
* P=0.345 P=0.190 P=0.686 P=0.109 P=0.903 
B-lymphocytes- T-lymphocytes P=0.173 P=0.689 P=0.463 P=0.800 P=0.463 P=0.225 P=0.432 
B-lymphocytes- Monocytes P=0.028
* 
P=0.020
* P=0.075 P=0.025
* P=0.463 P=0.500 P=0.108 
T-lymphocytes- Monocytes P=0.028
* 
P=0.013
* 
P=0.028
* 
P=0.001
*** P=0.345 P=0.225 P=0.183 
Table 5.6: Methylation in the different cell types isolated from the G-CSF mobilized samples 
Statistical differences were observed between different cell types in a small number of genes in the cells isolated from the G-CSF mobilized samples (n=6, Paired 
samples T-test for TUSC3, EpHA10 and HOXA4, Wilcoxon signed rank test for the other genes under study (SPSS)). 
A complete overview of the statistical analyses performed on the methylation levels between all cell types can be found in in Appendix C, Table C.4. 
 118 
 
  
Figure 5.5A and B: Methylation patterns during cell differentiation for TUSC3 and TWIST2  
A) Analyses of TUSC3 methylation patterns in the G-CSF mobilized samples revealed that significant differences were observed between methylation patterns of the 
B-lymphocytes and CD34
+
 the stem- and early progenitor cells. Methylation patterns in the B-lymphocyte population as a whole was significantly higher than the 
methylation patterns in the CD34
+
CD19
+
 B-cell progenitors and both the B-lymphocytes and T-lymphocytes methylation levels were significantly higher than the 
methylation levels of the monocytes (Table 5.6). 
B) TWIST2 methylation levels were significantly different between the CD34
+
 stem- and early progenitor cells and the T-lymphocytes and between both the B- and T-
lymphocytes and the monocytes in the G-CSF mobilized samples (Table 5.6).  
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Figure 5.5C-E: Methylation patterns during cell differentiation for HOXD4, EphA10 and HAND2 
C) No differences in methylation levels were observed between the CD34
+
 stem- and early progenitor cells and the cells later during differentiation for the HOXD4 
gene. A significant difference was observed between the differentiated T-lymphocytes and monocytes (Table 5.6). 
D) EphA10 methylation levels were significantly different between the CD34
+
 stem- and early progenitor cells and the T-lymphocytes and between both the B-
lymphocytes and the T-lymphocytes and the monocytes in the G-CSF mobilized samples (Table 5.6). 
E) No differences in methylation levels were observed between the stem-and early progenitor cells and the cell later during differentiation or between the different 
differentiated cell types for HAND2. 
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Figure 5.5F and G: Methylation patterns during cell differentiation for HOXA5 and HOXA4 
F and G) No differences in methylation levels were observed between any of the isolated cells types for the HOXA5 and the HOXA4 genes. 
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5.3.6 Correlations between genes in the specific cell types 
For five of the genes under study, TWIST2, TUSC3, EphA10, HOXD4 and 
HAND2, correlations between the methylation levels were observed in PBL from 
healthy individuals. In the specific cell types, again very clear similarities in the patterns 
of DNA methylation were seen for these five genes.  Therefore, the isolated cell types 
were examined for potential correlations between these five genes, to examine whether 
co-methylation occurred within the same populations of cells. 
In the young adults, strong correlations were observed in the methylation levels 
of the B-lymphocytes between these five genes, with the exception of HAND2 
methylation with the methylation levels of TUSC3 and HOXD4 (Table 5.7).  
These results suggest that methylation patterns are mainly driven by co-
methylation of genes within the same population of cells and not by inter individual 
differences in the cellular make-up of peripheral blood. This is also consistent with 
results obtained in a related study in the Newcastle 85+ study population which 
demonstrated that after correcting for differences in the % lymphocytes in individual 
samples the strong co-methylation between the genes still remained (Gautrey, 2012). 
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 TWIST2 TUSC3 HOXD4 EphA10 HAND2 HOXA5 HOXA4 
TWIST2  
R= 0.876 
P= 0.001
*** 
R= 0.920 
P<0.001
*** 
R= 0.845 
P= 0.002
** 
R= 0.691 
P= 0.027
* 
R= -0.098 
P= 0.775 
R= 0.200 
P= 0.555 
TUSC3   
R= 0.842 
P= 0.002
** 
R= 0.904 
P< 0.001
*** 
R= 0.568 
P= 0.087 
R= -0.343 
P= 0.301 
R= 0.290 
P= 0.387 
HOXD4    
R= 0.837 
P= 0.003
** 
R= 0.6121 
P= 0.060 
R= -0.471 
P= 0.143 
R= 0.374 
P= 0.257 
EphA10     
R= 0.683 
P= 0.029
* 
R= -0.138 
P= 0.685 
R= 0.295 
P= 0.378 
HAND2      
R= 0.013 
P= 0.970 
R= 0.415 
P= 0.204 
HOXA5       
R= -0.419 
P= 0.200 
HOXA4        
Table 5.7: Correlations between the methylation levels of genes in the isolated B-lymphocytes from the young adults 
In the B-lymphocytes, correlations were observed between TWIST2, TUSC3, HOXD4 and EphA10 and between HAND2 with TWIST2 and EphA10 in the young 
adults (n=10) 
The test used for these correlations is a Pearson’s correlation (SPSS). The R is indicating the correlation coefficient and the observed P the p-values. 
The correlations between these genes in the isolated lymphocyte and monocyte samples from the young adult participants can be found in Appendix C (Table C.5). 
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5.4 Discussion 
Our study showed that clear cell-type specific methylation patterns were present 
in peripheral blood in a subset of genes. It revealed that for seven of the genes under 
investigation methylation levels were significantly higher in cells from the lymphoid 
lineage (T-lymphocytes and B-lymphocytes) compared to the cells from the myeloid 
lineage (monocytes and granulocytes). Differences in methylation levels were not only 
observed between the cell types from the myeloid and lymphoid lineages, but even in 
cell types from the same lineage. All these blood cells derive from the same pool of 
stem cells, resulting in three possible hypotheses that might explain how these cell-type 
specific methylation differences occur; first of all, methylation differences might 
accumulate in stem cell populations and stem cells with higher levels of CpG island 
methylation might preferentially differentiate into lymphocytes. Secondly, accumulation 
of ‘seeds’ of methylation might occur in stem cells which are expanded during 
lymphoid differentiation only, and lastly cell-type specific methylation differences 
might arise during cell differentiation. 
In case of the first hypothesis, which states that stem cells with higher levels of 
methylation preferentially differentiated into lymphocyte lineages, increased levels of 
methylation should already be present in early B-cell progenitors. To test this 
hypothesis, CD34
+ 
stem- and early progenitor cells were isolated from a set of G-CSF 
mobilized samples, as well as C34
+
CD19
+
 early- B-cell progenitors. Analyses of these 
two cell populations did not show differences in methylation levels between the 
C34
+
CD19
+
 B-cell progenitors and the CD34
+ 
population as a whole, arguing against a 
mechanism involving preferential lymphoid differentiation of stem cells with increased 
CpG island methylation. However, the unexpectedly low levels of methylation in these 
samples in the differentiated B-lymphocytes suggest that further confirmation of these 
results might be useful. 
Interestingly, the cell type that showed highest levels of methylation for the 
genes under study, the B-lymphocytes, is the cell type that is longest lived. This 
suggests that the observed differences between the cell types might occur during the 
‘ageing’ of the cell during differentiation.  Analyses of both the C34+CD19+ early B-cell 
progenitors and B-lymphocytes did not show differences in methylation levels between 
these two cell populations. However, the methylation levels observed for the B-
lymphocytes in these G-CSF mobilized samples were significantly lower than the 
methylation levels of B-lymphocytes isolated from peripheral blood in individuals in a 
similar age-range. It is possible that, since these G-CSF mobilized samples are enriched 
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for early progenitor cells, they therefore contain more early B-lymphocytes than a 
normal blood sample. This might result in lower overall methylation levels in these 
samples if the methylation levels observed in B-lymphocytes occur during the process 
of differentiation. However, this means that the levels of early B-cell progenitors must 
be high to explain the large differences in methylation levels. For example, overall 
methylation levels in the B-lymphocytes for the TWIST2 gene was 13.75% in the cells 
isolated from blood, while this was 6.70% for this cell type in the G-CSF mobilized 
sample. Another possible explanation is that the B-lymphocytes isolated from the G-
CSF mobilized samples underwent less rounds of cell division than the B-lymphocytes 
isolated from blood and that those cells are therefore biologically younger. These 
observations are in line with the third hypothesis, which states that cell type specific 
methylation patterns might occur during the process of differentiation. Differentiated 
cells differ in their life span, where the B-lymphocytes are the cell type that is longest 
lived. It will be interesting to further investigate the effect of this expanded life span in 
the differentiated cells in subsequent studies, to study the full effect of ageing on 
different cell types during differentiation and to address to question whether the 
observed differences observed in our study could be explained by the longevity of the 
B-lymphocytes.  
It is possible that ageing may result in further differences in methylation levels 
between cell types, either just by random drift or because different cell types may be 
differentially sensitive to age-related influences on the epigenome. To investigate how 
ageing affects these cell type specific methylation patterns and how the cell-type 
specific methylation patterns related to the accumulation of age-related DNA 
methylation in PBL, monocytes, lymphocytes and B-lymphocytes were isolated from 
adults from different age groups; young adults (with an average age of 27.6 years) and 
older adults (with an average age of 51.6 year).  Small differences in methylation levels 
were observed between these two age groups for the cell types investigated even in our 
small group of individuals. The number of samples was low and the methylation 
differences small, such that some of the differences in methylation fell short of 
statistical significance. However, these results do suggest that age-related methylation 
differences occur in several cell types and that they are not occurring in one cell type 
specifically. This suggest that age-related differences in methylation levels observed for 
these genes, must occur in a pool of stem cells and that these do not solely occur during 
the process of differentiation. 
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The observed differences in methylation levels are of interest in understanding 
methylation differences during disease development. The inability to maintain 
methylation levels in stem cells during ageing might be an underlying factor of the 
increase of incidence of cancer, and potentially other disease, with an increasing age. 
The CpG island methylation patterns observed here in the isolated lymphoid and 
myeloid cell types from healthy individuals were mirroring patterns observed during 
leukaemia development. The genes under study all played a role in lymphoid leukaemia 
with the exception of both HOXA5 and HOXA4, which are hypermethylated in both 
myeloid and lymphoid leukaemias, and our results showed that even in healthy 
individuals, the lymphoid cells contained higher levels of methylation than the myeloid 
cells for this set of genes. This study also showed that the B-lymphocytes exhibited the 
highest levels of methylation for the genes investigation compared to any of the other 
cell types, including the T-lymphocytes. Interestingly, most haematological 
malignancies are B-lymphocyte derived, again suggesting a link between high levels of 
methylation and the development of a haematological malignancy. The expression 
levels of these genes under study were not investigated in these samples. However, even 
though B-lymphocytes exhibited the highest levels of DNA methylation, a study 
previously performed in our group showed that, at least three genes under study; 
TWIST2, TUSC3 and HOXA4, were expressed in B-lymphocytes (Thathia, 2012; 
Strathdee, 2006). This suggests that the high accumulation of DNA methylation 
observed for these genes in the B-lymphocytes does not only occur in genes that are not 
expressed in that cell type, in which case it would have had little or no significant 
biological impact. Instead, the accumulation of DNA methylation in these genes that are 
expressed in this cell type, suggests that the methylation is not restricted to non-
expressed genes and thus may well affect gene expression patterns. 
Overall, the results from this study showed that cell-type specific methylation 
patterns are present in healthy individuals and that these patterns mirror patterns 
observed during leukaemia development. These patterns are maintained during ageing, 
and age-related methylation changes were observed in the cell types for the set of genes 
under investigation. The results shown here are consistent with the hypothesis that low 
levels of DNA methylation accumulate in stem cells during ageing and that these low 
levels of methylation are then expanded in lymphoid, but not myeloid, cells. At least for 
the genes investigated here, the accumulation of age related CpG island methylation is 
predominantly present in cells of lymphoid origin. This supports the hypothesis that 
age-related DNA methylation may be a key factor in underlying disease susceptibility, 
 126 
 
by the inability of stem cells to stably maintain DNA methylation patterns during 
ageing. 
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Chapter 6. DNA methylation patterns during the development of age-
related diseases  
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6.1 Introduction 
DNA methylation is most extensively studied in cancers, although changes in 
DNA methylation have been described in multiple other diseases, such as 
cardiovascular, neurological and metabolic disorders and autoimmune diseases (Udali, 
2012; Jakovcevski, 2012; Bruce, 2011; Grolleau-Julius, 2010). However, while for 
cancers, a large body of evidence supports a key role for altered DNA methylation in 
cancer development, for other diseases, the functional significance of the observed 
changes in DNA methylation patterns is not clear.  
The main aim of this study was to test whether the acquisition of altered DNA 
methylation during normal ageing may have a significant effect on the likelihood of 
disease development during the life-course, such that individuals who acquire higher 
levels of altered DNA methylation may be at increased risk of disease development. In 
order to test this hypothesis, methylation patterns associated with cancer were examined 
in two of the main age related diseases, cancer and heart disease. This chapter will be 
divided into two parts. In the first part, the changes in methylation patterns in cancer 
patients, more specifically leukaemia and HNPCC patients, will be discussed and in the 
second part the focus will be on changes in methylation patterns in heart disease 
patients.  
 
6.2 Cancer 
During cancer development, reduced levels of global DNA methylation are 
observed, together with local areas of hypermethylation, particularly at CpG islands in 
gene promoters (Gama-Sosa, 1983; Bird, 1996). Many of the genes targeted by 
hypermethylation play roles in tumour suppression. Hypermethylation during cancer 
development within those promoters serves to turn off these critical genes that 
otherwise suppress tumourigenesis (Baylin, 2005). Whilst many tumour suppressor 
genes targeted by hypermethylation during cancer development are tumour-type 
specific, other tumour suppressor genes are shared by multiple tumour types (Hansen, 
2011), such as the p16/CDKN2 gene (Esteller, 2005), the RASSF1 gene and HIC1 gene 
(Teng). These observations suggest a key role of DNA methylation in the development 
of cancer and this leads to the hypothesis that those individuals with increased levels of 
DNA methylation abnormalities may be at a higher risk of cancer development. 
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6.2.1 Leukaemia 
ALL is the most common form of childhood cancer. ALL also occurs in the 
adult population, although it is a rarer disease in adults, compared with other tumour 
types. The survival rate between the childhood and adult ALL patients differs 
significantly. 80-90% of the childhood ALL patients survive the disease. However, 
ALL is still the 2
nd
 leading cause of cancer mortalities in children (Cancer-Research, 
2013). In the adult ALL patients, hematologic remission is obtained in over 90% of the 
patients, but the long-term survival rate (<5 years) is low (around 40%) (Goldstone, 
2008). Therefore, it is important to improve the survival rate of ALL patients. 
Prediction of patients at high risk of developing leukaemia, or patients that are at high 
risk of relapse, will help detecting those patients who can benefit from additional 
treatment.  
Hypermethylation of gene promoters is a feature of essentially all cancers, 
including leukaemia. This methylation can have dramatic consequences since 
hypermethylation of gene promoters leads to transcriptional silencing. Importantly, 
many genes with an established anti-tumourigenic role have been shown to be 
frequently methylated in cancer and promoter associated hypermethylation is believed 
to be one of the primary mechanisms for inactivating such genes.  
Our previous results, as discussed in Chapter 4, suggested a link between genes 
showing methylation changes with age and genes becoming methylated during 
leukaemia development. This would be compatible with the hypothesis that the 
development of age-related changes in DNA methylation may be an important 
underlying cause of cancer development. Therefore in this part of the study, we 
investigated whether apparently normal cells from leukaemia patients in remission, 
exhibited increased levels of methylation and we examined the potential of aberrant 
patterns of DNA methylation in identifying patients that are at high risk of developing 
the diseases. This was done by investigating methylation levels during remission in 
both childhood and adult leukaemia patient in several genes related to leukaemia 
development. 
 
6.2.1.1 Samples 
DNA was purified from peripheral blood collected from 24 childhood ALL 
patients and 21 adult ALL patients. Samples taken at diagnosis, remission and where 
applicable, relapse samples were obtained. All samples were obtained from the 
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Newcastle Haematology Biobank and had been collected with the appropriate ethical 
approval.  
Childhood ALL samples were taken from patients between 1 and 12 years of age, with 
an average age of 4.2. The adult ALL samples were taken from patients between 17 and 
65 years of age, with an average age of 38.8. 14 of the adult ALL patients did not 
survive the disease, and 6 of them were classified as long-term survivors (> 5 
years)(Table 6.1).  
The control samples used for the childhood ALL patients in this study were the 
neonate participants as described in Chapter 4. The controls for the adult ALL patients 
were the young adults and the adult participants as described in Chapter 4 (Table 6.1). 
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 Childhood ALL patients Adult ALL patients 
 Patients Controls Patients Controls 
Age (years) <1-12 
(average 4.2) 
0 
(average 0) 
18-65  
(average 37.0) 
17-50 
(average 39) 
Number of 
patients 
24 50 28 98 
Gender  10 male 
8 female 
6 unknown 
33 male 
15 female 
1 unknown 
14 male 
7 female 
7 unknown 
18 male 
80 female 
Leukaemia 18 Common 
2 B-lymphocyte 
3 T-lymphocyte 
1 non T-
lymphocyte 
 1 Common 
4 B-lymphocyte 
8 T-lymphocyte 
 
5 Calla 
1 Null 
1 Unkown 
 
Patient 
outcome 
22 non-relapse 
patients 
2 relapse patients 
24 long-term 
survivors 
 4 non-relapse 
patients 
24 relapse patients 
6 long-term 
survivors 
 
Available 
matched DNA 
samples  
 
22 diagnosis-
remission 
2 diagnosis-
remission-relapse  
 4 diagnosis-
remission  
17 diagnosis-
remission-relapse 
6 diagnosis-
relapse  
 
Table 6.1: An overview of the ALL study population 
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6.2.1.2 Results 
 
6.2.1.2.1 Relationship of remission methylation patterns with those seen at diagnosis 
and relapse in ALL patients. 
Methylation levels were examined in matched diagnostic, remission, and where 
applicable relapse, samples from our set of both childhood and adult ALL patients (as 
detailed in Table 6.1). As expected, methylation levels of the seven loci known to 
exhibit very frequent methylation changes in ALL were very high in diagnostic samples 
as well as in the relapse samples. Whereas, in contrast, the non-leukaemia associated 
gene IGF2 exhibited relatively stable methylation during both diagnosis and relapse. 
The methylation levels observed in the diagnostic and the relapse samples showed no 
significant differences for any of the genes examined. During remission, the 
methylation levels were significantly reduced compared to both the diagnostic and 
relapse samples for all the genes under study, with the exception of IGF2 (Table 6.2 and 
Figure 6.1) 
  As detailed above, methylation levels in the remission samples were far lower 
than those seen in either the diagnostic or relapse sample sets. To examine if there was 
evidence between a link of the altered methylation patterns in the leukaemia samples 
and the methylation levels in the matched remission samples, the data was examined for 
possible correlations. No significant correlations were observed between methylation 
levels during diagnosis and remission (available for 21 adult samples and 24 childhood 
samples), with the exception of a limited correlation for HAND2 in adult ALL. 
Similarly no significant correlations were observed between methylation levels in the 
remission samples and the methylation detected in the matched relapse samples 
(available for 17 adult samples). In contrast, correlations between the diagnostic and 
relapse samples were observed for 5 of the genes in the adult age group (available for 23 
adult samples), namely TWIST2, TUSC3, EphA10, HAND2, HOXA5 and IGF2 (Table 
6.3). In the childhood patients the number of relapsed patients was too small to perform 
the same statistical analyses. 
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A. 
  TWIST2 TUSC3 HOXD4 EphA10 HAND2 HOXA5 HOXA4 IGF2 
 A
d
u
lt
 A
L
L
 
Methylation 
levels at 
diagnosis (%) 
63.03 46.99 70.71 58.93 44.11 78.46 78.33 50.21 
Methylation 
levels during 
remission (%) 
11.65 12.26 16.22 12.00 7.73 64.44 44.35 41.00 
Methylation 
levels at 
relapse (%) 
72.38 47.83 74.59 64.15 53.13 81.96 77.62 49.22 
 
B. 
  TWIST2 TUSC3 HOXD4 EphA10 HAND2 HOXA5                                 HOXA4 IGF2
C
h
il
d
h
o
o
d
 A
L
L
 
Methylation 
levels at 
diagnosis (%) 
51.79 29.60 62.13 45.38 37.26 67.47 65.88 44.82 
Methylation 
levels during 
remission (%) 
5.77 5.80 9.15 6.72 4.53 59.22 39.10 40.33 
Methylation 
levels at 
relapse (%) 
28.81 6.49 31.99 20.43 19.43 64.20 51.31  
Table 6.2: Methylation levels at diagnosis, remission and relapse 
A) Average methylation levels at diagnosis, remission and relapse in the adult ALL 
patients (n=28) as assessed by pyrosequencing.  
B) Average methylation levels at diagnosis, remission and relapse in the childhood ALL 
patients (n=24) as assessed by pyrosequencing.  
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Figure 6.1A-E: Methylation levels during the different phases of adult ALL for TWIST2, TUSC3, HOXD4, EphA10 and HAND2 
A-E) The methylation levels in the paired adult ALL samples were significantly reduced during remission compared to both the diagnostic and relapse phase for 
TWIST2, TUSC3 , HOXD4, EphA10 and HAND2 (p<0.001 for all genes). No significant differences were observed in methylation levels during diagnosis and 
relapse for any of these genes (Wilcoxon signed rank test (SPSS)). 
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Figure 6.1F-H: Methylation levels during the different phases of adult ALL for HOXA5 and IGF2 
F and G) The methylation levels in the paired adult ALL samples were significantly reduced during remission compared to both the diagnostic and relapse phase 
for HOXA5 and HOXA4 (p=0.013 and p<0.001 respectively). No significant differences were observed in methylation levels during diagnosis and relapse for 
any of these genes (Wilcoxon signed rank test (SPSS)).  
H) No significant differences were observed between the different phases of the disease for the imprinted loci IGF2 (Wilcoxon signed rank test (SPSS)).
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TWIST2 TUSC3 HOXD4 EphA10 HAND2 HOXA5 HOXA4 IGF2 
C
h
il
d
re
n
 
         
Diagnosis- Remission 
R=-0.039 R=0.285 R=0.128 R=0.068 R=0.226 R=0.121 R=0.126 R=0.175 
P=0.861 P=0.188 P=0.560 P=0.757 P=0.300 P=0.583 P=0.566 P=0.424 
          
A
d
u
lt
s 
Diagnosis- Remission 
R=-0.185 R=0.285 R=-0.066 R=0.126 R=0.546 R=0.216 R=-0.014 R= 0.348 
P=0.122 P=0.421 P=0.211 P=0.777 P=0.587 P=0.010
**
 P=0.347 P=0.952 
Remission-Relapse 
R=-0.179 
P=0.491 
R=-0.151 R=-0.333 R=-0.185 R=0.345 R=0.050 R=0.294 R=-0.007 
P=0.979 P=0.563 P=0.191 P=0.478 P=0.176 P=0.850 P=0.252 
Diagnosis-Relapse 
R=0.842 R=0.813 R=0.224 R=0.607 R=0.677 R=0.580 R=0.454 R=0.565 
P=0.018* P<0.001
***
 P<0.001
***
 P=0.294 P=0.010
**
 P=0.003
**
 R=0.015
*
 P=0.067 
Table 6.3: Correlations between the ALL diagnostic, remission and relapse samples 
No correlations were observed between the diagnostic and remission samples for both the childhood (n=24) and the adult (n=21) patients, except for the HAND2 
gene in the adult population. No correlation was observed between the methylation levels during remission and relapse. Correlations were observed between 
methylation levels during diagnosis and relapse for 6 of the genes under study; TWIST2, TUSC3, EphA10, HAND2, HOXA5 and IGF2. 
The R is indicating the correlation coefficient and the P the observed p-values (Pearson correlation (SPSS)).  
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6.2.1.2.2 Methylation levels during ALL remission are significantly increased 
compared to healthy controls  
Methylation levels of both adult and childhood ALL remission patients were 
compared to the methylation levels of healthy control patients in a similar age-range. 
Although methylation levels were reduced in remission samples, compared to the 
diagnostic and relapse samples, the levels did not fall back to that seen in healthy 
controls. In childhood ALL a small, but statistically significant increase in methylation 
was still detectable for six loci at remission (Table 6.4 and Figure 6.2). The only genes 
not showing a significant increase in methylation in these childhood patients were 
EphA10 and HOXA5. This increase in methylation was even more pronounced in adult 
ALL, where remission samples exhibited an increase of about 70% relative to age-
matched controls for TWIST2, EphA10, HAND2, HOXD4 and TUSC3. In addition, 
methylation was also significantly increased in the adult ALL remission patients for 
both HOXA4 and HOXA5 (Table 6.4 and Figure 6.2). These results demonstrate that 
even during remission significant levels of abnormal methylation are retained. 
While this result could potentially be explained by the persistence of a low level 
of leukaemia cells in the remission samples (minimal residual disease (MRD)) several 
lines of evidence suggest that this is unlikely. First of all, there was no correlation 
observed between the methylation levels at diagnosis or relapse with the methylation 
levels during remission (Table 6.3). Also, for some individuals, methylation levels of 
the TUSC3 gene was increased during remission compared to the methylation levels 
during diagnosis and relapse (and was higher than that seen in any control sample), 
indicating that the increased methylation cannot be derived from the leukaemic clone 
(Table 6.5).  
MRD data was available for only a subset of patients, however the remission patient 
with the second highest levels of methylation was demonstrated to be MRD negative 
(and this sample therefore contained of less than 0.1% leukaemia cells) (Figure 6.3). 
This demonstrates that increased levels of methylation could be detected even in MRD 
negative samples, suggesting that, in adult ALL, the high levels of DNA methylation 
observed in remission cannot be accounted for by residual leukaemic cells. 
Another possible explanation for this increase in methylation during remission is 
that the treatment these patients received altered their methylation levels. Childhood 
ALL patients receive extensive treatment over a period of 2 years (for girls) or 3 years 
(for boys). If the increased methylation observed at initial remission was related to 
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leukaemia treatment, then it is possible that methylation levels may continue to increase 
while the patients are still receiving treatment. For nine of the childhood ALL samples, 
two remission samples were available: the first remission sample available was taken 
when the patients had been under treatment for 3 months, and a second remission 
sample was available after the patient had been under treatment for 2 years. Assessment 
of methylation levels in these samples demonstrated that for the five genes associated 
with ageing related methylation the level of methylation was essentially stable between 
the initial and long term remission samples, suggesting that additional treatment did not 
result in any further increase in methylation. In contrast though, the HOXA4 gene was 
found to exhibit significant increases in DNA methylation at the second remission time 
point, suggesting that methylation levels at this gene may be directly influenced by 
exposure to treatment (Table 6.6, Figure 6.4 and Appendix D, Figure D.). 
Another common feature of several cancers, including leukaemia, is CIMP, a 
phenotype in which multiple genes become co-ordinately methylated in individual 
patients. Indeed, in our group of ALL patients CIMP was observed for both the 
childhood and adult ALL patients during diagnosis and relapse. Interestingly, a CIMP 
like phenotype was also observed in the remission samples in the adult ALL group, 
where positive correlations were observed between methylation at TWIST2, TUSC3, 
HOXD4, EphA10 and HAND2, except for TWIST2 with HAND2. In the childhood 
samples, this CIMP was not observed during remission (Table 6.7). These results 
showed that, at least in the adult patients, the CIMP is not just a feature of the disease, 
but it is already present in the non-leukaemic cells of these individuals.  
These results show that altered levels of methylation are present in non-
leukaemia cells in ALL patients during remission compared to age-matched controls. 
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A. 
 TWIST2 TUSC3 HOXD4 EphA10 HAND2 HOXA5 HOXA4 IGF2 
Methylation levels adult ALL 
remission patients (%) 
11.65 12.26 16.22 12.00 7.73 64.44 44.35 41.00 
Methylation levels adult controls (%) 4.85 6.38 9.94 7.97 6.35 56.53 38.47 42.40 
         
ALL remission-controls P<0.001
*** 
P<0.001
***
 P<0.001
***
 P<0.001
***
 P=0.004
** 
P=0.001
*** 
P=0.029
* P=0.281 
B. 
 TWIST2 TUSC3 HOXD4 EphA10 HAND2 HOXA5 HOXA4 IGF2 
Methylation levels childhood ALL 
remission patients (%) 
5.77 5.80 9.15 6.72 4.53 59.22 39.10 40.33 
Methylation levels childhood 
controls (%) 
4.17 3.88 4.98 6.53 3.28 60.52 26.69 46.64 
         
ALL remission-controls P<0.001
***
 P<0.001
***
 P<0.001
***
 P=0.283 P<0.001
***
 P=0.391 P<0.001
***
 P<0.001
***
 
Table 6.4: Methylation levels in the ALL remission patients differ from the methylation levels observed in their age-matched controls 
A) Six of the genes under study showed significantly higher levels of methylation in the adult ALL patients during remission (n=21) compared to the healthy 
controls (n=98) (Wilcoxon rank sum test (SPSS)).  
B) In the childhood ALL remission patients (n=24), increased levels of methylation were observed for five of the genes under study compared to the healthy 
controls (n=50), while one gene, IGF2, showed significantly lower levels in these remission patients compared to the controls (Wilcoxon rank sum test 
(SPSS)). 
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 Figure 6.2A-E: Methylation levels in the ALL remission patients differ from the methylation levels observed in their age-matched controls for TWIST2, 
TUSC3 and HOXD4 
A-C) A significant increase in methylation levels was observed in both the childhood and adult ALL remission patients compared to the controls for TWIST2, 
TUSC3 and HOXD4 (Table 6.4). 
D) A significant increase in methylation levels was observed in the adult ALL remission patients compared to the controls for EphA10 (Table 6.4).  
E) A significant increase in methylation levels was observed in both the childhood and adult ALL remission patients compared to the controls for HAND2 
(Table 6.4). 
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Figure 6.2F-H: Methylation levels in the ALL remission patients differ from the methylation levels observed in their age-matched controls  
F) A significant increase in methylation levels was observed in the adult ALL remission patients compared to the controls for HOXA5 (Table 6.4). 
G) A significant decrease in methylation levels was observed in the childhood ALL remission patients compared to the controls for HOXA4 and a significant 
increase in methylation levels were observed for this gene in the adult ALL remission patients compared to the controls (Table 6.4).  
H) A significant increase in methylation levels was observed in the childhood ALL remission patients compared to the controls for IGF2 (Table 6.4). 
 
  
142 
 
Sample Methylation at diagnosis (%) Methylation during remission (%) Methylation at relapse (%) 
Patient 1 7.61 12.70 4.91 
Patient 2 5.21 6.90 4.99 
Patient 3 5.31 11.21 8.49 
 
Table 6.5: TUSC3 methylation for two patients was increased in the remission sample compared to the diagnostic and relapse samples 
For three of the adult ALL patients in this study, methylation levels during diagnosis and relapse were shown to exhibit levels comparable as observed in the healthy 
controls, while during remission, methylation levels were increased for TUSC3.  
Patient 1 and 3 showed methylation levels during remission that were higher than seen in any of the control samples. 
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Figure 6.3: Methylation levels in one of the MRD negative ALL patients was higher than 
that seen in any of the healthy control samples 
Methylation levels for four of the genes assessed (as indicated) are represented by box and 
whisker plots to illustrate the range of methylation levels in healthy controls and a black dot for 
the remission sample from the MRD negative remission patient. Even though this sample was 
determined to be MRD negative, it nevertheless still exhibits methylation levels well in excess 
of that seen in any healthy control sample for multiple genes 
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 TWIST2 TUSC3 HOXD4 EphA10 HAND2 HOXA5 HOXA4 
Methylation levels at 3 months 
into remission (%) 
5.90 5.62 9.95 6.90 4.33 64.46 37.72 
Methylation levels at 2 years 
into remission (%) 
4.79 3.55 8.10 7.28 4.80 55.92 52.93 
        
3 Months - 2 Years P=0.356 P<0.001
*** P=0.278 P=0.499 P=0.999 P=0.354 P=0.006
** 
Table 6.6: Methylation levels are relatively stable during remission 
Methylation levels were relatively stable during remission for most of the genes under study for the ten childhood patients for which several remission samples were 
available. Only the genes TUSC3 and HOXA4 showed a significant increase in methylation levels during remission (Paired samples T-test (SPSS)). 
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Figure 6.4: Methylation levels are relatively stable during ALL remission 
A) Overall methylation levels during remission are relatively stable in the childhood 
patients. Some patients exhibited a further increase in methylation, while other patients 
exhibited a reduction later into remission (n=10). The results as shown here for 
TWIST2, was similar for other different genes (Appendix D, Figure D.1), except for 
TUSC3 and HOXA4 (Paired samples T-test, SPSS). 
B) HOXA4 methylation levels are increased after 24 months remission compared to the 
first remission sample, taken at 3 months into remission (n=10, Paired samples T-test, 
SPSS). 
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A. 
  TWIST2 TUSC3 HOXD4 EphA10 HAND2 HOXA5 HOXA4 IGF2 
A
d
u
lt
 p
a
ti
en
ts
 
TWIST2  
R= 0.906 
P< 0.001
***
 
R= 0.799 
P< 0.001
***
 
R= 0.796 
P< 0.001
***
 
R= 0.287 
P= 0.207 
R=0.212 
P=0.207 
R=0.561 
P=0.008
**
 
R=0.282 
P=0.215 
TUSC3  
 R= 0.870 
P< 0.001
***
 
R= 0.814 
P< 0.001
***
 
R= 0.438 
P= 0.047
*
 
R=0.312 
P=0.169 
R=0.438 
P=0.047
*
 
R=0.186 
P=0.420 
HOXD4  
  R= 0.854 
P< 0.001
***
 
R= 0.555 
P= 0.009
**
 
R=0.307 
P=0.176 
R=0.347 
P=0.123 
R=-0.044 
P=0.849 
EphA10     
R= 0.507 
P= 0.019
*
 
R=0.404 
P=0.055 
R=0.549 
P=0.010
** 
R=0.146 
P=0.527 
HAND2      
R=0.361 
P=0.108 
R=-0.018 
P=0.938 
R=-0.115 
P=0.619 
HOXA5       
R=0.110 
P=0.635 
R=0.045 
P=0.846 
HOXA4        
R=0.139 
P=0.547 
IGF2         
Table 6.7A: Correlation between genes during remission in the adult ALL patients 
The adults ALL patients (n=21) showed a strong correlation between genes during remission, showing a phenotype similar to the CIMP that is observed in 
cancer patients. The R is indicating the correlation coefficient and the P the observed p-values (Pearson correlation (SPSS)). 
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B. 
  TWIST2 TUSC3 HOXD4 EphA10 HAND2 HOXA5 HOXA4 IGF2 
C
h
il
d
h
o
o
d
 p
a
ti
en
ts
 
TWIST2  
R= 0.295 
P= 0.162 
R= 0.281 
P= 0.183 
R= 0.324 
P= 0.122 
R= -0.343 
P= 0.101 
R=0.451 
P=0.027
*
 
R=-0.149 
P=0.363 
R=-0.361 
P=0.083 
TUSC3  
 R= 0.084 
P= 0.697 
R= 0.396 
P= 0.058 
R= 0.393 
P= 0.058 
R=0.108 
P=0.615 
R=-0.135 
P=0.528 
R=0.307 
P=0.144 
HOXD4  
  R= 0.272 
P= 0.199 
R= -0.216 
P= 0.310 
R=0.382 
P=0.066 
R=-0.027 
P=0.900 
R=-0.136 
P=0.525 
EphA10     
R= 0.302 
P= 0.152 
R=0.433 
P=0.034
*
 
R=0.238 
P=0.262 
R=0.292 
P=0.166 
HAND2      
R=-0.050 
P=0.816 
R=0.249 
P=0.241 
R=0.743 
P<0.001 
HOXA5       
R=-0.339 
P=0.105 
R=-0.031 
P=0.887 
HOXA4        
R=0.270 
P=0.202 
IGF2         
Table 6.7B: Correlations between genes during remission in the childhood ALL patients 
The correlation between genes as observed in the adult ALL remission patients was not observed for the childhood patients during remission (n=24).  
The R is indicating the correlation coefficient and the P the observed p-values (Pearson correlation (SPSS)). 
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6.2.1.2.3 High levels of CpG island methylation in remission samples is associated 
with poor outcome in adult ALL 
Outcome data was available for the adult ALL samples in this study. Outcome 
in adult ALL remains poor and indeed, from the 21 adult patients for whom a remission 
sample was available, six patients exhibited long term survival (>5 years), whereas 15 
patients died of the disease. Methylation levels were compared between long term 
survivors and those that died of their disease. Methylation levels were significantly 
higher in patients who died of their disease for seven of the genes, while methylation 
levels in long term survivors was comparable to that see in healthy controls for six of 
these examined genes. Despite the small sample numbers this difference in methylation 
levels between the survivors and the non-survivors was statistically significant (Table 
6.8 and Figure 6.5) and suggests further study of remission methylation levels as a 
potential prognostic marker would be merited. 
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 TWIST2 TUSC3 HOXD4 EphA10 HAND2 HOXA5 HOXA4 IGF2 
Methylation levels controls (%) 4.85 6.38 9.94 7.97 6.35 56.53 38.47 42.40 
Methylation levels ALL 
remission-survivors (%) 
8.17 8.64 12.95 9.46 6.01 61.18 41.57 39.14 
Methylation levels ALL 
remission- non-survivors (%) 
13.04 13.70 17.53 13.02 8.41 65.74 45.46 41.75 
         
Survivor- Non survivor P=0.018
*
 P=0.016
*
 P=0.036
*
 P=0.043
*
 P=0.020
*
 P=0.312 P=0.697 P=0.350 
Survivor- Control P<0.001
***
 P=0.157 P=0.759 P=0.503 P=0.387 P=0.354 P=0.329 P=0.568 
Non survivor- control P<0.001
***
 P<0.001
***
 P<0.001
***
 P<0.001
***
 P<0.001
***
 P<0.001
***
 P=0.039
*
 P=0.801 
Table 6.8: A difference in methylation levels is observed between adult ALL survivors and non-survivors 
A significant difference was observed in the methylation levels between the adult ALL survivors (n=6) versus the non-survivors (n=15) for 5 of the 
genes examined; TWIST2, TUSC3, HOXD4, Epha10 and HAND2. All the genes examined, with the exception of IGF2, showed a significant difference 
in methylation levels between the non-survivors and the controls, while the methylation levels of the survivors versus the controls were only 
significantly different for TWIST2 (Wilcoxon rank sum test, SPSS).  
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Figure 6.5A-E: Methylation levels during ALL remission in ALL survivors and non-survivors for TWIST2, TUSC3, HOXD4, EphA10 and HAND2 
A-E) A significant difference between the methylation levels of the adult ALL survivors (n=6) compared to the non-survivors (n=15) was observed for TWIST2, 
TUSC3, HOXD4, EphA10 and HAND2. The non-survivors showed methylation levels significantly higher than the controls for these five genes, while only 
TWIST2 showed a significant difference in methylation levels between the ALL survivors and the controls (Table 6.8). 
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Figure 6.5 F-H: Methylation levels during ALL remission in ALL survivors and non-survivors for TWIST2, TUSC3, HOXD4, EphA10 and HAND2 
F and G) No significant differences were observed between the methylation levels during remission of the adult ALL survivors (n=6) and the non-survivors 
(n=15) for HOXA5 and HOXA4. Significant differences were observed between the methylation levels of the non-survivors and the controls for these genes, 
whereas no significant differences were observed between the methylation levels of the controls and the ALL survivors (Table 6.8). 
H) No differences were observed between the methylation levels during remission of the adult ALL survivors (n=6) and the non-survivors (n=15) for HOXA5. 
A significant difference was observed between the methylation levels of the non-survivors and the controls, whereas no significant difference was observed 
between the methylation levels of the controls and the ALL survivors (Table 6.8). 
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6.2.1.3 Discussion 
Alterations in DNA methylation, particularly increased methylation of promoter 
associated CpG islands, is a central feature of cancer development. However, the 
underlying mechanisms that causes these changes and how this changes across the 
course of the disease is not well understood. Here we have studied methylation changes 
during the different phases of ALL. Of particular note, we found that although aberrant 
methylation was much lower during remission than at either diagnosis or relapse, the 
level of methylation still remained significantly higher than age matched healthy 
controls.  
The remission methylation levels could not be attributed to a low level of 
surviving leukaemic blasts and studies of serial remission samples suggests that the 
increase in methylation is relatively stable. This implies that the increased methylation 
is either an intrinsic feature of individuals who develop ALL, i.e. the increased 
methylation existed prior to disease development and may have played an important 
role in disease development, or alternatively, that the increased methylation is a product 
of exposure to anti-leukaemic therapy. This could either be due to direct induction of 
altered methylation by one or more of the specific drugs used or it could be a product of 
rapid proliferation to re-populate the haematopoietic niche following induction therapy. 
For at least one locus, HOXA4, the increased methylation observed seems likely to be 
treatment related, as methylation levels were clearly increased when patients had been 
in remission for 2 years versus the initial remission samples at 2 months, consistent 
with the idea that more prolonged therapy leads to increased accumulation of altered 
methylation. This effect of anti-leukaemic treatment would be a particular concern for 
treatment of childhood ALL patients. With the increasing success of treatment of 
childhood ALL leading to larger numbers of survivors, the focus for further 
modifications of treatment will increasingly be on reducing the long term health effects. 
It is now clear that long term survivors of childhood leukaemia suffer from dramatically 
increased levels of multiple physical and mental health problems (Kanellopoulos, 2013) 
and stable alterations in the epigenome could be an important factor contributing to 
these long term health effects.  Furthermore, in adult ALL the patient population is also 
relatively young, the average age of diagnosis is 55, and so long term health impacts of 
treatment will also be a concern for this patient population. 
This study also suggests that methylation levels measured in remission samples 
may have potential as a novel prognostic marker, as the levels of methylation at 
remission significantly correlated with long term survival. Patients who survived long 
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term generally exhibited methylation levels at or near the level of healthy controls. In 
contrast, patients that died of their disease exhibited methylation levels significantly 
above those seen in healthy controls. It has been previously suggested that methylation 
levels at diagnosis may predict outcome in some ALL patients (Milani, 2010), but this 
is the first study to find evidence that methylation differences in remission samples may 
be predictive of subsequent patient outcome, at least in adult ALL. Further studies will 
be required to confirm this observation and more clearly define the strength of 
remission methylation levels as a prognostic marker. MRD analysis is already a 
standard prognostic marker in ALL. The data presented here demonstrate that the 
increased DNA methylation in adult ALL remission does not appear to be MRD 
derived, suggesting that remission methylation may provide information that could 
augment prognosis based on MRD alone, although further studies will be required. 
While we did not observe a correlation in these patients between methylation 
levels during remission and diagnosis or relapse, we did observe a strong correlation 
between the methylation levels in the diagnostic and relapse samples. This suggests that 
both the original leukaemia and the relapse are derived from cells with similar 
methylation patterns. Previous studies have shown that the clonal architecture of 
relapsed ALL is often very different from that at diagnosis, and that relapses are often 
derived from clones which were minor at diagnosis (Anderson, 2011; Ding, 2012). The 
stability of methylation between diagnosis and relapse suggests that most or all clones at 
diagnosis had very similar patterns of aberrant methylation. This is similar to recent 
observations in CLL (Cahill, 2012), showing that methylation in this disease is very 
stable during disease progression. These studies provide further evidence that altered 
methylation is likely to be one of the earliest events in leukaemia development.    
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6.2.2 Hereditary nonpolyposis colorectal cancer 
HNPCC, or Lynch syndrome, is a genetic disease of autosomal dominant 
inheritance, caused by a germ-line mutation in one of a set of DNA mismatch repair 
genes; MLH1, MSH2, MSH6, MLH3 and/or PMS2. This mutation prevents accurate 
repair of base mismatches and small insertion/deletions produced during DNA 
replication and this leads to a characteristic mutator phenotype, namely MSI and loss of 
MMR protein expression (Peltomaki, 1997; Bonnet, 2012). Patients with this germ-line 
mutation confer an increased risk for various types of cancers, particularly of the colon 
and the endometrium. It’s prevalence in the general population is about 1 in 500, and it 
causes about 2% to 3% of all colorectal cancers. Lifetime cancer risk for descendant of 
an affected family member is around 50%, while for the identified gene carriers this risk 
is much higher (Aaltonen, 1998).  
The Amsterdam criteria established diagnostic criteria for HNPCC in 1990. 
These criteria only described colorectal cancer, but were reviewed in 1999 when 
endometrial cancer, small intestine cancer, urethral cancer and kidney cancer were also 
included as HNPCC spectrum cancers. A HNPCC family is clinically diagnosed if; 
three or more patients with histologically confirmed HNPCC spectrum cancers are 
present in a family line and one is a first relative to the other two; this cancer develops 
over two generations; and at least one case is diagnosed at younger than 50 years old 
(Vasen, 1999).  
A new, rarer, type of HNPCC has been found with no pathologic mutation in 
MMR genes, but epimutation in the promoter region of hMLH1 or hMSH2. These 
findings suggested that epimutation in germline hMLH1 or hMSH2 can be a cause of 
HNPCC (Chan, 2006; Crepin, 2012). This also suggests that DNA methylation might 
play a role in HNPCC and that it might be used as a diagnostic marker of identifying 
HNPCC patients. 
Not all HNPCC mutation carriers develop HNPCC related cancers and those that do 
develop these cancers do that at highly variable ages, with most of these patients being 
well into adulthood. This suggests that multiple secondary events are likely necessary to 
develop cancer in these mutation carriers. Several studies reported alterations in 
methylation levels in the cancers related to HPCC. For example, MGMT and CDKN2 
hypermethylation is frequently observed in colorectal cancers (Farzanehfar, 2013; Xing, 
2013) as well as hypomethylation of LINE-1 (Antelo, 2012). Alterations in the 
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methylation levels of these genes constitute a potentially important feature of colorectal 
cancer. 
A study performed by O’Hagan et al showed that cellular reactive oxygen 
species (ROS), and the accompanied oxidative DNA damage, can potentially lead to 
aberrant patterns of DNA methylation and transcriptional silencing (O'Hagan). This 
suggests that deficient DNA repair may be linked to aberrant patterns of DNA 
methylation. This is of particular interest in these HNPCC patients, since they carry a 
germ-line mutation affecting key DNA repair pathways. Analogous to what was 
reported for oxidative damage, this defect in DNA repair may lead to increased levels of 
DNA methylation in HNPCC patients, which may in turn affect likelihood of 
developing cancer. 
Therefore, in this study we investigated methylation patterns in a set of eight 
genes in a group of HNPCC patients to investigate whether aberrant patterns of DNA 
methylation are present in these patients and to study the potential link between DNA 
mismatch repair defects and promoter methylation. This study was designed to look for 
an event that would potentially increase the general level of aberrant methylation. As a 
result, genes that were known to be susceptible to age-related methylation and that 
showed aberrant pattern of methylation in leukaemia patients were included in this 
study, as well as the mismatch repair gene MLH1.  
 
6.2.2.1 Samples 
Peripheral blood DNA samples were obtained from 50 HNPCC patients, 
between 29 and 75 years of age (with an average age of 53.34), originally collected as 
part of the CAPP2 study. All patients were proven carriers of a pathologic mismatch-
repair mutation or members of a family that met the Amsterdam diagnostic criteria and 
had a personal history of a cured HNPCC neoplasm. All the samples were taken before 
the start point of the intervention treatment. Of these 50 patients, 13 carried the MSH2 
mutation and 20 carried the MLH1 mutation (Table 6.9). 
The control samples in this study were the young adults, adults and the older 
adult participants as described in Chapter 4 (Table 6.9) 
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 HNPCC patients Control patients 
Age (years) 29-75 (average 53.34) 17-85 (average 54.26) 
Number of patients 50 148 
 15 male 
7 female 
28 unknown 
41 male 
107 female 
Mutation 13 MSH2 carrier 
20 MLH1 carrier 
2 Normal 
15 Unknown 
 
Table 6.9: An overview of the HNPCC study population 
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6.2.2.2 Results 
 
6.2.2.2.1  Changes in methylation levels in HNPCC patients 
Methylation levels, as assessed by pyrosequencing, were examined for 
differences between the HNPCC patients and the healthy controls to examine if altered 
methylation levels are a feature of these HNPCC patients. Three of the genes under 
study, HAND2, HOXA5 and MLH1, showed significant differences in methylation 
patterns between the HNPCC patients and the controls. Methylation levels for HAND2 
and HOXA5 were significantly increased in the HNPCC patient group. For HAND2 the 
methylation levels of the HNPCC patients showed values that were on average 1.46% 
higher than the controls, namely 8.15% in the HNPCC patient group and 6.69% in the 
control group (Table 6.10 and Figure 6.6A). The HNPCC patient group showed average 
levels of 63.46% for the HOXA5 gene, compared to 58.18% in the control group, 
resulting in a 5.28% increase in the HNPCC patient group (Table 6.10 and Figure 6.6B). 
The methylation levels of the MLH1 gene was significantly reduced in the HNPCC 
patient group. Overall methylation levels for this gene was low (1.34% in the control 
group, compared to 1.07% in the HNPCC patient group), resulting in only a decrease of 
0.27% in the HNPCC patient group (Table 6.10 and Figure 6.6C). For the other five 
genes under investigation, TWIST2, TUSC3, HOXD4, EphA10 and HOXA4, no 
differences in methylation levels were observed between the HNPCC patients and the 
controls (Table 6.10 and Figure 6.7). 
 
 
 
 
 
 158 
 
 TWIST2 TUSC3 HOXD4 EphA10 HAND2 HOXA5 HOXA4 MLH1 
Methylation levels HNPCC patients (%) 5.77 7.32 11.21 8.60 8.15 63.46 40.72 1.07 
Methylation levels controls (%) 6.05 7.23 11.56 9.32 6.69 58.18 39.50 1.34 
         
HNPCC- Controls P=0.122 P=0.475 P=0.465 P=0.659 P<0.001
*** 
P=0.002
** P=0.883 P<0.001
*** 
Table 6.10: Methylation levels in the HNPCC patients were significantly different compared to the controls for HAND2, HOXA5 and MLH1. 
Three of the genes under study showed significantly different levels of methylation in the HNPCC patients (n=50) compared to the controls (n=148) Wilcoxon 
Signed Ranks test (SPSS)). 
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Figure 6.6: Significant differences in methylation patterns between HNPCC patients and controls was observed for HAND2, HOXA5 and MLH1 
A) Methylation levels for HAND2 are significantly increased in the HNPCC patient group compared to the controls (Table 6.10).  
B) Methylation levels for HOXA5 are significantly increased in the HNPCC patient group compared to the controls (Table 6.10). 
C) Methylation levels are significantly reduced for the MLH1 gene in the HNPCC patients compared to the controls (Table 6.10). 
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Figure 6.7: No difference in methylation patterns were observed between HNPCC patients and controls for TWIST2, TUSC3, HOXD4, EphA10 and HOXA4 
No differences in methylation levels between the HNPCC patients and their age-matched controls were observed for TWIST2, TUSC3, HOXD4, EphA10 and 
HOXA4. 
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6.2.2.2.2 Differences in methylation levels between patient mutation groups 
Mutations in MLH1 and MSH2 are by far the most commonly seen in HNPCC. 
As they play different roles in mismatch repair function it is possible they may have 
differential effects on the accumulation of methylation changes. To investigate this, 
differences in methylation patterns between HNPCC patients from different mutational 
subgroups (MLH1 or MSH2 mutations), were assessed. This analysis found significant 
differences between these mutational subgroups for both HOXA5 and MLH1 (Table 
6.11). For HOXA5, the patients carrying the MLH1 mutation showed methylation levels 
that were on average 6.19% higher than the methylation levels of patients carrying the 
MSH2 mutation; the patients carrying the MSH2 mutation showed average methylation 
levels of 36.72%, compared to 42.48% for the MLH1mutational subgroup. Due to the 
low levels of methylation observed for the MLH1 gene, the difference in methylation 
between the two mutational subgroups for this gene was only 0.40%; the patients 
carrying the MSH2 mutation showed average methylation levels of 0.85%, compared to 
1.25% for the MLH1 mutational subgroup (Table 6.11 and Figure 6.8).  
These results suggest that the different patterns of methylation observed in the 
HNPCC patient group can be partly explained by the aberrant patterns of methylation in 
the patient group carrying the MSH2 mutation. Indeed, when we examine the 
differences in methylation of each of the mutational subgroups compared to the 
controls, a significant difference was observed for HOXA5 and MLH1 between the 
patients carrying the MSH2 mutation and the controls, but this difference was not 
observed between the patients carrying the MLH1 mutation and the controls (Table 6.11 
and Figure 6.8). For HAND2, an increase in methylation levels was observed in patients 
carrying both mutations compared to the controls, while this gene did not show a 
significant difference in methylation levels between the two HNPCC mutational 
subgroups (Table 6.11 and Figure 6.8). These results suggest that the increase in 
HOXA5 methylation and the decrease in MLH1 methylation are greater in the MSH2 
mutational subgroup compared to the MLH1 mutational subgroup. 
The differences observed between MSH2 and MLH1 mutation carriers raises the 
possibility that while increased methylation at the other 5 genes studies wasn’t seen in 
the whole cohort, that there may be MSH2 mutation carrier specific effects. However, 
the other genes under study did not show any significant differences in methylation 
levels between either the different HNPCC mutation subgroups or between the control 
patients and patients from either one of the mutational subgroups (Table 6.11 and 
Figure 6.9). 
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 TWIST2 TUSC3 HOXD4 EphA10 HAND2 HOXA5 HOXA4 MLH1 
Methylation levels controls (%) 6.05 7.23 11.56 9.32 6.69 58.18 39.50 1.34 
Methylation levels MSH2 
mutation carriers (%) 
4.66 6.94 11.25 8.60 7.62 67.21 36.72 0.85 
Methylation levels MLH1 
mutation carriers (%) 
6.30 7.46 10.93 8.40 8.02 61.01 42.48 1.25 
         
MLH1 mutation carriers-  
MSH2 mutation carriers 
P=0.548 P=0.123 P=0.689 P=0.826 P=0.396 P=0.014
* 
P=0.023
* 
P=0.007
**
 
MLH1 mutation carriers- 
controls 
P=0.656 P=0.334 P=0.792 P=0.868 P=0.029
* P=0.152 p=0.368 P=0.062 
MSH2 mutation carriers- 
controls 
P=0.039
* P=0.539 P=0.856 P=0.682 P=0.019
* 
P=0.001
*** P=0.254 P<0.001
*** 
Table 6.11: Methylation levels of HNPCC patients carrying the MLH1 or the MSH2 mutation and the controls 
Methylation levels differed significantly between the HNPC patients carrying either the MLH1 (n= 20) or MSH2 (n=13) mutation for HOXA5, HOXA4 and MLH1. 
The methylation levels of the MLH1 mutation carriers differed significantly from those of the controls for HAND2, while a significant difference between the 
methylation levels of the MSH2 mutation carriers and the controls was observed for TWIST2, HAND2, HOXA5 and MLH1 (Independent samples T-test for HAND2 
and HOXA5, Wilcoxon Signed Ranks test for the other genes under study (SPSS)). 
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Figure 6.8: Methylation patterns are significantly different between HNPCC patients carrying the MLH1 and patients carrying the MSH2 mutation for 
HOXA5 and MLH1 
A) For the HAND2 gene, methylation levels of both HNPCC mutational subgroups were significantly increased compared to the control patients, whereas there 
was no significant difference observed in methylation levels between patients carrying either the MLH1 or MSH2 mutation (Table 6.11).  
B) A significant difference in methylation levels was observed between the HNPCC patients carrying the MSH2 mutation and the patients carrying the MLH1 
mutation for HOXA5. Patients carrying the MSH2 mutation showed significantly different levels of methylation than the control samples, while this 
difference in methylation levels was not observed for the patients carrying the MLH1 mutation compared to the controls (Table 6.11). 
C) A significant difference in methylation levels was observed between the HNPCC patients carrying the MSH2 mutation and the patients carrying the MLH1 
mutation for MLH1. Patients carrying the MSH2 mutation showed significantly different levels of methylation than the control samples, while this difference 
in methylation levels was not observed for the patients carrying the MLH1 mutation compared to the controls (Table 6.11). 
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Figure 6.9: Methylation patterns between the HNPCC patients carrying the MLH1 and patients carrying the MSH2 mutation for TWIST2, TUSC3, HOXD4, 
EphA10 and HOXA4 
No differences in methylation levels were observed between the HNPCC patients carrying either the MLH1 or the MSH2 mutation for TWIST2, TUSC3, HOXD4, 
EphA10 and HAND2. From these genes, only TWIST2 showed a significant difference in methylation levels between patients carrying the MSH2 mutation compared to 
the controls and only HOXA4 showed a significant difference in methylation levels between patients carrying the MLH1 mutation and the controls . These differences 
were not observed in any of the other five genes (Table 6.11). 
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6.2.2.3 Discussion 
In our study we examined methylation patterns in PBL of HNPCC patients in a 
set of eight genes. These methylation levels were compared to methylation levels 
measured in healthy individuals in a similar age-range to examine a potential genome 
wide effect of methylation changes due to the mutation in the DNA mismatch repair 
genes these patients are carrying. Our results indicate that such a genome wide effect 
does not occur in these patients, since aberrant patterns of methylation was only found 
in three of the eight genes under study; HAND2, HOXA5 and MLH1. However, the 
presence of altered methylation in this subset of genes does suggest that HNPCC 
mutation carriers may have frequent methylation changes across the genome and that 
altered methylation might be a common feature of the condition.  
Why it were the genes HAND2, HOXA5 and MLH1 that showed altered levels of 
in the HNPCC patients remains currently uncertain. The genes under study were not 
chosen on the basis of potential functional roles in HNPCC. Also, the tissue analysed in 
this tissue, PBL, is not the tissue type known to be affected by the condition and it is 
therefore unlikely that the methylation changes that we detected in these HNPCC 
patients play a direct role in this condition. 
Our results suggest that methylation levels in HNPCC patients are significantly 
different from patients not carrying this condition, and that substantial methylation 
defects might be present in these HNCC patients. It is well possible that these 
methylation defects may be replicated, or are even increased, in tissues and genes that 
are more directly linked to HNPCC associated conditions. As a result, methylation 
levels have to be examined in a wider range of tissues and at more loci to get a clearer 
understanding of the prevalence of methylation differences and their potential impact of 
the disease.  
Interestingly MLH1, one of the DNA mismatch repair genes and one of the 
genes targeted by mutations in a subgroup of HNPCC patients, showed methylation 
levels that were significantly lower in the patients carrying the MSH2 compared to the 
controls, but no apparent decrease in carriers of MLH1 mutations was observed. While 
this may at first seem counter-intuitive, one potential explanation could be that mutation 
of MSH2 leads to a compensatory up-regulation of transcriptional activity of the MMR 
genes (or MLH1 specifically), although a wider study of methylation and expression at 
all MMR genes would be required to assess this possibility more fully. Also we did not 
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assess methylation at the MSH2 promoter and therefore cannot tell if this would have 
shown a corresponding mutation specific change in methylation status. 
Our patient cohort did not allow us to examine whether the observed 
methylation changes in these HNPCC patients were associated with differential 
susceptibility to develop one of the HNPCC related diseases, due to the low number of 
patients and the lack of patients who developed a HNPCC related disease in the follow 
up period. It could be of interest for further study to examine the potential of DNA 
methylation in the prediction of disease susceptibility, in both in the affected tissues by 
HNPCC as well as in PBL as this might mirror the methylation patterns in the tissues. 
Overall, the results of this study showed aberrant patterns of DNA methylation 
in HNPCC patients for three genes under study. 
 
6.3 Heart disease 
Heart diseases are currently one of the leading causes of death and disability in 
the world and the incidence of heart disease increases with age. What, if any, role 
alterations in DNA methylation have in the development of a heart disease remains 
currently uncertain, however several studies have identified altered patterns of DNA in 
a subset of genes which cover functions in lipid oxidation, inhibition of endothelial cell 
migration and formation, the control of cell proliferation and angiogenesis (Friso, 2012; 
Hiltunen, 2002; Movassagh; Post, 1999). Our previous study showed that promoter 
methylation patterns change significantly with an increasing age (as discussed in 
Chapter 4). This led us to the hypothesis that the rate of accumulation of altered DNA 
methylation during ageing might have an important impact on the development of heart 
disease.  
Therefore, this study was designed to investigate methylation patterns in patients 
who had suffered a heart attack, to examine if the heart disease patients exhibited 
different patterns of methylation as compared to healthy controls. The genes under 
study included a set of five genes previously identified to show age-related methylation 
changes; TWIST2, TUSC3, HOXD4, EphA10 and HAND2; and two genes, HOXA4 and 
HOXA5, that have been implicated to act as positive regulators of the RGS genes, 
especially RGS2 (unpublished results). The RGS genes are involved in the regulation of 
G-protein coupled signalling and multiple studies have found that reduced expression of 
RGS2 is associated with the development of heart disease (Tsang, 2010).  
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6.3.1 Samples 
MNC DNA was extracted from 55 patients, between 42 and 74 years of age 
(with an average age of 58.3), who had previously suffered a heart attack as part of the 
‘Role of T-cells in Coronary Artery Disease’ study. Clinical characteristics of this 
cohort are detailed in Table 6.12. The samples from the patients with an Acute 
Myocardial Infarction (AMI) were taken 24 hours following primary percutaneous 
coronary intervention (PCI) for ST elevation myocardial infarction (STEMI) and they 
all had stents 24 hours earlier to unblock the occluded coronary artery. The samples of 
the chronic patients were all taken at least three months after STEMI. They all had a 
previous infarct, but were stable at the time of sample collection. The patients with the 
Congestive Heart Failure (CHF) had larger infarcts than the patients without CHF; these 
patients had smaller or moderate size infarcts.  
The methylation levels from the young adults, adults and older adult 
participants, as described in Chapter 4, were used as a first control group. The DNA 
samples from these participants were extracted from PBL. Therefore, as a second 
control group, the methylation levels from DNA samples extracted from both PBL and 
MNC were used from 8 adult participants that participated in the cell-type specific 
methylation study, as described in Chapter 5 (Table 6.12). 
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Heart disease 
patients 
Controls 1 Controls 2 
Age (years) 42-74 (average 58.3) 
17-85 (average 
54.26) 
43-60 (average 
51.6) 
Number of patients 55 148 8 
Gender 
2 female 
44 male 
9 unknown 
106 female 
41 male 
1 unknown 
5 female 
3 male 
Source of DNA 
sample 
MNCs PBL PBL and MNC 
Patient group 
33 Acute Myocardial 
Infarction (AMI) 
10 Congestive Heart 
Failure (CHF) 
7 Stable post AMI 
and no CHF 
5 unknown 
  
Amount of vessel 
affected 
23  1 vessel 
12  2 vessels 
7   3 vessels 
13 unknown 
  
Family history of 
heart disease 
15 yes 
13 no 
27 unknown 
  
Previous heart 
surgery 
13 yes 
16 no 
26 unknown 
  
Table 6.12: An overview of the cardiovascular disease study population 
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6.3.2 Results 
 
6.3.2.1 Methylation levels in heart disease patients compared to controls 
Variable levels of methylation were observed in the heart disease patients in 
seven of the genes under study; TWIST2, TUSC3, HOXD4, EphA10, HAND2, HOXA5 
and HOXA4. To examine if these levels of methylation were different than the 
methylation observed in healthy controls, the methylation levels of the two groups were 
compared to each other. The methylation levels of these six genes showed increased 
levels of methylation in these patients compared to the methylation levels observed in 
their age matched controls (Table 6.13), however the cell composition was different 
between these two groups (MNC versus PBL). Previous results, as described in Chapter 
5, showed significant differences in the methylation levels between the matched MCN 
and PBL samples in healthy individuals. Overall methylation levels were higher in 
DNA extracted from MNC compared to the DNA extracted from PBL for all the genes 
under study, although this difference was relatively small for the genes HOXA5 and 
HAND2 (Table 6.13).  
When the increase of methylation levels in the heart disease patients compared 
to the healthy controls was compared to the increase of methylation levels in the MNC 
versus PBL, it showed that the increase in methylation levels in the heart disease 
patients was likely too large to be solely explained by the difference in cell composition 
for several genes under study, namely HOXD4, HAND2, HOXA5 and HOXA4. For these 
genes, an increase in methylation of respectively 4.72%, 2.7%, 7.8% and 7.8% was 
observed in the heart disease patients compared to the controls, whereas the methylation 
levels of the MNC samples compared to the paired PBL samples only showed an 
increase of respectively 2.56%, 0.45%, 0.37% and 2.24%. For the other genes under 
study, the differences between the heart disease patients versus controls and the MNC 
versus PBL was less than 2%, suggesting that these differences might be explained by 
the difference in cell composition (Table 6.13).  
To perform some statistical analyses to examine if the methylation levels of 
these heart disease patients are significantly different from the controls, an Independent 
samples T-test was performed on the relative differences between the methylation levels 
of the heart disease patients and the healthy controls 1 and the relative difference 
between the methylation levels of the paired PBL and MNC controls 2. The relative 
differences between the patients and controls were calculated by subtracting the average 
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levels of methylation measured in the control samples from the methylation levels 
observed in each individual heart disease patient. The relative difference between the 
paired MNC and PBL were calculated by subtracting the methylation levels observed in 
the PBL samples from the methylation levels of the paired MNC samples. This analysis 
revealed statistically significant differences in the methylation of the relative differences 
of these two groups for seven of the genes under study, namely TWIST2, TUSC3, 
HOXD4, EphA10, HAND2, HOXA4 and HOXA5 (Table 6.14).  
These results suggest that aberrant patterns of methylation are present in heart 
disease patients, however to confirm these results, methylation analyses will have to be 
performed on both heart disease patient and control samples with the same sample 
composition.  
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 TWIST2 TUSC3 HOXD4 EphA10 HAND2 HOXA5 HOXA4 IGF2 
Methylation levels heart disease patients (%) 8.74 10.03 16.28 12.26 9.39 65.36 46.68 42.66 
Methylation levels controls 1 (%) 6.05 7.23 11.56 9.32 6.69 58.18 39.50 41.47 
         
Methylation difference heart disease patients-
controls 1 
2.69 2.8 4.72 2.94 2.7 7.18 7.18 1.19 
Methylation difference PBL- MNC controls 2 1.61 1.9 2.56 1.71 0.49 0.37 2.24 1.99 
Table 6.13: Methylation levels of the heart disease patients compared to the controls 
For four genes under study; HOXD4, HAND2, HOXA5 and HOXA4, the differences between the differences in methylation levels between the heart disease patients 
and the controls 1 and the difference in methylation levels between PBL and MNC was greater than 2% and are therefore unlikely to be solely explained by the 
differences in cell composition of the DNA.  
 
 TWIST2 TUSC3 HOXD4 EphA10 HAND2 HOXA5 HOXA4 IGF2 
Relative difference between heart disease 
patients and controls 1 versus relative difference 
between PBL and MNC controls 2 
P<0.001* P<0.001* P<0.001* P<0.001* P<0.001* P=0.029* P=0.005* 0.187 
Table 6.14: Significant differences were observed between the relative difference in methylation levels between the heart disease patients and the controls 
Statistical analysis of the relative differences between the methylation levels of the heart disease patients compared to their age-matched controls 1 versus the 
relative difference between methylation levels between the paired PBL and MNC from the second control group, showed significant differences in methylation 
levels for 7 genes under study: namely TWIST2, TUSC3, HOXD4, EphA10, HAND2, HOXA5 and HOXA4 (Independent samples T-test (SPSS)). 
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6.3.2.2 Differences in methylation levels between patient groups 
The heart disease patients under investigation could be divided into different 
groups of disease characteristics. To investigate for differences in methylation patterns 
between heart disease patients with a subset of the different disease characteristics, 
statistical analyses were performed. 
No consistent significant differences were seen between the methylation levels 
of any of the available clinical characteristics of the patients. The only observed 
differences were between the patients with a family history of heart disease and the 
patients without such a family history for the HOXA4 gene, and between the patients 
with one or three vessels affected by the disease for HOXA5 (Table 6.15-Table 6.18 and 
Appendix D, Figure D.2-Figure D.5) 
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 TWIST2 TUSC3 HOXD4 EphA10 HAND2 HOXA5 HOXA4 IGF2 
Methylation levels AMI group (%) 8.80 9.62 15.85 12.44 9.07 66.91 46.15 43.00 
Methylation levels CHF group (%) 8.96 11.23 17.13 11.80 9.39 46.39 47.98 42.81 
Methylation levels stable post MI,  
no CHF group (%) 
8.71 9.68 17.84 12.72 10.16 63.20 46.50 42.35 
         
AMI-CHF P=0.701 P=0.535 P=0.301 P=0.443 P=0.169 P=0.785 P=0.626 P=0.768 
AMI-stable post MI, no CHF P=0.761 P=0.987 P=0.211 P=0.612 P=0.607 P=0.492 P=0.839 P=0.361 
CHF-stable post MI, no CHF P=0.722 P=0.591 P=0.594 P=0.657 P=0.195 P=0.717 P=0.594 P=0.657 
Table 6.15: No differences in methylation levels in heart disease patients within different patient groups 
No differences were observed between the AMI, CHF or stable post MI, no CHF patient groups for any of the genes under study (Independent samples T-test for 
HAND2 and HOXA5, Wilcoxon Signed Ranks test for the other genes under study (SPSS)) 
 
 TWIST2 TUSC3 HOXD4 EphA10 HAND2 HOXA5 HOXA4 IGF2 
Methylation levels previous surgery (%) 9.31 11.51 18.82 12.57 9.26 65.64 46.75 42.28 
Methylation levels no previous surgery (%) 8.80 9.29 15.93 12.15 9.91 65.73 45.05 43.84 
         
Previous surgery-no previous surgery P=0.539 P=0.105 P=0.087 P=0.614 P=0.957 P=0.672 P=0.219 P=0.511 
Table 6.16: Methylation levels did not differ between heart disease patients who underwent a previous surgery and the patients who did not  
No differences were observed between the heart disease patients who underwent a previous surgery and the patients who did not for any of the genes under study 
(Independent samples T-test for HAND2 and HOXA5, Wilcoxon Signed Ranks test for the other genes under study (SPSS)). 
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 TWIST2 TUSC3 HOXD4 EphA10 HAND2 HOXA5 HOXA4 IGF2 
Methylation levels 1 affected vessel (%) 8.50 9.39 16.15 12.69 8.97 66.11 46.22 42.93 
Methylation levels 2 affected vessels (%) 9.79 11.39 17.43 12.32 9.98 64.58 48.14 41.41 
Methylation levels 3 affected vessels (%) 8.80 9.17 14.88 11.93 9.39 68.16 45.71 46.09 
         
1 vessel- 2 vessel 0.065 0.076 0.118 0.972 0.264 0.123 0.889 0.862 
1 vessel- 3 vessels 0.418 0.914 0.787 0.391 0.522 0.034
* 0.573 0.315 
2 vessels- 3 vessels 0.554 0.375 0.151 0.499 0.086 0.083 0.299 0.482 
Table 6.17: Methylation levels between patients with 1, 2 or 3 affected vessels by their heart disease 
No differences were observed between the patients with 1, 2 or 3 vessels affected for any of the genes under study, with an exception for HOXA5 (Independent 
samples T-test for HAND2 and HOXA5, Wilcoxon Signed Ranks test for the other genes under study (SPSS)). 
 
 TWIST2 TUSC3 HOXD4 EphA10 HAND2 HOXA5 HOXA4 IGF2 
Methylation levels family history (%) 9.06 9.82 15.83 11.82 9.45 66.43 42.86 42.51 
Methylation levels no family history (%) 8.67 9.88 17.89 12.89 9.85 66.86 50.52 43.94 
         
Family history-no family history 0.807 0.558 0.118 0.143 0.270 0.717 0.036
* 0.770 
Table 6.18: Methylation levels in heart disease patients with a family history of heart disease and in the patients without such a family history 
No differences were observed between the heart disease patients with and without a family history of heart disease for any of the genes under study, with the 
exception of HOXA4 (Independent samples T-test for HAND2 and HOXA5, Wilcoxon Signed Ranks test for the other genes under study (SPSS)).
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6.3.3 Discussion 
An increase in methylation levels was observed in the heart disease patients 
compared to their healthy age-matched controls for seven of the genes under study. 
Statistical analyses revealed that these differences in methylation levels are likely not 
caused by the difference in cell composition between these groups. These analyses are 
not perfectly validated: the difference in cell composition between these two groups 
made it not possible to perform direct statistical analyses on the observed methylation 
levels. Unfortunately, there were no PBL DNA samples available for the heart disease 
patients, or MNC DNA from a larger group of age-matched controls. As a result, the 
statistical analyses were performed on the relative differences between the patients and 
the controls and the previously measured differences in MNC and PBL. These analyses 
revealed altered levels of methylation in the heart disease patients compared to healthy 
controls, although the transformation of the data into relative differences might have 
influenced the statistical analyses. However, for some of the genes under study, for 
example HAND2 and HOXA5, the differences between the methylation levels of the 
paired MNC and PBL samples was small. Also, for some of the other genes under 
study, the methylation differences between the heart disease patients and the controls 
were over 2% higher than the methylation differences between the paired MNC and 
PBL samples. These observations together suggest that the increase observed in the 
heart disease patients in these genes cannot be solely explained by the difference in cell 
composition and that these patients carry aberrant patterns of DNA methylation. 
Nevertheless, to confirm these results, methylation levels should be analysed in a 
greater number of DNA samples with the same cell composition in both the patient and 
the control group. 
The exact role of the methylation changes observed in the heart disease patients 
in this study remains largely unknown. Interestingly, an increase of both HOXA4 and 
HOXA5 methylation was observed in these heart disease patients. Previous expression 
profiling results performed in our group showed that multiple RGS genes were 
positively regulated by these genes, with the most extensive upregulation seen for the 
RGS2 gene (unpublished results). Deregulation of RGS2 is thought to play a crucial 
role in the pathogenesis of cardiovascular diseases. It does that by deregulation of the G 
protein-coupled receptor (GPCR) signalling pathways, involved in blood pressure 
homeostasis, by promoting chronic constriction of the peripheral vasculature, leading to 
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hypertension and downregulation of RGS2 is observed in cardiac hypertrophy (Tsang, 
2010). 
None of the other genes under investigation have been previously described to 
play a role in the development of heart diseases. However, these genes under study did 
show clear age-related methylation changes (as described in Chapter 4). Thus one 
hypothesis that could explain the increased methylation observed would be that heart 
disease patients have higher levels of age-related DNA methylation in MNCs than 
healthy individuals. In this study we cannot examine what the role of these methylation 
changes are in the development of a heart disease, due to a number of limitations in our 
study set up. First of  all, the methylation levels were measured in patients that had 
already developed a heart disease, making it unknown whether these methylation 
differences were already present before the development of the disease or if they 
occurred afterwards. Secondly, we have only examined methylation levels in MNCs in 
these heart disease patients. Even though these cells are important in the development 
atherosclerosis, it would be interesting to test whether these methylation changes could 
be confirmed in different cell types. In our study, we did not examine expression levels, 
so it is unknown what the effect of the observed increase in methylation levels does to 
the expression of the genes and if these aberrant patterns of methylation observed in the 
heart disease patients are having an important biological effect. 
Overall, our results show that altered patterns of methylation are present in blood 
samples of heart disease patients. What the role is of these altered methylation patterns 
remains currently unknown and further research is necessary to examine this role in 
greater detail. 
 
6.4 Chapter discussion 
The results discussed in this chapter show that the CpG island methylation levels 
of the genes that were previously identified as being age-related are overlapping with 
the genes showing aberrant patterns of DNA methylation in the age-related diseases 
examined; cancer, more specifically leukaemia and HNPCC, and heart disease. Both the 
leukaemia patients and the heart disease patients showed aberrant patterns of 
methylation in most of the genes under study, whereas for the HNPCC patients, only a 
subset of the genes under study showed aberrant patters of methylation. This suggests 
that, at least in case of patients with a disease related to age, leukaemia and heart 
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disease, higher levels of age-related DNA methylation was observed in these patients 
compared to healthy controls.  
Even though the methylation levels in all of these patients were significantly 
different than the methylation observed in the age-matched controls, the extent of 
methylation measured in these patients varied significantly; while hypermethylation was 
observed during ALL diagnosis and relapse, which is almost certainly leading to 
transcriptional silencing, this increase in methylation was not as extreme in the non-
diseased samples of these ALL patients, nor in the heart disease and HNPCC patients. 
However, even though the extent of methylation changes observed in these patients was 
generally not very large, these methylation changes might be significant at the cellular 
level and thus biological and expression changes may be present in a subset of cells. As 
is suggested by the cancer clonal expansion theory, cancer likely develops from clonal 
expansion of a single mutant cell. This suggests that altered levels of methylation which 
leads to inactivation of a gene in even a small fraction of cells could have important 
roles in cancer development. How this relates to the development of other age-related 
diseases is less clear. It is possible that the inability to maintain DNA methylation 
during ageing is a result of an overall decline of the body and the inability to maintain 
important biological processes with an increasing age. This suggests that patients who 
are biologically older, contain higher levels of DNA methylation and are more likely to 
develop a disease related to age. In this case changes in DNA methylation could 
function as a marker of increased risk of developing disease, but perhaps have no direct 
role in the development of the disease. Alternatively accumulation of altered 
methylation patterns in a subset of cells may contribute to loss of tissue homeostasis and 
thus potentially have a more direct impact on disease development.  
At the moment, it is unknown whether these increases in methylation levels 
observed in these patients were already present in these patients before the development 
of the disease, or if these methylation patterns occurred after disease progression. 
Therefore, more research is necessary to explore the exact role of these methylation 
patterns in the development of these diseases. However, increased levels of methylation 
was also observed for a subset of the genes analysed in the HNPCC patients, patients 
with a condition leading to an increased risk of developing a disease, although all these 
patients analysed were disease free at the time of sample collection. This suggests that, 
at least in the HNPCC patients, aberrant patterns of methylation are already presents in 
these patients before they develop the disease. It is therefore likely that similar 
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mechanisms occur in other diseases as well, suggesting that the aberrant patterns of 
methylation in both the leukaemia remission patients and the heart disease patients 
might have been pre-existing before the development of the disease. This hypothesis 
suggests that aberrant patterns of DNA methylation in apparently healthy individuals 
might be used as a predictive marker of patients that are more likely to develop one of 
these age-related diseases. This hypothesis is strengthened by the observation that 
aberrant patterns of DNA methylation during ALL remission might predict future 
relapse, suggesting a link between underlying methylation patterns and patient outcome.  
Overall, we showed that aberrant patterns of DNA methylation is a feature of 
several diseases related to age. This suggests that patients with these age-related 
diseases have higher levels of age-related DNA methylation in blood compared to 
healthy individuals.  
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Chapter 7. Discussion 
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7.1 Aberrant patterns of methylation during ageing 
The results from our study demonstrated that age-related methylation changes 
occur in a subset of genes in PBL samples. For at least five of the genes, TWIST2, 
TUSC3, HOXD4, EphA10 and HAND2, it was shown that with an increasing age, there 
is also an increase in the extent of methylation as well as an increase in the variance of 
methylation, which is steadily acquired during the ageing process.  Three of the genes 
under study HOXA4, HOXA5 and IGF2 showed different patterns of methylation during 
aging compared to the other five genes. For these genes, the patterns of methylation 
were relatively stable during aging, although a difference in variance was observed 
within the different age groups. For one of the genes under study, MLH1, no sign of 
changes in methylation patterns with an increasing age was observed. In this study, only 
nine genes were investigated.  
The consistency with which multiple genes in our study showed strong 
similarities in the patterns of age-related methylation, which is steadily acquired over 
the life span,  makes it highly likely that there are other genes following similar patterns 
of age-related methylation. Further studies are necessary to identify the amount of genes 
following similar patterns as observed in our study. What is causing these methylation 
changes during aging remains currently unclear, but it might be caused by an unstable 
maintenance of the replication of DNA methylation patterns during cell divisions during 
aging. 
Interestingly, the genes that show variable methylation during ageing in PBL are 
closely related to the genes that become methylated during cancer development from the 
same tissue, whereas the MLH1 gene, which is frequently methylated in solid tumours 
but not in haematological malignancies, did not exhibit increasing methylation with age. 
This is supported by the analyses of the methylation levels in our leukaemia patients, 
were a great overlap was observed between the genes showing variable methylation 
during ageing and those that became hypermethylated during leukaemia development. 
The methylation patterns of these genes were found to be stable during disease 
progression; strong correlations were found in our paired ALL diagnostic and relapse 
samples. This suggests that altered methylation levels are consistent during disease 
progression, which is supported by the observation that during CLL development, 
global methylation patterns were shown to be relatively stable with time and within 
different CLL compartments (Cahill, 2012). These results imply that although 
methylation is highly abnormal in these patients, it is not necessarily unstable in cancer 
cells. Other studies have shown that altered levels of DNA methylation were observed 
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in early stages of the disease (van Hoesel, 2013; Heuck, 2013), suggesting that altered 
levels of methylation might be an early event in tumour development.  
All these observations together, leads to the hypothesis that the susceptibility of 
developing leukaemia, and potentially other diseases which increases with age, may be 
caused by the inability of cells to stably maintain the DNA methylation levels during 
aging and/or cell division. This hypothesis is strengthened by the observation that the 
observed correlation of the methylation levels of these genes in the older adult 
population, and in a lower extent also in the younger age groups, is following a similar 
pattern as the CIMP described in cancer, which is a phenotype that describes the 
presence of widespread CpG island methylation in tumours. In the older adult 
population the presence of such a widespread CpG island methylation is also observed 
in the five genes we tested and TWIST2, TUSC3, HOXD4, EphA10 and HAND2 exhibit 
similar patterns of age related changes in DNA methylation. This again suggests that 
DNA methylation levels at these genes are closely related to each other in healthy 
individuals. This CIMP was not driven by changes in the cellular composition of PBL 
samples during ageing, as it was also seen in specific cell types after cell sorting. 
 
7.2 Methylation patterns during cell differentiation 
The results from our study into methylation patterns in specific cell types, 
showed that, for the genes under investigation in this study, the specific isolated cell 
types were mirroring patterns as observed during leukaemia development, where the 
lymphocytes, and most specifically the B-lymphocytes, showed higher levels of 
methylation than the myeloid cell types. Further investigation into early B-cell 
progenitors showed that these B-cell lineage specific progenitor cells did not mirror the 
increase in methylation levels as observed in the isolated differentiated B-lymphocytes, 
suggesting that cell-type specific methylation differences in CpG island methylation 
examined in this study must occur during the process of differentiation. Even though 
several other studies have shown that methylation patterns can change during cell 
differentiation (Bocker; Calvanese), their results suggested that these methylation 
changes were related to the differentiation program of that specific cell type. In contrast, 
our results imply a more general phenomenon, in which it are the B-lymphocytes that 
acquire increased CpG island methylation of a large group of genes that are also under 
influence of age-related methylation changes. This acquisition of promoter methylation 
does not appear to be involved in gene silencing. For example; TWIST2 accumulated 
high levels of promoter methylation in B-lymphocytes, even though it was shown that 
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this gene is also expressed in differentiated B-lymphocytes (Thathia, 2012). At the same 
time, the methylation levels that were observed in the B-lymphocytes our study were 
not high enough to suggest a controlled mechanism for promoter methylation in gene 
activation in all cells.  
We also investigated methylation changes in specific cell types related to age. 
These results showed that age-related methylation changes occur in several cell types 
and that they are not just occurring in one cell type specifically. Most of the genes under 
study showed a slight, but not always significant, difference in the methylation levels of 
the isolated cells between the two age groups. This suggests that age-related differences 
in methylation levels observed for these genes do not solely occur during the process of 
differentiation but that they must occur in a pool of stem cells. This inability to stably 
maintain methylation levels in stem cells during ageing are of interest in understanding 
methylation changes during disease development. Age-related DNA methylation may 
be a key factor in underlying disease susceptibility by this inability of stem cells to 
stably maintain DNA methylation. 
The genes included in this study were all lymphoid leukaemia specific, with the 
exception of HOXA4 and HOXA5, which are both methylated in all types of leukaemia, 
and we did not investigate methylation patterns during ageing and in specific cell types 
in blood in myeloid leukaemia related genes. It would be interesting to examine the 
patterns in this set of genes to investigate if the methylation patterns are different 
between the different cell types for those genes. In order to identify other genes of 
interest, a 450K-methylation array was performed on both isolated cell types from the 
myeloid and lymphoid lineage, as well as for AML and ALL patients. This array was 
performed to identify more myeloid leukaemia related genes, as well as to identify 
similarities and differences in the patterns of the lineage-specific cell types from healthy 
individuals and the leukaemia derived from these cell types.  
Unfortunately, the analysis of this array was not completed yet before thesis writing. 
 
7.3 Allelic distribution 
To examine the allelic distribution of the methylation levels, as measured by 
pyrosequencing, bisulphite sequencing was performed on two ALL remission samples. 
These results showed that the methylation patterns might not be randomly distributed 
among the different alleles, but that they are more restricted to a subset of alleles. As 
shown in two ALL remission samples for the TUSC3 gene (with respectively 28.54% 
and 20.34% of methylation as assessed by pyrosequencing), most of the alleles remain 
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methylation free, where only a subset of alleles show methylated CpG sites. For one of 
the samples there were even no methylated CpG sites detected at all during bisulphite 
sequencing (Figure 7.1). This suggests that most methylation in this sample is likely to 
be found in a small percentage of alleles as opposed to being evenly spread across all 
alleles (such that all alleles had 1 or 2 CpG sites methylated). It is well possible that this 
pattern as observed in the non-leukaemic cells from two leukaemia patients, also occurs 
in healthy individuals. Interestingly, the presence of highly methylated alleles is one of 
the known features of leukaemia, suggesting that even in the non-leukaemic samples, 
similar patterns of allelic distribution is observed compared to the leukaemia phase. 
However, the number of alleles analysed so far is small and the lack of methylation 
identified by this technique suggests some bias towards unmethylated alleles. 
Further investigations by HTS will have to give us a more accurate and in-dept 
analysis of the epi-alleles and will give us more insight on what the methylation 
patterns, as measured by pyrosequencing, mean in the context of individual alleles or 
cells. This HTS technique allows us to examine around 100,000 of alleles per individual 
per gene instead of the small numbers as analysed by bisulphite sequencing. Healthy 
individuals in different age groups, as well as paired diagnostic and remission samples 
from six ALL patients, were included in this analysis. 
Unfortunately, these analyses were not completed before thesis writing.   
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Figure 7.1: Bisulphite sequencing results of two ALL remission patients 
Bisulphite sequencing results on two ALL patients that were into remission showed, with 
methylation levels of respectively 28.54% and 20.34% as assessed by pyrosequencing, showed 
that the CpG methylation is not randomly distributed among the different alleles. A high 
number of alleles remain completely methylation free, while other show methylation patterns. 
No methylated CpGs were identified in sample 2, suggesting that the methylation patterns of the 
other, not identified alleles, must be hypermethylated to reach a total amount of methylation of 
20.34% 
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7.4 Aberrant patterns of methylation in age-related diseases 
Our investigation into aberrant patterns of methylation in diseases related to an 
increasing age, such as cancer, more specifically leukaemia, and heart disease, revealed 
that aberrant patterns of methylation was observed both during the development of 
leukaemia and in patients who had suffered a heart attack. These genes were identified 
due to their role in leukaemia development, and indeed, seven of the genes under study 
showed levels of hypermethylation during both the diagnostic and relapsed phase of the 
disease. Aberrant patterns of methylation were even observed in patients who had 
suffered a heart attack, suggesting that genes that are under influence of age-related 
methylation changes also show aberrant patterns of methylation in at least two diseases 
related to age.  
DNA methylation is most extensively studied in cancer and increasing numbers 
of evidence suggest that DNA methylation plays an important role in this development. 
Earlier studies already showed that aberrant patterns of DNA methylation do occur in 
other pathologies in addition to cancer, however, whereas for cancers the causal role of 
DNA methylation is well established, for other diseases, the direct functional role of 
these altered methylation patterns is not as clear. During cancer development clonal 
selection occurs, and thus an epigenetic or genetic change which occurs even in a small 
subset of cells can have dramatic consequences if those cells clonally expand. Most 
other diseases do not develop from clonal expansion, and therefore, the effect of 
changes even in a small number of cells remain less clear. Our results however, showed 
that aberrant patterns of methylation increases over the life course and is likely to affect 
a reasonable high number of alleles, which might be sufficient to affect tissue 
homeostasis. In several diseases, such as atherosclerosis, only local areas of altered cell 
behaviour are required to develop the disease. The levels of methylation changes 
observed during ageing and in the patients who suffered from a heart disease might 
underlie such changes in a fraction of cells. However, this is currently speculation and 
more research is necessary to investigate this mechanism.  
This study was an observational study and therefore cannot tell if altered 
methylation could be a cause or a consequence of the disease. However, while studying 
a relatively small number of genes, this study was able to identify methylation 
differences in multiple diseases, which does lend further credence to the idea that 
altered methylation may have a more widespread clinical consequences outside of the 
oncology field. 
  
 186 
 
 
Several  observations together lead to the hypothesis that the observed 
alterations in the methylation levels of our leukaemia patients might have been pre-
existing before the development of the disease, and as a result, might underlie disease 
susceptibility. First of all, aberrant patterns of methylation were observed even in the 
non-diseased cells from our set of leukaemia patients. These analyses were performed 
on the ALL remission samples, and as a result, we can’t rule out the possibility that the 
treatment these patients received altered their methylation levels, such as the 
chemotherapeutic drugs and/or the rapid proliferation that was required to re-populate 
the haematopoietic niche. However, it is possible that these methylation patterns were 
pre-existing before the patients developed the disease. This suggests that patients with 
higher levels of methylation are more likely to develop leukaemia. This is supported by 
the observation that the ALL patients that have poor survival showed higher levels of 
methylation in these non-diseased cells compared to the patients who survived the 
disease.  
Secondly, when we examined methylation patterns in a set of HPCC patients, patients 
with a condition leading to an increased risk of the disease, although all the patients 
were disease free at the time of sample collection, three of the genes under study, 
previously identified of showing both age-related methylation changes and altered 
methylation levels in our leukaemia and heart disease patients, also showed altered 
levels of methylation in these HPCC patients. This means that in these patients, altered 
levels of methylation were present before the development of the cancers related to 
HNPCC. However, these patients do have an inherited mutation that might cause 
alterations in their methylation levels, which are not present in the other patients groups.  
To further examine the hypothesis of pre-existing alterations in the DNA 
methylation patterns of gene promoters prior to disease development, DNA samples 
were collected from the EPIC-Norfolk study (Day, 1999). These samples were collected 
from patients two to five years before they were diagnosed with either leukaemia or 
lymphoma and, as a result, all these participants were disease-free at time of sample 
collection. DNA samples were also collected from age-, gender- and SES-matched 
controls that stayed disease free in the follow-up years. Analyses of the methylation 
levels in these individuals will allow us to test whether altered levels of methylation, in 
patients diagnosed with haematological cancers, are already present before disease 
development and to test the hypothesis that apparently healthy individuals with higher 
levels of methylation are more likely to develop the disease.  
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Unfortunately, these analyses were not completed yet at the moment of thesis writing. 
 
7.5 Cross-talk between methylation changes during ageing and disease 
susceptibility: the pre-existing methylation hypothesis 
All of our results combined led us to the hypothesis that pre-existing 
methylation may underlie the susceptibility of haematological malignancies, and 
potentially other cancers. When we go 10-20 years back in time, the main focus was on 
promoter methylation levels during cancer development. However, what we know now, 
mainly due to more sensitive techniques, such as pyrosequencing, is that methylation 
levels are already present in healthy individuals, and in fact, are already present at birth, 
although at much lower levels than during cancer development. These methylation 
patterns might not be randomly distributed (as indicated in Figure 7.2A), since our 
preliminary bisulphite sequencing results showed that methylation patterns are likely 
more restricted to specific alleles, such that an allele is either densely methylated or 
remains mostly methylation free. This will result in a pattern in which each cell has one 
or two densely methylated genes, whereas the other genes in this cell remain mostly 
methylation free (Figure 7.2 B). This hypothesis might even be expanded, since 
analyses of our healthy individuals showed strong correlations between genes within 
individuals, and even within specific cell types. This suggest a co-methylation, where 
several genes are methylated simultaneously. This might result in a pattern in which 
there is a small subset of cells which have several genes hypermethylated, which are 
likely transcriptionally inactive, while these genes remain mostly methylation free in 
other cells (Figure 7.2C).  
This hypothesis suggests that a subset of cells is pre-primed by aberrant patterns 
of DNA methylation, mirroring patterns as observed during leukaemia progression. This 
co-ordinated methylation of genes is of particular interest in the development of 
leukaemia, and potentially other cancers. If a subset of cells is pre-primed by aberrant 
patterns of methylation, clonal expansion of one of these cells is sufficient to provide 
the leukaemia-like methylation phenotype. Our results suggest that the amount of these 
pre-primed cells are increased with an increasing age, providing a potential explanation 
of why older individuals are more likely to develop such a disease. Subsets of these 
cells however, are already present at birth and these pre-primed cells may thus alter 
disease susceptibility throughout life.  
The hypothesis that pre-primed methylation patterns might lead to an increased 
risk of developing diseases is supported by the observation that during ALL remission, 
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patients with aberrant patterns of methylation subsequently relapsed, while the patients 
with methylation levels similar to the methylation levels observed in the healthy 
controls, survived the disease. 
 All these results together suggest that cancer, and potentially other age-related 
diseases, develops in cells which are pre-primed by the presence of aberrant patterns of 
DNA methylation.  
 
 
 
 
 
Figure 7.2: Pre-existing methylation hypothesis 
All the results of the methylation patterns in healthy individuals combined led us to the 
hypothesis that pre-existing methylation patterns may underlie the susceptibility of cancer, and 
potentially other age-related diseases. 
Methylation levels of leukaemia-related genes were observed in healthy individuals, and they 
were even already present at birth. These methylation levels might not be as randomly 
distributed as indicated by A, since preliminary results suggest that methylation might only be 
present in a small subset of alleles, while other alleles remain completely methylation free, as 
indicated by B. However, strong correlations were observed in the methylation levels of a 
subset of genes, suggesting co-ordinated methylation levels of these genes simultaneously. This 
might results in patterns of methylation as indicated by C, where a small number of cells show 
several genes hypermethylated, while other cell remain methylation free for the same set of 
genes.  
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DNA isolation 
Reagent B (Nucleon) 
400 mM  Tris/Cl 
60 mM  EDTA 
150 mM NaCl 
1% SDS 
Adjust pH to 8.0 
5M sodium perchlorate 
720 gr Chlorate 
Adjust to 1 litre with dH2O 
 
Cell isolations 
Cell seperation buffer 1 
PBS + 0.1% BSA + 2 mM EDTA 
For a total amount of 10ml:  
10 ml PBS + 10μl  BSA + 4μl  0.5M 
EDTA 
Cell separation buffer 2 
PBS + 0.1% BSA 
For a total amount of 10ml:  
10 ml PBS + 10μl  BSA, ph 7.4 
0.5M EDTA 
Dilute 186.1 gram Na2EDTA.2H2O in 800 
ml dH2O 
Adjust pH to 8.0 with NaOH 
Adjust volume to 1 litre with dH2O 
 
Gel electrophoresis 
50x TAE (1 litre) 
242 gram Tris 
57.1 ml Acetic acid 
18.6 gram EDTA/ 100 ml 0.5M EDTA 
(pH 8.0) 
Adjust volume to 1 litre with dH2O 
1x TAE (1 litre) 
20 ml 50x TAE 
1980 ml dH2O 
PCR loading buffer 
30 ml glycerol 
70 ml dH2O 
Add Orange G until the buffer is coloured 
orange 
1Kb+ Ladder 
250μl  1µg/µl 1 Kb+ ladder from 
invitrogen 
Add 250μl  loading buffer 
Add 1000μl  dH2O 
Table A.1: An overview of the basic buffers used in this study 
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Bisulphite sequencing 
LB media 
10g tryptone 
5g yeast extract 
10g NaCl 
Ajust volume to 1 litre with dH2O 
Adjust pH to 7  
After autoclaving, add 50 µg/ml 
Kanamycin 
Agar plates 
10g tryptone 
5g yeast extract 
10g NaCl 
15g Agar 
Ajust volume to 1 litre with dH2O 
Adjust pH to 7  
After autoclaving, add 50 µg/ml 
Kanamycin 
Pour agar solution into the plates, allow to 
cool down and store 4 ºC 
High-throughput sequencing 
TE 
1 ml of 1M Tris-Hcl (pH 8.0) 
0.2 ml of 0.5M EDTA 
Adjust volume to 100 ml with dH2O 
 
Table A.1: An overview of the basic buffers used in this study 
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Gene Description 
TWIST2 TWIST2 (Dermo-1) is a basic helix-loop-helix protein, which regulates 
transcription factors that are known to regulate proliferation and differentiation of 
myeloid lineage progenitors (Sharabi, 2008). TWIST2 is one of the main 
regulators of CD7 in mature T-cells, and the failure of TWIST2 regulation may 
results in the generation of abnormal T-cell populations (Koh, 2009). TWIST2 is 
shown to act as a negative regulator of osteogenic differentiation, while 
promoting mesenchymal stromal/stem cell growth and adipogenesis (Isenmann, 
2009). In ALL, epigenetic inactivation of TWIST2 is shown to play a dual role; it 
alters cells growth and survival properties, and at the same time, it increases the 
resistance to chemotherapeutic treatment (Thathia, 2012). 
TUSC3 TUSC3, also known as N33 or putative prostate cancer tumour suppressor gene, 
is a magnesium transporter (science, 2012) and it is suggested to act as a 
potential tumour suppressor gene in several cancers, like breast cancer and 
pancreatic cancer (Cooke, 2008; Levy, 1999). TUSC3 is methylated during ALL 
development, but not during AML development (Scholz, 2005). 
EphA10 EphA10 is a member of the EPH family, which are receptors for ephrin family 
ligands (Aasheim, 2005), and they are important in the cell signalling pathway 
(Kandouz, 2012).  EphA10 was found to be hypermethylated in various 
leukaemia cell lines and ALL patients (Kuang) and a high frequency of EphA10 
expression was observed in CLL cases (Alonso, 2009). 
HAND2 HAND2 is a basic helix-loop-helix transcription factor and it is affecting cell 
differentiation and cell type-specific gene expression in neural crest-derived 
noradrenergic sympathetic ganglion neurons. (Hendershot, 2008). It is one of the 
transcription factors that control cardiac gene expression (Bondue, 2010) and 
heart development and in mice it has been shown to be able to reprogram cardiac 
fibroblasts into functional cardiac-like myocytes (Song, 2012). 
IGF2 Insulin-like growth factor 2 (IGF2), also known as the somatomedin A, is one of 
the key players being involved in fetal growth and development (St-Pierre, 
2012), and is monoallelic expressed on the parental chromosome. In patients with 
the Beckwith-Wiedemann syndrome it was shown that some of the patients carry 
a constitutional mutation that results in biallelic expression of IGF2 (Weksberg, 
1993). 
Table A.2: Overview of the genes examined in this project 
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Gene Description 
MLH1 MutL homolog 1 (MLH1) is a DNA mismatch repair gene, that is associated 
with hereditary nonpolyposis colorectal cancer (HNPCC) (Ward, 2012). It was 
shown that the ATPase domain of MLH1 is important to transmit the class 
switch recombination signaling cascade, that lead to the affinity maturation and 
isotype switching, required to generate protective antibodies, both upstream and 
downstream of the generation of double-strand breaks (Chahwan, 2012). 
  
HOX genes The HOX genes encode homeodomain-containing transcription factors which 
are known to be key regulators of embryonic development. They are also 
expressed in adult cells, in which they play important roles in the control of 
cellular differentiation. The human genome contains 4 HOX clusters (A-D) 
(Cillo, 2001).   
HOXD4 HOXD4 is a sequence-specific transcription factor which is part of a 
developmental regulatory system that provides cells with specific positional 
identities (science, 2012). HOXD4 is able to up-regulate the neuronal marker 
NEFM, but it cannot induce cell cycle arrest and morphologic differentiation 
(Zha, 2012). It is proposed that a HOXD4 mutation is involved in the 
occurrence of childhood ALL (van Scherpenzeel Thim, 2005). 
HOXA5 HOXA5 is an important regulator of myeloid cell proliferation and 
differentiation. It functions as an important regulator of hematopoietic lineage 
determination and maturation (Fuller, 1999). HOXA5 exhibit cell type specific 
methylation within normal cells, which correlates with gene expression. 
Indistinguishable levels of methylation was observed in both myeloid and 
lymphoid cells (Strathdee, 2007b). This gene is hypermethylated in all types of 
leukaemias. In AML, hypermethylation of HOXA5 was associated with good 
prognosis (Strathdee, 2007a). 
HOXA4 HOXA4 might be important for maintaining spatial identity even in the adult 
aorta and downregulation of HOXA4 expression may increase susceptibility to 
aortic disease such as human abdominal aortic aneurysms (Lillvis). As HOXA5, 
HOXA4 is hypermethylated in all types of leukaemia and hypermethylation of 
HOXA4 was associated with good prognosis (Strathdee, 2007a).  
Table A.2: Overview of the genes examined in this project 
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Appendix B. Alterations of DNA methylation patterns with age 
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  Methylation 
levels 
neonates (%) 
Methylation 
levels young 
adults (%) 
Methylation 
levels adults 
(%) 
Methylation 
levels older 
adults (%) 
 Neonates
- Young 
adults 
Young 
adults- 
Adults 
Adults- 
Older 
adults 
T
U
S
C
3
 
CpG1 9.72 11.09 14.37 15.49  P=0.005 P<0.001 P=0.148 
CpG2 4.91 5.98 8.17 8.93 P<0.001 P<0.001 P=0.121 
CpG3 1.43 2.49 3.92 6.22 P<0.001 P<0.001 P<0.001 
CpG4 2.76 3.86 5.41 7.23 P<0.001 P<0.001 P=0.001 
CpG5 2.76 4.03 6.68 7.40 P<0.001 P<0.001 P=0.186 
CpG6 1.76 3.61 6.23 8.23 P<0.001 P<0.001 P=0.017 
 
T
W
IS
T
2
 
CpG1 3.76 3.36 4.68 8.27  P=0.345 P=0.001 P<0.001 
CpG2 4.35 4.54 5.78 9.10 P=0.720 P<0.001 P<0.001 
CpG3 3.33 3.31 4.65 8.72 P=0.821 P<0.001 P<0.001 
CpG4 5.23 5.08 6.82 8.73 P=0.689 P<0.001 P=0.006 
 
H
O
X
D
4
 
CpG1 6.58 8.88 10.75 13.84  P=0.001 P=0.002 P=0.015 
CpG2 6.58 11.43 14.57 19.11 P<0.001 P=0.002 P=0.001 
CpG3 3.42 7.64 10.70 14.93 P<0.001 P<0.001 P<0.001 
CpG4 3.32 7.28 9.09 11.90 P<0.001 P=0.002 P=0.019 
CpG5 5.00 8.61 11.13 14.30 P<0.001 P<0.001 P=0.002 
 
E
p
h
A
1
0
 
CpG1 14.97 16.39 18.90 22.91  P=0.025 P<0.001 P<0.001 
CpG2 4.58 5.07 6.55 8.03 P=0.054 P<0.001 P=0.047 
CpG3 2.00 2.33 3.22 5.00 P=0.137 P<0.001 P=0.001 
CpG4 4.57 5.52 5.68 8.56 P=0.001 P=0.363 P<0.001 
 
H
A
N
D
2
 
CpG1 2.82 3.84 4.59 5.05  P<0.001 P=0.001 P=0.715 
CpG2 5.02 8.89 10.48 10.70 P<0.001 P=0.001 P=0.842 
CpG3 3.54 5.35 6.99 7.13 P<0.001 P<0.001 P=0.359 
CpG4 1.99 4.13 6.50 6.50 P<0.001 P<0.001 P=0.308 
Table B.1: Difference in levels methylation levels within age groups per individual 
CpG sites 
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H
O
X
A
5
 
CpG1 52.65 50.55 51.76 57.24  P=0.347 P=0.414 P=0.026 
CpG2 60.91 56.42 58.00 63.11 P=0.028 P=0.393 P=0.048 
CpG3 61.20 55.57 57.17 61.79 P=0.002 P=0.303 P=0.054 
CpG4 63.10 58.88 58.91 63.41 P=0.046 P=0.972 P=0.099 
CpG5 64.52 49.45 58.58 63.65  P=0.003 P=0.966 P=0.073 
 
H
O
X
A
4
 
CpG1 26.45 34.26 35.49 40.34  P<0.001 P=0.584 P=0.018 
CpG2 25.98 36.48 38.57 39.94 P<0.001 P=0.316 P=0.376 
CpG3 23.62 39.99 43.67 44.46 P<0.001 P=0.147 P=0.647 
CpG5 30.64 38.54 40.32 41.55 P=0.001 P=0.371 P=0.513 
 
Table B.1: Difference in levels methylation levels within age groups per individual 
CpG sites 
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Appendix C. Cell type specific DNA methylation 
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 TWIST2 TUSC3 HOXD4 EphA10 HAND2 HOXA5 HOXA4 IGF2 MLH1 
PBL – MNC P=0.169 P=0.005** P=0.028* P=0.013* P=0.878 P=0.199 P=0.169 P=0.575 P=0.056 
PBL-Lymphocytes P=0.005
** 
P=0.005
**
 P=0.013
* 
P=0.007
** P=0.359 P=0.392 P=0.013
* P=0.314 P=0.176 
PBL- B-lymphocytes P=0.005
**
 P=0.005
**
 P=0.005
**
 P=0.005
** 
P=0.028
* 
P=0.025
* 
P=0.005
**
 P=0.139 P=0.928 
PBL – Monocytes P=0.005** P=0.009** P=0.009** P=0.203 P=0.013
* 
P=0.032
* 
P=0.022
* P=0.959 P=0.057 
MNC- Lymphocytes P=0.074 P=0.721 P=0.241 P=0.037 P=0.799 P=0.143 P=0.143 P=0.515 P=0.547 
MNC- B-lymphocytes P=0.005
**
 P=0.005
**
 P=0.005
**
 P=0.005
**
 P=0.013
* 
P=0.002
** 
P=0.005
**
 P=0.260 P=0.113 
MNC- Monocytes P=0.005
**
 P=0.005
**
 P=0.005
** 
P=0.007
** 
P=0.022
*
 P=0.319 P=0.037 P=0.760 P=0.979 
B-lymphocytes- Lymphocytes P=0.006
** 
P=0.005
**
 P=0.005
**
 P=0.005
**
 P=0.005
**
 P=0.241 P=0.037
* P=0.374 P=0.183 
Lymphocytes- Monocytes P=0.003
** 
P=0.005
**
 P=0.005
**
 P=0.005
**
 P=0.022
* 
P=0.032
* 
P=0.013
* P=0.214 P=0.382 
B-lymphocytes- Monocytes P=0.003
** 
P=0.005
**
 P=0.005
**
 P=0.005
**
 P=0.005
**
 P=0.005
**
 P=0.005
**
 P=0.086 P=0.066 
Table C.1: Differences in methylation levels between cell types isolated from the young adult population 
Significant differences in methylation levels were observed between the different cell types in the young adults for seven of the genes under study (Paired samples 
T-test for the genes HOXA5 and MLH1, Wilcoxon signed rank test for all the other genes under study (SPSS)). 
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 TWIST2 TUSC3 HOXD4 EphA10 HAND2 HOXA5 HOXA4 IGF2 
PBL- MNC P=0.036
* 
P=0.012
*
 P=0.012
*
 P=0.036
* 
P=0.262 P=0.398 P=0.149 P=0.225 
PBL- Lymphocytes P=0.017
* 
P=0.017
* 
P=0.012
*
 P=0.012
*
 P=0.012
*
 P=0.612 P=0.330 P=0.442 
PBL- B-lymphocytes P=0.012
* 
P=0.012
* 
P=0.012
* 
P=0.012
*
 P=0.018 P=0.237 P=0.054 P=0.026
* 
PBL- T-lymphocytes P=0.017
* 
P=0.012
*
 P=0.035
* 
P=0.012
*
 P=0.575 P=0.043
* 
P=0.286 P=0.919 
PBL- Monocytes P=0.012
* 
P=0.012
*
 P=0.012
*
 P=0.012
*
 P=0.012
*
 P=0.612 P=0.140 P=0.697 
PBL- Granulocytes P=0.572 P=0.263 P=0.484 P=0.123 P=0.750 P=0.499 P=0.386 P=0.521 
MNC- Lymphocytes P=0.575 P=0.327 P=0.036
* 
P=0.012
*
 P=0.093 P=0.310 P=0.830 P=0.019
* 
MNC- B-lymphocytes P=0.012
*
 P=0.012
*
 P=0.017
* 
P=0.012
*
 P=0.012
*
 P=0.091 P=0.054 P=0.003
** 
MNC- T-lymphocytes P=0.093 P=0.327 P=0.093 P=0.050 P=0.674 P=0.063 P=0.974 P=0.293 
MNC- Monocytes P=0.012
* 
P=0.012
* 
P=0.012
*
 P=0.012
*
 P=0.012
*
 P=0.176 P=0.085 P=0.217 
MNC- Granulocytes P=0.093 P=0.025
* 
P=0.036
* 
P=0.025
* 
P=0.327 P=0.389 P=0.053 P=0.678 
Lymphocytes- B-lymphocytes P=0.012
* 
P=0.012
* 
P=0.017
* 
P=0.017
* 
P=0.025 P=0.063 P=0.031
* 
P<0.001
*** 
Lymphocytes- T-lymphocytes P=0.161 P=0.674 P=0.889 P=0.123 P=0.889 P=0.398 P=0.905 P=0.308 
Lymphocytes- Monocytes P=0.012
*
 P=0.012
*
 P=0.012
*
 P=0.012
*
 P=0.012
*
 P=0.237 P=0.185 P=0.090 
Lymphocytes- Granulocytes P=0.012
*
 P=0.017
* 
P=0.012
*
 P=0.012
*
 P=0.093 P=0.398 P=0.194 P=0.064 
B-lymphocytes- T-lymphocytes P=0.012
*
 P=0.012
*
 P=0.036
* 
P=0.327 P=0.012
** 
P=0.043* P=0.243 P=0.017
* 
B-lymphocytes- Monocytes P=0.012
*
 P=0.012
*
 P=0.012
*
 P=0.012
*
 P=0.012
* 
P=0.612 P=0.049
* 
P=0.009* 
B-lymphocytes- Granulocytes P=0.012
*
 P=0.012
*
 P=0.012
*
 P=0.012
*
 P=0.017
* 
P=0.735 P=0.047
* 
P=0.033
* 
T-lymphocytes- Monocytes P=0.012
*
 P=0.012
*
 P=0.012
*
 P=0.012
*
 P=0.025
* 
P=0.028* P=0.131 P=0.713 
T-lymphocytes- Granulocytes P=0.012
*
 P=0.017
* 
P=0.012
*
 P=0.012
* 
P=0.123 P=0.018
* 
P=0.221 P=0.281 
Monocytes- Granulocytes P=0.017
* 
P=0.017
* 
P=0.012
* 
P=0.05
*
 P=0.208 P=1.000 P=0.541 P=0.445 
Table C.2: Differences in methylation levels between cell types isolated from the adult population 
Significant differences in methylation levels were observed between the different cell types in the adult population for seven of the genes under study (Paired 
samples T-test for the genes HOXA4 and IGF2, Wilcoxon signed rank test for all the other genes under study (SPSS)). 
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  TWIST2 TUSC3 HOXD4 EphA10 HAND2 HOXA5 HOXA4 IGF2 
1
st
 5 genes 
combined 
B
-
ly
m
p
h
o
cy
te
s Methylation levels young adults (%) 11.14 14.44 20.44 14.64 10.80 57.09 46.18 49.20 14.29 
Methylation levels adults (%) 13.03 13.88 19.85 15.87 13.48 56.51 51.43 47.13 15.22 
          
Young adults- Adults P=0.481 P=0.481 P=0.888 P=0.743 P=0.011
* P=0.743 P=0.114 P=0.773 P=0.290 
Table C.3: Median methylation levels in the B-lymphocytes in the young adult population compared to the adult population  
One of the participants of the young adult age group exhibited high levels of methylation. To examine if the differences observed between the age groups was driven 
by that one outlier, the median was determined rather than the mean (Wilcoxon signed rank test (SPSS)). 
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 TWIST2 TUSC3 HOXD4 EphA10 HAND2 HOXA5 HOXA4 
Stem-and early progenitor cells- B-cell progenitors P=0.600 P=0.232 P=0.893 P=0.204 P=0.893 P=0.109 P=0.651 
Stem-and early progenitor cells-  
Stem- and early progenitor cells minus B-cell 
progenitors 
P=0.833 P=0.860 P=0.715 P=0.712 P=0.500 P=0.273 0.968 
Stem-and early progenitor cells- B-lymphocytes P=0.460 P=0.011
** P=0.463 P=0.097 P=0.345 P=0.893 P=0.128 
Stem-and early progenitor cells- T lymphocytes P=0.046 P=0.058 P=0.345 P=0.021
* P=0.345 P=0.463 P=0.195 
Stem-and early progenitor cells- Monocytes P=0.735 P=0.521 P=0.116 P=0.516 P=0.917 P=0.345 P=0.317 
B-cell progenitors - Stem- and early progenitor cells 
minus B-cell progenitors 
0=0.345 P=0.685 P=0.715 P=0.372 P=0.500 P=0.655 P=0.479 
B-cell progenitors- B-lymphocytes P=0.752 P=0.038
* P=0.345 P=0.190 P=0.686 P=0.109 P=0.903 
B-cell progenitors- T-lymphocytes P=0.917 P=0.003
** P=0.686 P=0.231 P=0.500 P=0.109 P=0.898 
B-cell progenitors- Monocytes P=0.463 P=0.566 P=0.686 P=0.183 P=0.893 P=0.109 P=0.770 
B-lymphocytes- T-lymphocytes P=0.173 P=0.689 P=0.463 P=0.800 P=0.463 P=0.225 P=0.432 
B-lymphocytes- Monocytes P=0.028
*
 P=0.020
*
 P=0.075 P=0.025
*
 P=0.463 P=0.500 P=0.108 
T-lymphocytes- Monocytes P=0.028
*
 P=0.013
*
 P=0.028
*
 P=0.001
***
 P=0.345 P=0.225 P=0.183 
Table C.4: Comparisons of methylation levels in the different cell types isolated from the G-CSF mobilized samples 
Statistical differences were observed between different cell types in a small number of genes (Paired samples T-test for TUSC3, EpHA10 and HOXA4, Wilcoxon 
signed rank test for the other genes under study, SPSS). 
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A. 
 TWIST2 TUSC3 HOXD4 EphA10 HAND2 HOXA5 HOXA4 
TWIST2  
R= 0.843 
P= 0.001 
R= 0.864 
P= 0.001 
R= 0.800 
P= 0.003 
R= 0.308 
P= 0.361 
R= -0.531 
P= 0.093 
R= 0.701 
P= 0.016 
TUSC3   
R= 0.844 
P= 0.001 
R= 0.711 
P= 0.014 
R= 0.182 
P= 0.593 
R= -0.481 
P= 0.134 
R= 0.573 
P= 0.065 
HOXD4    
R= 0.628 
P= 0.038 
R= 0.269 
P= 0.424 
R= -0.514 
P= 0.105 
R= 0.531 
P= 0.093 
EphA10     
R= 0.490 
P= 0.126 
R= -0.137 
P= 0.689 
R= 0.531 
P= 0.092 
HAND2      
R= 0.260 
P= 0.440 
R= 0.432 
P= 0.185 
HOXA5       
R= -0.226 
P= 0.504 
HOXA4        
Table C.5A: Correlations between genes in the isolated cell types in the young adults; the lymphocytes 
In the lymphocyte samples, correlations were observed between TWIST2, TUSC3, HOXD4 and EphA10 (p<0.05). A correlation was observed between 
TWIST2 and HOXA4. The R is indicating the correlation coefficient and the P the observed p-values (Pearson correlation (SPSS)). 
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B. 
 TWIST2 TUSC3 HOXD4 EphA10 HAND2 HOXA5 HOXA4 
TWIST2  
R= 0.070 
P= 0.839 
R= -0.198 
P= 0.559 
R= 0.313 
P= 0.349 
R= -0.258 
P= 0.044 
R= -0.648 
P= 0.031 
R= 0.532 
P= 0.092 
TUSC3   
R= -0.112 
P= 0.743 
R= -0.140 
P= 0.682 
R= -0.312 
P= 0.349 
R= -0.306 
P= 0.359 
R= 0.083 
P= 0.809 
HOXD4    
R= 0.546 
P= 0.082 
R= 0.651 
P= 0.030 
R= 0.232 
P= 0.493 
R= 0.515 
P= 0.105 
EphA10     
R= 0.645 
P= 0.032 
R= 0.046 
P= 0.892 
R= 0.730 
P= 0.011 
HAND2      
R= 0.617 
P= 0.043 
R= 0.341 
P= 0.305 
HOXA5       
R= -0.266 
P= 0.430 
HOXA4        
Table C.5B: Correlations between genes in the isolated cell types in the young adults; the monocytes 
In the monocyte samples, there are correlation observed between HAND2 with HOXD4 and EphA10, between EphA10 and HOXA4 and between HOXA5 
with TWIST2 and HAND2. The R is indicating the correlation coefficient and the P the observed p-values (Pearson correlation (SPSS)). 
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Appendix D. DNA methylation patterns during the development of 
age-related diseases 
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Figure D.1A-E: Methylation levels are relatively stable during ALL remission 
A)   TUSC3 methylation showed lower levels after 2 years remission compared to the first remission sample, taken at 3 months into remission. 
B-E) Overall methylation levels during remission are relatively stable in the childhood patients for HOXD4, EphA10, HAND2 and HOXA5. Some patients 
exhibited a further increase in methylation, while other patients exhibited a reduction later into remission.  
 
 206 
 
 
Figure D.2A-F: No differences in methylation levels in heart disease patients within different patient groups  
A-F) No differences were observed between the heart disease patients within different patient groups for any of the genes under study. 
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Figure D.2G and H: No differences in methylation levels in heart disease patients within different patient groups  
G and H) No differences were observed between the heart disease patients within different patient groups for any of the genes under study. 
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Figure D.3A-F: Methylation patterns between disease patient groups: previous heart surgery 
A-F) No significant differences in methylation levels were observed between the heart disease patients who underwent previous heart surgery and patients 
who did not, for all genes under study. 
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Figure D.3G and H: Methylation patterns between disease patient groups: previous heart surgery 
G and H)| No significant differences in methylation levels were observed between the heart disease patients who underwent previous heart surgery and 
patients who did not, for all genes under study. 
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Figure D.4A-F: Methylation patterns between heart disease patient groups: number of vessels affected 
A) A significant difference in methylation levels is observed between the patients with one vessel affected and the patients with three vessels affected for 
HOXA5 (p=0.034, Independent samples T-test, SPSS). 
B-F) No differences in methylation levels were observed between heart disease patients with one, two or three vessels affected by the heart disease for 
TWIST2, TUSC3, HOXD4, EphA10 and HAND2. 
 211 
 
. 
Figure D.4G and H: Methylation patterns between heart disease patient groups: number of vessels affected 
G and H) No differences in methylation levels were observed between heart disease patients with one, two or three vessels affected by the heart disease for 
HOXA4 and IGF2. 
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Figure D.5A-F: Methylation patterns between disease patient groups: family history of heart disease 
A)  A significant differences was observed in the methylation levels of the heart disease patients with a family history of heart disease and the patients without 
such a family history for HOXA4 (p=0.036, Mann-Whitney U and Wilcoxon Signed Ranks test, SPSS) 
B-F) No significant differences were observed in the methylation levels of heart disease patients with a family history of heart disease and patients without such 
a family history for TWIST2, TUSC3, HOXD4, EphA10 and HAND2. 
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Figure D.5G and H: Methylation patterns between disease patient groups: family history of heart disease 
G and H) No significant differences were observed in the methylation levels of heart disease patients with a family history of heart disease and patients 
without such a family history for HOXA5 and IGF2.  
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